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A B S T R A C T
Background
In people with acute pancreatitis, it is unclear what the role should be for medical treatment as an addition to supportive care such as
fluid and electrolyte balance and organ support in people with organ failure.
Objectives
To assess the effects of different pharmacological interventions in people with acute pancreatitis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL, 2016, Issue 9), MEDLINE, Embase, Science Citation
Index Expanded, and trial registers to October 2016 to identify randomised controlled trials (RCTs). We also searched the references
of included trials to identify further trials.
Selection criteria
We considered only RCTs performed in people with acute pancreatitis, irrespective of aetiology, severity, presence of infection, language,
blinding, or publication status for inclusion in the review.
Data collection and analysis
Two review authors independently identified trials and extracted data. We did not perform a network meta-analysis as planned because
of the lack of information on potential effect modifiers and differences of type of participants included in the different comparisons,
when information was available. We calculated the odds ratio (OR) with 95% confidence intervals (CIs) for the binary outcomes and
rate ratios with 95% CIs for count outcomes using a fixed-effect model and random-effects model.
Main results
We included 84 RCTs with 8234 participants in this review. Six trials (N = 658) did not report any of the outcomes of interest for
this review. The remaining 78 trials excluded 210 participants after randomisation. Thus, a total of 7366 participants in 78 trials
contributed to one or more outcomes for this review. The treatments assessed in these 78 trials included antibiotics, antioxidants,
aprotinin, atropine, calcitonin, cimetidine, EDTA (ethylenediaminetetraacetic acid), gabexate, glucagon, iniprol, lexipafant, NSAIDs
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(non-steroidal anti-inflammatory drugs), octreotide, oxyphenonium, probiotics, activated protein C, somatostatin, somatostatin plus
omeprazole, somatostatin plus ulinastatin, thymosin, ulinastatin, and inactive control. Apart from the comparison of antibiotics versus
control, which included a large proportion of participants with necrotising pancreatitis, the remaining comparisons had only a small
proportion of patients with this condition. Most trials included either only participants with severe acute pancreatitis or included a
mixture of participants with mild acute pancreatitis and severe acute pancreatitis (75 trials). Overall, the risk of bias in trials was unclear
or high for all but one of the trials.
Source of funding: seven trials were not funded or funded by agencies without vested interest in results. Pharmaceutical companies
partially or fully funded 21 trials. The source of funding was not available from the remaining trials.
Since we considered short-term mortality as the most important outcome, we presented only these results in detail in the abstract.
Sixty-seven studies including 6638 participants reported short-term mortality. There was no evidence of any differences in short-
term mortality in any of the comparisons (very low-quality evidence). With regards to other primary outcomes, serious adverse events
(number) were lower than control in participants taking lexipafant (rate ratio 0.67, 95% CI 0.46 to 0.96; N = 290; 1 study; very low-
quality evidence), octreotide (rate ratio 0.74, 95% CI 0.60 to 0.89; N = 770; 5 studies; very low-quality evidence), somatostatin plus
omeprazole (rate ratio 0.36, 95% CI 0.19 to 0.70; N = 140; 1 study; low-quality evidence), and somatostatin plus ulinastatin (rate
ratio 0.30, 95% CI 0.15 to 0.60; N = 122; 1 study; low-quality evidence). The proportion of people with organ failure was lower in
octreotide than control (OR 0.51, 95% CI 0.27 to 0.97; N = 430; 3 studies; very low-quality evidence). The proportion of people with
sepsis was lower in lexipafant than control (OR 0.26, 95% CI 0.08 to 0.83; N = 290; 1 study; very low-quality evidence). There was
no evidence of differences in any of the remaining comparisons in these outcomes or for any of the remaining primary outcomes (the
proportion of participants experiencing at least one serious adverse event and the occurrence of infected pancreatic necrosis). None of
the trials reported heath-related quality of life.
Authors’ conclusions
Very low-quality evidence suggests that none of the pharmacological treatments studied decrease short-term mortality in people with
acute pancreatitis. However, the confidence intervals were wide and consistent with an increase or decrease in short-term mortality due
to the interventions. We did not find consistent clinical benefits with any intervention. Because of the limitations in the prognostic
scoring systems and because damage to organs may occur in acute pancreatitis before they are clinically manifest, future trials should
consider including pancreatitis of all severity but power the study to measure the differences in the subgroup of people with severe
acute pancreatitis. It may be difficult to power the studies based on mortality. Future trials in participants with acute pancreatitis should
consider other outcomes such as complications or health-related quality of life as primary outcomes. Such trials should include health-
related quality of life, costs, and return to work as outcomes and should follow patients for at least three months (preferably for at least
one year).
P L A I N L A N G U A G E S U M M A R Y
Medical treatment for people with acute pancreatitis (sudden inflammation of the pancreas)
Background
The pancreas is an organ in the abdomen (tummy) that secretes several digestive enzymes (substances that enable and speed up chemical
reactions in the body) into the pancreatic ductal system before it empties into the small bowel. It also contains the Islets of Langerhans,
which secrete several hormones including insulin (helps regulate blood sugar). Acute pancreatitis is life-threatening illness characterized
by sudden inflammation of the pancreas, which can lead to failure of other organs, such as the lungs and kidneys. There is a lot of
research into different medical treatments for the treatment of acute pancreatitis, but it is not clear what benefits each treatment has,
or indeed if any medical treatment is beneficial apart from supportive treatment. This care includes body hydration and intensive care
treatment for people with organ failure (to support the failing organs). We sought to resolve this issue by searching for existing studies
on the topic. We included all randomised controlled trials (clinical studies where people are randomly put into one of two or more
treatment groups) whose results were reported to 7 October 2016.
Study characteristics
We included 84 RCTs with 8234 participants in this review. Six trials (658 participants) did not report any of the outcomes of interest
for this review. In the remaining 78 trials, 210 participants were excluded after randomisation. Thus, a total of 7366 participants in
78 trials contributed to one or more outcomes for this review. Apart from the comparison of whether antibiotics should be used, the
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other comparisons included only a small percentage of people with pancreatic necrosis (an extremely severe form of pancreatitis, which
results in pancreatic destruction). Most trials included only the severe form of acute pancreatitis or included both mild and severe forms
of pancreatitis.
Source of funding: seven trials were not funded or were funded by agencies without vested interest in results. Twenty-one trials were
partly or fully funded by pharmaceutical companies. The source of funding was not available from the remaining trials.
Quality of the evidence
The overall quality of evidence was low for all the measures because the trials were at unclear or high risk of bias (a systematic error or
deviation from the truth that affects the results, favouring one treatment over another) and were small trials. As a result, further studies
are required on this topic.
Key results
Sixty-seven studies including 6638 participants reported short-term deaths. Overall, an average 12% of people who received only
supportive care died. There was no evidence that any of the treatments decreased short-term deaths. There was evidence that various
treatmentsmight be beneficial in a number of outcomes; however, these results were not consistent, and we cannot make any conclusions
as to whether any of the treatments may be beneficial. None of the trials reported health-related quality of life.
In conclusion, based on low quality evidence, there is no evidence that any drug treatment added on to supportive care decreases short-
term deaths. Future trials in participants with acute pancreatitis should include health-related quality of life, costs, and return to work
as outcomes and should follow patients for at least three months (preferably for at least one year).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Pharmacological interventions for treatment of acute severe pancreatitis (mortality)
Patient or population: people with acute pancreat it is
Settings: secondary or tert iary sett ing
Intervention: various treatments
Control: inact ive control
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk
Inactive control
Corresponding risk
Various treatments
Short- term mortality
Follow-up: up to 3 months
Antibiotics OR 0.81
(0.57 to 1.15)
1058
(17 studies)
⊕©©©
Very lowa,b,c
120 per 1000 99 per 1000
(72 to 135)
Antioxidants OR 2.01
(0.53 to 7.56)
163
(4 studies)
⊕©©©
Very lowa,b,c
120 per 1000 215 per 1000
(68 to 508)
Aprotinin OR 0.68
(0.40 to 1.14)
651
(7 studies)
⊕©©©
Very lowa,b,c
120 per 1000 85 per 1000
(52 to 135)
Calcitonin OR 0.55
(0.15 to 2.00)
125
(2 studies)
⊕©©©
Very low1,² ,3
120 per 1000 69 per 1000
(20 to 214)
Cimetidine OR 1.00
(0.06 to 17.18)
40
(1 study)
⊕©©©
Very lowa,b,c
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120 per 1000 120 per 1000
(8 to 701)
EDTA OR 0.94
(0.12 to 7.08)
64
(1 study)
⊕©©©
Very low1,² ,3
120 per 1000 113 per 1000
(17 to 491)
Gabexate OR 0.79
(0.48 to 1.30)
576
(5 studies)
⊕©©©
Very lowa,b,c
120 per 1000 98 per 1000
(62 to 151)
Glucagon OR 0.97
(0.51 to 1.87)
409
(5 studies)
⊕©©©
Very low1,² ,3
120 per 1000 117 per 1000
(65 to 203)
Iniprol OR 0.14
(0.01 to 1.67)
24
(1 study)
⊕©©©
Very lowa,b,c
120 per 1000 19 per 1000
(2 to 185)
Lexipafant OR 0.55
(0.30 to 1.01)
423
(3 studies)
⊕©©©
Very low1,² ,3
120 per 1000 70 per 1000
(40 to 121)
Octreotide OR 0.76
(0.47 to 1.23)
927
(6 studies)
⊕©©©
Very lowa,b,c
120 per 1000 94 per 1000
(60 to 143)
Probiotics OR 1.70
(0.87 to 3.30)
358
(2 studies)
⊕©©©
Very lowa,b,c,d
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120 per 1000 188 per 1000
(106 to 310)
Activated protein C OR 8.56
(0.41 to 180.52)
32
(1 study)
⊕©©©
Very lowa,b,c
120 per 1000 539 per 1000
(52 to 961)
Somatostatin OR 0.57
(0.29 to 1.10)
493
(6 studies)
⊕©©©
Very lowa,b,c
120 per 1000 72 per 1000
(39 to 130)
Somatostatin plus omeprazole OR 0.23
(0.05 to 1.11)
140
(1 study)
⊕©©©
Very lowa,b,c
120 per 1000 30 per 1000
(6 to 132)
Somatostatin plus ulinastatin OR 0.43
(0.15 to 1.23)
122
(1 study)
⊕©©©
Very lowa,b,c
120 per 1000 55 per 1000
(20 to 144)
Thymosin Not estimable 24
(1 study)
⊕©©©
Very lowa,b,c
120 per 1000 not estimable
Ulinastatin OR 0.45
(0.12 to 1.72)
132
(2 studies)
⊕©©©
Very lowa,b,c
120 per 1000 58 per 1000
(16 to 190)
Long- term mortality
Follow-up: 1 year
None of the trials with inact ive treatment in the control group reported long-term mortality
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* The basis for the assumed risk is the average control group proport ion across all comparisons. The corresponding risk (and its 95% conf idence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence intervals; OR: odds rat io; EDTA: ethylenediaminetetraacet ic acid.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aRisk of bias: downgraded by one level.
bImprecision: downgraded one level for wide conf idence intervals.
cImprecision: downgraded one level for small sample size.
dHeterogeneity: downgraded one level for lack of overlap of conf idence intervals and high I².
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B A C K G R O U N D
Description of the condition
The pancreas is an abdominal organ that secretes several digestive
enzymes into the pancreatic ductal system before it empties into
the small bowel. The pancreas also lodges the Islets of Langerhans,
which secrete several hormones including insulin (NCBI 2014).
Acute pancreatitis is a sudden inflammatory process in the pan-
creas, with variable involvement of nearby organs or other organ
systems (Bradley 1993). The annual incidence of acute pancreati-
tis ranges from 5 to 30 per 100,000 population (Roberts 2013;
Yadav 2006). There has been an increase in the incidence of acute
pancreatitis in the last 10 to 20 years in the UK and USA (Roberts
2013; Yang 2008). Acute pancreatitis is the commonest gastroin-
testinal (digestive tract) cause of hospital admission in the USA
(Peery 2012), and gallstones and alcohol are the two main causes.
Approximately, 50% to 70% of acute pancreatitis is caused by gall-
stones (Roberts 2013; Yadav 2006); these slip into the common
bile duct and obstruct the ampulla of Vater (a common channel
formed by the union of common bile duct and pancreatic duct),
resulting in obstruction to the flow of pancreatic enzymes and
leading to activation of trypsinogen within the pancreas and acute
pancreatitis (Sah 2013).
Advanced age, male sex, and lower socioeconomic class are asso-
ciated with higher incidence of acute pancreatitis (Roberts 2013).
Clinicians generally diagnose acute pancreatitis when at least two
of the following three features are present (Banks 2013).
1. Acute onset of a persistent, severe, epigastric pain, often
radiating to the back.
2. Serum lipase activity (or amylase activity) at least three
times greater than the upper limit of normal.
3. Characteristic findings of acute pancreatitis on contrast-
enhanced computed tomography (CECT) and less commonly
magnetic resonance imaging (MRI) or transabdominal
ultrasonography.
Depending upon the type of inflammation, acute pancreatitis
can be classified into interstitial oedematous pancreatitis (diffuse
(widespread) or occasionally localised enlargement of the pancreas
due to inflammatory oedema as seen on CECT) or necrotising
pancreatitis (necrosis involving either the pancreas, peripancreatic
tissues, or both) (Banks 2013). Approximately 90% to 95% of
people with acute pancreatitis have interstitial oedematous pan-
creatitis, while the remainder have necrotising pancreatitis (Banks
2013). Necrotising pancreatitis may be sterile or infected (Banks
2013). Various theories exist as to how pancreatic and peripancre-
atic tissues get infected. These include spread from blood circula-
tion, lymphatics, bile, and the small bowel (duodenum) through
the pancreatic duct, as well as movement (translocation) through
the large bowel wall (Schmid 1999).
Local complications of acute pancreatitis include acute peripan-
creatic fluid collection, pancreatic pseudocyst, acute necrotic col-
lection, and walled-off necrosis (Banks 2013). The systemic com-
plications of acute pancreatitis include worsening of pre-existing
illnesses such as heart or chronic lung disease (Banks 2013). The
mortality rates following an attack of acute pancreatitis are be-
tween 6% and 20% (Roberts 2013; Yadav 2006), according to
severity. Acute pancreatitis can be classified as mild, moderate, or
severe, depending on the presence of local or systemic complica-
tions, transient organ failure involving one of more of lungs, kid-
neys, and cardiovascular system (heart and blood vessels) lasting
up to 48 hours, or persistent failure of these organs lasting beyond
48 hours. Mild pancreatitis has the best prognosis, and there are
no local or systemic complications or organ failure. In moderately
severe acute pancreatitis, there may be local or systemic compli-
cations or transient organ failure. Severe acute pancreatitis carries
the worst prognosis in terms of mortality, and there is persistent
organ failure (Banks 2013).
The clinical manifestation of acute pancreatitis is believed to be
caused by activation of inflammatory pathways either directly by
the pathologic insult or indirectly by activation of trypsinogen
(an enzyme that digests protein or a protease), resulting in forma-
tion of trypsin, a protease that can break down the pancreas (Sah
2013). This activation of inflammatory pathways manifests clini-
cally as systemic inflammatory response syndrome (SIRS) (Banks
2013; Sah 2013; Tenner 2013). Systemic inflammatory response
syndrome is characterised by two or more of the following criteria
(Bone 1992).
1. Temperature of less than 36°C or more than 38°C.
2. Heart rate less than 90 beats/minute.
3. Respiratory rate more than 20/min or PCO less than 32
mm Hg.
4. White blood cell count more than 12,000/mm³, less than
4000/mm³, or more than 10% immature (band) forms.
See Appendix 1 for a glossary of terms.
Description of the intervention
The main purpose of treatment is to decrease the mortality and
morbidity associated with acute pancreatitis. The various phar-
macological interventions that have been evaluated in the treat-
ment of acute pancreatitis include agents such as somatostatin or
octreotide that decrease pancreatic secretions; protease inhibitors
such as gabexate mesilate, aprotinin, ulinastatin, and nafamostat;
antioxidants such as vitamin C and selenium; platelet activating
factor such as lexipafant; other agents that modulate the inflam-
matory pathway such as steroids and tumour necrosis factor-al-
pha (TNF-α) antibody; probiotics; and antibiotics (Bang 2008;
Neumann 2011; Rada 2011; Yang 2011). We included any phar-
macological intervention aimed at the treatment of acute pancre-
atitis.
We did not cover endoscopic sphincterotomy for the treatment
of common bile duct stones (Ayub 2010), nor did we focus on
8Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
endoscopic, radiology-guided percutaneous treatments or surgi-
cal treatments for treatment of complications of acute pancre-
atitis (Tenner 2013). Furthermore, we did not cover the use of
non-steroidal anti-inflammatory drugs (NSAIDs) or other drugs
such as somatostatin analogues for preventing postendoscopic ret-
rograde cholangiopancreatography (post-ECRP)-induced pancre-
atitis (Elmunzer 2012; Zhang 2009).
How the intervention might work
Somatostatin and its analogues decrease pancreatic secretion
(Bang 2008). Since autodigestion (breakdown of pancreas) due to
trypsinogen activation is one of the mechanisms believed to cause
acute pancreatitis, decreasing pancreatic secretion can decrease
the amount of trypsinogen. Inhibition of trypsin by protease in-
hibitorsmay result in decreased damage to the pancreas (Neumann
2011). Antioxidants, platelet-activating factor inhibitors, steroids,
and TNF-α antibody are all aimed at decreasing the inflammatory
response or at mitigating the damage resulting from the inflam-
matory response (Bang 2008). Probiotics decrease the bacterial
colonisation of the gut, and antibiotics have antibacterial actions
(Bang 2008).
Why it is important to do this review
Despite various pharmacological interventions being evaluated in
acute pancreatitis, none is currently recommended in the treat-
ment of acute pancreatitis, with the exception of antibiotics in in-
fected necrotising pancreatitis (Tenner 2013). Systematic reviews
and meta-analyses increase the precision of the treatment effects
(i.e. they provide a narrower range of the average treatment effect)
(Higgins 2011), and so decrease the risk of a type II error (con-
cluding that there is no difference between treatments when there
is actually a difference). Systematic reviews also help in identifying
the differences in the treatment effects between studies and allow
exploration of the reasons behind these differences. Many studies
have compared these interventions with placebo or with no treat-
ment. It is therefore not possible to obtain accurate information
on how one treatment compares with another treatment. Multiple
treatment comparisons or a network meta-analysis allow compari-
son of several treatments simultaneously and provide information
on the relative effect of one treatment versus another, even when
there is no direct comparison. There is no Cochrane Review or
network meta-analysis on this topic. So, we planned to perform
a network meta-analysis if the type of participants were included
across all the comparisons. This systematic review will identify the
relative effects of different treatments and identify any research
gaps.
O B J E C T I V E S
To assess the effects of different pharmacological interventions in
people with acute pancreatitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs). We in-
cluded studies reported as full text, those published as abstract
only, and unpublished data.
Types of participants
We included adults with acute pancreatitis irrespective of the sever-
ity (mild, moderately severe, or severe acute pancreatitis) or the
type of acute pancreatitis (acute interstitial oedematous pancreati-
tis or necrotising pancreatitis).
Types of interventions
We included trials comparing any pharmacological interventions
mentioned above with another, with placebo, or with no interven-
tion, provided that the only difference between the randomised
groups was the pharmacological intervention or interventions be-
ing assessed. Some of the interventions that we included are listed
below.
• Activated protein C.
• Antibiotics.
• Antioxidants.
• Aprotinin.
• Calcitonin.
• Cimetidine.
• EDTA (ethylenediaminetetraacetic acid).
• Gabexate.
• Glucagon.
• Iniprol.
• Lexipafant.
• Octreotide.
• Omeprazole.
• Probiotics.
• Somatostatin.
• Thymosin.
• Ulinastatin.
We did not combine the different somatostatin analogues (such as
somatostatin or octreotide) as a single treatment in order to avoid
further clinical heterogeneity. We assessed a combination of drugs
as a separate treatment.
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Types of outcome measures
Primary outcomes
1. Mortality.
i) Short-term mortality (in-hospital mortality or
mortality within six months).
ii) Long-term mortality (at maximum follow-up).
2. Serious adverse events (within six months). We accepted the
definition of serious adverse events from the International
Conference on Harmonisation - Good Clinical Practice
guideline (ICH-GCP 1997): any untoward medical occurrence
that results in death, is life-threatening, requires inpatient
hospitalisation or prolongation of existing hospitalisation, or
results in persistent or significant disability/incapacity. Wealso
accepted other variations of ICH-GCP classifications such as
Food and Drug Administration (FDA) classification (FDA
2006), Medicines and Healthcare products Regulatory Agency
(MHRA) classification (MHRA 2013).
i) Proportion of people who developed serious adverse
events (i.e. the percentage of people who developed one or more
serious adverse events) and the number of serious adverse events
(i.e. the total number of serious adverse events in each group
regardless of the number of people in whom the serious adverse
events developed).
ii) Organ failure (however reported by authors).
iii) Infected necrotising pancreatitis (cytology or positive
culture).
iv) Sepsis (however reported by authors).
3. Health-related quality of life (using any validated scale).
i) Short-term (four weeks to three months).
ii) Medium-term (three months to one year).
iii) Long-term (more than one year).
4. Health-related quality of life (using any validated scale).
i) Short-term (four weeks to three months).
ii) Medium-term (three months to one year).
iii) Long-term (more than one year).
Secondary outcomes
1. Adverse events (within six months). We accepted all adverse
events reported by the trial authors, irrespective of the severity of
the adverse event.
2. Measures of decreased complications and earlier recovery
(within six months).
i) Length of hospital stay (including the index admission
for acute pancreatitis and any disease-related or intervention-
related readmissions including those for recurrent episodes).
ii) Length of intensive care unit (ICU) stay (including the
index admission for acute pancreatitis and any disease- or
intervention-related readmissions).
iii) Requirement for additional invasive intervention such
as necrosectomy for pancreatic necrosis, endoscopic or
radiological drainage of collections.
iv) Time to return to normal activity (return to pre-acute
pancreatitis episode mobility without any additional caregiver
support).
v) Time to return to work (in those who were employed
previously).
3. Costs (within six months).
We chose the above clinical outcomes based on the necessity to
assess whether the pharmacological interventions were effective in
decreasing complications, thereby decreasing the length of ICU
and hospital stay, decreasing any additional interventions, and
resulting in earlier return to normal activity and work as well as
improvement in quality of life. The costs provide an indication of
resource requirement.
We did not regard the reporting of the outcomes listed here as an
inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We conducted a literature search to identify all published and un-
published randomised controlled trials. The literature search iden-
tified potential studies in all languages. We translated the non-
English language papers and fully assessed them for potential in-
clusion in the review as necessary.
We searched the following electronic databases for identifying po-
tential studies.
• Cochrane Central Register of Controlled Trials
(CENTRAL; Issue 9, 2016; searched 7 October 2016; Appendix
2).
• MEDLINE (1966 to 7 October 2016; Appendix 3).
• Embase (1988 to 7 October 2016; Appendix 4).
• Science Citation Index (1982 to 7 October 2016; Appendix
5).
We also conducted a search of ClinicalTrials.gov (Appendix 6) and
World Health Organization International Clinical Trials Registry
Platform (WHO ICTRP) (Appendix 8) on 7 October 2016.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We contacted authors of iden-
tified trials and asked them to identify any other published and
unpublished studies.
We searched for errata or retractions from eligible trials on
www.ncbi.nlm.nih.gov/pubmed on 7 October 2016.
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Data collection and analysis
Selection of studies
Two review authors (KG and AB) independently screened titles
and abstracts of all the potential studies that we identified through
the searches and coded them as ’retrieve’ (eligible or potentially el-
igible/unclear) or ’do not retrieve’. We retrieved the full-text study
reports, and two review authors (KG and RK or EM) indepen-
dently screened them and identified studies for inclusion; we iden-
tified and recorded reasons for exclusion of the ineligible studies.
We resolved any disagreement through discussion. We identified
and excluded duplicates and collated multiple reports of the same
study so that each study rather than each report was the unit of
interest in the review. We planned to contact the investigators of
trials of unclear eligibility. We recorded the selection process in
sufficient detail to complete a PRISMA flow diagram (Figure 1)
and a ’Characteristics of excluded studies’ table.
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Figure 1. Study flow diagram.
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Data extraction and management
We used a standard data collection form for study characteristics
and outcome data, which had been piloted on three studies in the
review. Two review authors (KG and RK or EM) independently
extracted the following study characteristics.
1. Methods: study design, total duration study and run-in,
number of study centres and location, study setting,
withdrawals, date of study.
2. Participants: number (N), mean age, age range, sex, severity
and type of acute pancreatitis, inclusion criteria, exclusion
criteria.
3. Interventions: intervention, comparison, co-interventions,
number of participants randomised to each group.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported. For binary outcomes, we
obtained the number of participants with events and the number
of participants included in the analysis in each group. For
continuous outcomes, we obtained the unit or scale of
measurement, mean, standard deviation, and the number of
participants included in the analysis for each group. For count
outcomes, we obtained the number of events and number of
participants included in the analysis in each group. For time-to-
event outcomes, we obtained the proportion of people with
events, the average duration of follow-up of participants in the
trial, and the number of participants included in the analysis for
each group.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (KG and RK or EM) independently extracted
outcome data from included studies. If outcomes were reported at
multiple time points, we planned to extract the data for all time
points. We obtained information on the number of participants
with adverse events (or serious adverse events) and the number of
such events where applicable. We planned to extract all informa-
tion on costs using the currency reported by the trial authors and
planned to convert this to USD at the conversion rates on the day
of the analysis. We extracted data for every trial arm that was an
included intervention. If studies reported outcome data in an un-
usable way, we attempted to contact the trial authors and tried to
obtain usable data. If we were unable to obtain usable data despite
this, we planned to summarise the unusable data in an appendix.
We resolved disagreements by consensus. One review author (EM)
copied across the data for ’Characteristics of included studies’ and
’Characteristics of excluded studies’ from the data collection form
into the Review Manager 5 (RevMan 5) file (RevMan 2014). One
review author (KG) copied across the data for ’Data and analyses’
from the data collection form into the RevMan 5 file. We double-
checked that the data were entered correctly by comparing the
study reports with how the data were presented in the systematic
review.
Assessment of risk of bias in included studies
Two review authors (KG and RK or EM) independently assessed
the risk of bias for each study using the criteria outlined in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). We resolved any disagreements by discussion. We assessed
the risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Bias due to funding source.
8. Other potential bias.
We graded each potential source of bias as high, low, or unclear and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ tables. We summarised
the risk of bias judgements across different studies for each of the
domains listed.We considered blinding separately for different key
outcomes where necessary, for example, for unblinded outcome
assessment, risk of bias for all-causemortalitymay be very different
than for a participant-reported pain scale. Where information on
risk of bias relates to unpublished data or to correspondence with a
trial author, we planned to note this in the ’Risk of bias’ table. We
presented the risk of bias in each pair-wise comparison in Table 1.
When considering treatment effects, we took into account the
risk of bias for the studies that contribute to that outcome by a
sensitivity analysis.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol
and reported any deviations from it in the ’Differences between
protocol and review’ section of this review.
Measures of treatment effect
For dichotomous variables (short-term mortality, proportion of
participants with adverse events, requirement for additional inter-
ventions), we calculated the odds ratio (OR) with 95% confidence
interval (CI). For continuous variables, such as length of hospital
stay, ICU stay, time to return to normal activity, time to return
to work, and costs, we planned to calculate the mean difference
(MD) with 95% CI. We planned to use standardised mean differ-
ence (SMD) with 95% CI for quality of life if different scales were
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used. For count outcomes such as the number of adverse events,
we calculated the rate ratio with 95% CIs. For time-to-event data,
such as long-term mortality, we planned to use the hazard ratio
(HR) with a 95% CI. However, only one trial reported mortal-
ity beyond 3 months and presented the number of deaths at two
years. We analysed this information as binary data.
A common way that trial authors indicate when they have skewed
data is by reporting medians and interquartile ranges. When we
encountered this, we reported the difference in means or medians
in a table.
Unit of analysis issues
The unit of analysis was individual participants with acute pan-
creatitis. As anticipated, we did not find any cluster-randomised
trials for this comparison.
Inmulti-arm trials, themodels account for the correlation between
trial-specific treatment effects from the same trial.
Dealing with missing data
We attempted to contact investigators or study sponsors in or-
der to verify key study characteristics and obtain missing numer-
ical outcome data where possible (e.g. when a study was identi-
fied as abstract only). For binary, count, and time-to-event out-
comes, we performed an intention-to-treat analysis whenever pos-
sible (Newell 1992). Since this was not possible, we performed an
available-case analysis but planned to assess the impact of ’best-
best’, ’best-worst’, ’worst-best’, and ’worst-worst’ scenario analyses
on the results for binary outcomes. For continuous outcomes, we
planned to perform an available-case analysis. If we were unable to
obtain the information from the investigators or study sponsors,
we planned to impute themean from themedian (i.e. consider the
median as themean) and the standard deviation from the standard
error, interquartile range, or P values according to the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
but we planned to assess the impact of including such studies
as indicated in a sensitivity analysis. If we were unable to calcu-
late the standard deviation from the standard error, interquartile
range, or P values, we planned to impute the standard deviation
as the highest standard deviation in the remaining trials included
in the outcome, being fully aware that this method of imputation
would decrease the weight of the studies in the meta-analysis of
mean difference and shift the effect estimate towards no effect for
standardised mean difference. We planned to assess the impact of
including such studies by sensitivity analysis.
Assessment of heterogeneity
We assessed the heterogeneity in each pair-wise comparison by
assessing the Higgins I² (Higgins 2003), the Chi² test with signif-
icance set at a P value less than 0.10, and by visual inspection.
Assessment of reporting biases
We attempted to contact trial authors, asking them to provide
missing outcome data. Where this was not possible, and if we
thought that the missing data may introduce serious bias, we
planned to explore the impact of including such studies in the
overall assessment of results by a sensitivity analysis.
If we were able to pool more than 10 trials for a specific compar-
ison, we created and examined a funnel plot to explore possible
publication biases. We used Egger’s test to determine the statistical
significance of the reporting bias (Egger 1997). We considered a P
value of less than 0.05 to indicate statistically significant reporting
bias.
Data synthesis
We undertook meta-analyses only where this was meaningful (i.e.
if the treatments, participants and the underlying clinical ques-
tion were similar enough for pooling to make sense). In general,
we favoured performing a meta-analysis and clearly highlighted
the reason for not performing one if we decided against it. We
used both the fixed-effect and random-effects model, reporting
the fixed-effect model when the choice of models did not alter
the conclusion and the random-effects model when it did. We did
not perform a network meta-analysis as planned because of the
lack of information on potential effectmodifiers and differences of
type of participants included in the different comparisons, when
information was available (i.e. the transitivity assumption was not
satisfied).
Subgroup analysis and investigation of heterogeneity
We planned to perform the following subgroup analyses regardless
of heterogeneity.
1. Different types of acute pancreatitis (acute interstitial
oedematous pancreatitis or necrotising pancreatitis).
2. Different severity of acute pancreatitis (mild pancreatitis
versus moderate or severe acute pancreatitis).
3. Presence of persistent organ failure (mild or moderate acute
pancreatitis versus severe acute pancreatitis).
4. Presence of infection (infected necrotising pancreatitis
versus non-infected necrotising pancreatitis).
We planned to calculate the test for subgroup differences to iden-
tify differences between subgroups.
Sensitivity analysis
We planned to perform the following sensitivity analyses defined
a priori to assess the robustness of our conclusions.
1. Excluding trials at unclear or high risk of bias (one or more
of the ’Risk of bias’ domains classified as unclear or high).
2. Excluding trials in which either the mean or the standard
deviation or both were imputed.
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3. Imputation of binary outcomes under ’best-best’, ’best-
worst’, ’worst-best’, and ’worst-worst’ scenarios.
’Summary of findings’ table
Although we planned to create a ’Summary of findings’ table using
all the outcomes, this would have resulted in a incomprehensible
table. So, we presented the ’Summary of findings’ table for the
primary outcomes only. We used the five GRADE considerations
(study limitations, inconsistency of effect, imprecision, indirect-
ness and publication bias) to assess the quality of the body of ev-
idence as it related to the studies contributing data to the meta-
analyses for the prespecified outcomes. We justified all decisions
to down- or upgrade the quality rating of studies using footnotes,
making comments to aid the reader’s understanding of the review
where necessary. We considered whether there was any additional
outcome information that we were not able to incorporate into
meta-analyses and planned to note this in the comments, stating
whether it supported or contradicted the information from the
meta-analyses.
Reaching conclusions
We based our conclusions only on findings from the quantitative
or narrative synthesis of included studies for this review. We have
avoided making recommendations for practice, and our implica-
tions for research give the reader a clear sense of where the focus of
any future research in the area should be and what the remaining
uncertainties are.
R E S U L T S
Description of studies
Results of the search
We identified a total of 13,825 references through electronic
searches of CENTRAL (1345 records), MEDLINE (5649
records), Embase (4102 records), Science Citation Index Ex-
panded (2604 records), World Health Organization International
Clinical Trials Registry Platform (78 records) and ClinicalTri-
als.gov (47 records). After removing 3548 duplicates, we obtained
10,277 references. We then excluded 10,030 clearly irrelevant ref-
erences through screening titles and reading abstracts. We sought
247 references for further assessment but could not obtain 2
(Hansen 1966; Perez 1980). Seven references were ongoing trials,
suspended trials, or completed trials identified from clinical reg-
isters with no interim reports available (ChiCTR-IPR-16008301;
EUCTR2014-004844-37-ES; NCT01132521; NCT02025049;
NCT02212392; NCT02692391; NCT02885441). We did not
identify any new trials by scanning reference lists of the identi-
fied randomised trials. We excluded 102 references for the reasons
listed under the table ’Characteristics of excluded studies’. In total,
136 references (84 trials) met the inclusion criteria. The reference
flow is summarised in the study flow diagram (Figure 1).
Included studies
A total of 8234 participants were included in these 84 trials. Six
trials (N = 658) did not report any of the outcomes of interest
for this review (Birk 1994; Chooklin 2007; Marek 1999; Moreau
1986; Plaudis 2010; Wang 2013b). The remaining 78 trials ex-
cluded 210 participants after randomisation. Thus, a total of 7366
participants in 78 trials contributed to one or more outcomes for
this review.
One trial included only participants with acute interstitial oede-
matous pancreatitis (Chen 2002a); 12 trials included only par-
ticipants with acute necrotising pancreatitis (Barreda 2009; Chen
2002b; Delcenserie 2001; Dellinger 2007; Frulloni 1994; Garcia-
Barrasa 2009; Llukacaj 2012; Nordback 2001; Pederzoli 1993a;
Rokke 2007; Sainio 1995; Xue 2009); the remaining trials did
not state clearly whether they included any participants with acute
necrotising pancreatitis. All the trials that included acute necro-
tising pancreatitis either stated explicitly or implied that they ex-
cluded participants with infected necrotising pancreatitis.
Two trials included only participants with mild acute pancreatitis
(Chen 2002a; Yang 2012). Twenty-six trials included only severe
acute pancreatitis (Balldin 1983; Berling 1994; Birk 1994; Chen
2000; Chen 2002b; Chooklin 2007; Delcenserie 1996; Dellinger
2007; Garcia-Barrasa 2009; Grupo Español 1996; Guo 2015;
Hejtmankova 2003; Luiten 1995; Martinez 1984; Olah 2007;
Pettila 2010; Plaudis 2010; Rokke 2007; Spicak 2002; Spicak
2003; Wang 2011; Wang 2013a; Wang 2016; Xia 2014; Xue
2009; Zhu 2014). Two trials reported data separately for mild and
severe acute pancreatitis (Abraham 2013; Wang 2013c). These
trials presented the data separately for mild pancreatitis and acute
severe pancreatitis. The remaining trials either included mild and
severe acute pancreatitis or did not state the severity of pancreatitis
in the participants. It should be noted that none of the trials used
the current definition of severe acute pancreatitis (i.e. organ failure
persisting for 48 hours or more).
The potential effect modifiers, arranged by comparisons, are
shown in Table 2. As shown in the table, important potential ef-
fect modifiers were missing. In addition, it appeared that most
trials in the comparison on antibiotics versus no active interven-
tion included participants with necrotising pancreatitis. Because
of this, there were serious concerns about the inclusion of similar
participants in the different comparisons.
Source of funding: seven trials were not funded or they were funded
by agencies without vested interest in results (Bansal 2011; Garcia-
Barrasa 2009; Wang 2013a; Wang 2013c; Wang 2016; Xue 2009;
Yang 2012). Pharmaceutical companies partially or fully funded
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21 trials (Balldin 1983; Berling 1994; Besselink 2008; Dellinger
2007; Ebbehøj 1985; Hansky 1969; Imrie 1978; Isenmann 2004;
Johnson 2001; Kingsnorth 1995; McKay 1997b; Moreau 1986;
MRC Multicentre Trial 1977; Pettila 2010; Rokke 2007; Sharma
2011; Siriwardena 2007; Trapnell 1974; Tykka 1985; Uhl 1999;
Valderrama 1992). The source of funding was not available from
the remaining trials.
Excluded studies
None of the excluded studies were eligible for this review. The
reasons for exclusion are listed in ’Characteristics of excluded
studies’.
Risk of bias in included studies
We summarised the overall risk of bias in Figure 2 and Figure 3.
Only Wang 2016 was at low risk of bias in all the domains and
can be considered a trial at overall low risk of bias.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Fifteen trials were at low risk of bias for random sequence genera-
tion (Besselink 2008; Buchler 1993; Delcenserie 1996; Dellinger
2007;McKay 1997a; Pederzoli 1993a; Sateesh 2009; Sillero 1981;
Siriwardena 2007; Trapnell 1974; Valderrama 1992;Wang 2013c;
Wang 2016; Xue 2009; Yang 2012). Twenty-six trials were at low
risk of bias for allocation concealment (Barreda 2009; Berling
1994; Besselink 2008; Buchler 1993; Choi 1989; Debas 1980;
Dellinger 2007; Freise 1986; Gilsanz 1978; Gjørup 1992; Imrie
1978; Isenmann 2004; Luengo 1994; Luiten 1995;McKay 1997a;
McKay 1997b; Perezdeoteyza 1980; Pettila 2010; Sharma 2011;
Sillero 1981; Siriwardena 2007; Storck 1968; Trapnell 1974; Uhl
1999; Valderrama 1992; Wang 2016). Eight trials were at low risk
of selection bias (Besselink 2008; Buchler 1993; Dellinger 2007;
McKay 1997a; Siriwardena 2007; Trapnell 1974; Valderrama
1992; Wang 2016). The remaining trials were at unclear risk of
selection bias since they did not describe random sequence gener-
ation or allocation concealment.
Blinding
Forty-five trials were at low risk of bias for blinding of partic-
ipants, healthcare providers, and outcomes assessors (Abraham
2013; Berling 1994; Besselink 2008; Buchler 1993; Debas 1980;
Dellinger 2007; Dürr 1978; Ebbehøj 1985; Freise 1986; Garcia-
Barrasa 2009; Gilsanz 1978; Gjørup 1992; Goebell 1979; Goebell
1988; Grupo Español 1996; Imrie 1978; Imrie 1980; Isenmann
2004; Johnson 2001; Kingsnorth 1995; Kronborg 1980; Llukacaj
2012; Luengo 1994; McKay 1997a; McKay 1997b; Moreau
1986;MRCMulticentre Trial 1977; Olah 2007; Pederzoli 1993b;
Perezdeoteyza 1980; Pettila 2010; Plaudis 2010; Sharma 2011;
Siriwardena 2007; Storck 1968; Trapnell 1974; Tykka 1985; Uhl
1999; Usadel 1985; Valderrama 1992; Vege 2015; Wang 2011;
Wang 2013a; Wang 2016; Zhu 2014). While Bansal 2011 and
Wang 2013c were also at low risk of bias for the blinding of out-
come assessors, Bansal 2011 was at high risk and Wang 2013c
at unclear risk for the blinding of participants and healthcare
providers. Overall, five trials were at high risk of bias due to lack of
blinding (Bansal 2011; Hansky 1969; Paran 1995; Rokke 2007;
Sateesh 2009). The remaining trials were at unclear risk of bias for
blinding.
Incomplete outcome data
Nineteen trials were at low risk of attrition bias due to missing
outcome data (Berling 1994; Buchler 1993; Delcenserie 1996;
Dellinger 2007; Ebbehøj 1985; Marek 1999; Martinez 1984;
McKay 1997a; Pederzoli 1993a; Pettila 2010; Poropat 2015;
Rokke 2007; Sainio 1995; Sharma 2011; Siriwardena 2007;
Tykka 1985; Uhl 1999; Vege 2015; Wang 2016). Twenty-five
trials were at high risk of attrition bias (Abraham 2013; Bansal
2011; Barreda 2009; Besselink 2008; Chen 2002a; Chen 2002b;
Finch 1976; Garcia-Barrasa 2009; Goebell 1988; Grupo Español
1996; Isenmann 2004; Johnson 2001; Kalima 1980; Luiten
1995; McKay 1997b; MRC Multicentre Trial 1977; Nordback
2001; Olah 2007; Paran 1995; Pederzoli 1993b; Sateesh 2009;
Valderrama 1992; Wang 2013c; Xue 2009; Yang 2012). The re-
maining trials were at unclear risk of attrition bias.
Selective reporting
Forty-nine trials were at low risk of selective reporting bias (
Abraham 2013; Balldin 1983; Bansal 2011; Barreda 2009; Berling
1994; Besselink 2008; Buchler 1993; Chen 2000; Choi 1989;
Debas 1980;Delcenserie 1996;Delcenserie 2001;Dellinger 2007;
Finch 1976; Freise 1986; Frulloni 1994; Garcia-Barrasa 2009;
Gilsanz 1978; Gjørup 1992; Goebell 1979; Goebell 1988; Guo
2015; Hejtmankova 2003; Imrie 1978; Johnson 2001; Kalima
1980; Kirsch 1978; Luiten 1995; McKay 1997a; Nordback 2001;
Paran 1995; Pederzoli 1993a; Pederzoli 1993b; Poropat 2015;
Rokke 2007; Sainio 1995; Sateesh 2009; Siriwardena 2007; Spicak
2002; Spicak 2003; Tykka 1985; Uhl 1999; Valderrama 1992;
Vege 2015; Wang 2013a; Wang 2013c; Wang 2016; Xia 2014;
Xue 2009). The remaining trials were at high or unclear risk of
reporting bias.
Other potential sources of bias
Source of funding bias: seven trials were at low risk of due to
source of funding (Bansal 2011; Garcia-Barrasa 2009; Wang
2013a;Wang 2013c;Wang 2016; Xue 2009; Yang 2012). Twenty-
one trials were at high risk of bias due to source of funding
(Balldin 1983; Berling 1994; Besselink 2008; Dellinger 2007;
Ebbehøj 1985; Hansky 1969; Imrie 1978; Isenmann 2004;
Johnson 2001; Kingsnorth 1995; McKay 1997b; Moreau 1986;
MRC Multicentre Trial 1977; Pettila 2010; Rokke 2007; Sharma
2011; Siriwardena 2007; Trapnell 1974; Tykka 1985; Uhl 1999;
Valderrama 1992). The remaining trials were at unclear risk of
bias due to the source of funding.
No other bias was noted in any of the trials.
Effects of interventions
See: Summary of findings for themain comparison Summary of
findings (mortality);Summary of findings 2Summary of findings
(other primary outcomes)
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Primary outcomes
Mortality
Short-term mortality
A total of 67 studies (N = 6638) reported short-term mortal-
ity (Abraham 2013; Balldin 1983; Bansal 2011; Barreda 2009;
Berling 1994; Besselink 2008; Buchler 1993; Chen 2000; Choi
1989;Debas 1980;Delcenserie 1996;Delcenserie 2001;Dellinger
2007;Dürr 1978; Finch 1976; Freise 1986; Frulloni 1994;Garcia-
Barrasa 2009; Gjørup 1992; Goebell 1979; Goebell 1988; Grupo
Español 1996; Guo 2015; Hansky 1969; Hejtmankova 2003;
Imrie 1978; Imrie 1980; Johnson 2001; Kalima 1980; Kingsnorth
1995; Kirsch 1978; Kronborg 1980; Llukacaj 2012; Luengo 1994;
Luiten 1995; Martinez 1984; McKay 1997a; McKay 1997b;
MRC Multicentre Trial 1977; Nordback 2001; Olah 2007; Paran
1995; Pederzoli 1993a; Pederzoli 1993b; Perezdeoteyza 1980;
Pettila 2010; Poropat 2015; Rokke 2007; Sainio 1995; Sateesh
2009; Siriwardena 2007; Spicak 2002; Spicak 2003; Storck 1968;
Trapnell 1974; Tykka 1985; Uhl 1999; Usadel 1985; Valderrama
1992; Vege 2015; Wang 2011; Wang 2013a; Wang 2013c; Wang
2016; Xia 2014; Xue 2009; Yang 2012). There was no evidence
of difference in any of the comparisons (Analysis 1.1).
Long-term mortality (maximum follow-up)
Only one study (N = 62) reported mortality beyond six months
(Gilsanz 1978). There was no evidence of difference in the only
comparison possible.
Serious adverse events
A total of 17 studies (N = 1139) reported serious adverse events as
a proportion or participants who experienced at least one serious
adverse event (i.e. each person with a serious adverse event will
be counted only once regardless of the number of serious adverse
events that the person develops) (Bansal 2011; Chen 2002a;Debas
1980; Delcenserie 1996; Dellinger 2007; Freise 1986; Frulloni
1994; Garcia-Barrasa 2009; Gjørup 1992; Goebell 1988; Kalima
1980; Llukacaj 2012; McKay 1997a; Sainio 1995; Siriwardena
2007; Tykka 1985; Yang 1999). There was no evidence of differ-
ence in any of the comparisons (Analysis 1.2).
A total of 37 studies (N = 3804) reported the number of serious
adverse events observed in all participants (i.e. if a person develops
more than one serious adverse event, the number of serious ad-
verse events that the person develops is included) (Balldin 1983;
Bansal 2011; Barreda 2009; Berling 1994; Besselink 2008; Buchler
1993; Chen 2000; Choi 1989; Debas 1980; Delcenserie 1996;
Delcenserie 2001; Garcia-Barrasa 2009; Gjørup 1992; Guo 2015;
Imrie 1978; Isenmann 2004; Johnson 2001; Kirsch 1978; McKay
1997a; Nordback 2001; Olah 2007; Paran 1995; Pederzoli 1993a;
Poropat 2015; Sainio 1995; Sillero 1981; Spicak 2002; Spicak
2003; Tykka 1985;Uhl 1999; Valderrama1992; Vege 2015;Wang
2013a;Wang 2013c; Xia 2014; Xue 2009; Zhu 2014). There were
fewer serious adverse events in participants receiving lexipafant
(rate ratio 0.67, 95% CI 0.46 to 0.96; participants = 290; stud-
ies = 1), octreotide (rate ratio 0.74, 95% CI 0.60 to 0.89; par-
ticipants = 770; studies = 5), somatostatin plus omeprazole (rate
ratio 0.36, 95% CI 0.19 to 0.70; participants = 140; studies = 1),
and somatostatin plus ulinastatin (rate ratio 0.30, 95% CI 0.15 to
0.60; participants = 122; studies = 1) than control. There were also
fewer serious adverse events in participants taking octreotide plus
ulinastatin compared to octreotide (rate ratio 0.30, 95% CI 0.17
to 0.51; participants = 120; studies = 1) and in participants taking
somatostatin plus ulinastatin versus somatostatin (rate ratio 0.28,
95% CI 0.15 to 0.56; participants = 123; studies = 1). There was
no evidence of difference in the remaining comparisons (Analysis
1.3).
Organ failure
A total of 18 studies (N = 2220) reported organ failure (Abraham
2013; Bansal 2011; Besselink 2008; Delcenserie 1996; Freise
1986;Garcia-Barrasa 2009; Johnson 2001;McKay 1997a;McKay
1997b; Olah 2007; Pederzoli 1993a; Poropat 2015; Rokke 2007;
Sateesh 2009; Siriwardena 2007; Vege 2015; Wang 2013c; Wang
2016). The proportion of people with organ failure was lower in
the octreotide group than in control (OR 0.51, 95% CI 0.27 to
0.97; participants = 430; studies = 3). There was no evidence of
difference in any of the remaining comparisons (Analysis 1.4).
Infected pancreatic necrosis
A total of 15 studies (N = 1173) reported infected pancre-
atic necrosis (Barreda 2009; Besselink 2008; Delcenserie 1996;
Dellinger 2007; Garcia-Barrasa 2009; Isenmann 2004; Llukacaj
2012; McKay 1997a; Olah 2007; Pederzoli 1993a; Poropat 2015;
Rokke 2007; Spicak 2002; Spicak 2003; Zhu 2014). As shown
in Analysis 1.5, there was no evidence of difference in any of the
comparisons.
Sepsis
A total of 11 studies (N = 1350) reported sepsis (Balldin 1983;
Berling 1994; Buchler 1993; Freise 1986; Frulloni 1994; Johnson
2001;Olah2007; Paran1995; Sainio 1995;Uhl 1999;Valderrama
1992). The proportion of people with sepsis was lower in those
receiving lexipafant compared to control (OR 0.26, 95% CI 0.08
to 0.83; participants = 290; studies = 1). There was no evidence
of difference in any of the remaining comparisons (Analysis 1.6).
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Health-related quality of life
None of the trials reported health-related quality of life at any time
point.
Secondary outcomes
Adverse events
A total of 27 studies (N = 2807) reported adverse events as a
proportion or participants who experienced at least one adverse
event (i.e. each person with an adverse event will be counted only
once regardless of the number of adverse events that the person
develops) (Bansal 2011; Buchler 1993; Chen 2002a; Chen 2002b;
Debas 1980; Dellinger 2007; Finch 1976; Freise 1986; Frulloni
1994; Gjørup 1992; Goebell 1979; Kalima 1980; Kingsnorth
1995; Llukacaj 2012;McKay 1997a; Nordback 2001; Olah 2007;
Paran 1995; Pederzoli 1993b; Rokke 2007; Sainio 1995; Tykka
1985; Uhl 1999; Valderrama 1992; Wang 2016; Xia 2014; Yang
1999). This proportion was lower in those receiving antibiotics
(OR 0.51, 95% CI 0.32 to 0.80; participants = 429; studies = 6)
and somatostatin plus omeprazole (OR0.00, 95%CI0.00 to 0.04;
participants = 140; studies = 1) compared to control. There was
no evidence of difference in the remaining comparisons (Analysis
1.7).
A total of 40 studies (N = 3894) reported the number of ad-
verse events observed in all participants (i.e. if a person de-
velops more than one adverse event, the number of adverse
events that the person develops is included) (Abraham 2013;
Balldin 1983; Bansal 2011; Barreda 2009; Berling 1994; Besselink
2008; Buchler 1993; Chen 2000; Choi 1989; Debas 1980;
Garcia-Barrasa 2009; Gilsanz 1978; Gjørup 1992; Goebell 1979;
Guo 2015; Hejtmankova 2003; Imrie 1978; Isenmann 2004;
Johnson 2001;Kirsch 1978;Kronborg 1980; Luiten1995;McKay
1997a; Nordback 2001; Olah 2007; Paran 1995; Pederzoli 1993a;
Pederzoli 1993b; Poropat 2015; Sainio 1995; Sateesh 2009;
Sillero 1981; Spicak 2002; Spicak 2003; Tykka 1985; Uhl 1999;
Valderrama 1992;Wang 2013c; Xue 2009; Zhu 2014). Compared
to control, there were fewer adverse events in participants receiv-
ing antibiotics (rate ratio 0.75, 95% CI 0.58 to 0.95; participants
= 755; studies = 12), gabexate (rate ratio 0.76, 95% CI 0.61 to
0.95; participants = 375; studies = 3), and lexipafant (rate ratio
0.61, 95% CI 0.44 to 0.85; participants = 290; studies = 1). There
were also fewer adverse events for the octreotide plus ulinastatin
group versus ulinastatin alone (rate ratio 0.29, 95% CI 0.17 to
0.48; participants = 120; studies = 1). There was no evidence of
difference in any of the remaining comparisons (Analysis 1.8).
Measures of decreased complication or earlier recovery
Length of hospital stay
Forty-four trials (N = 4405) reported the length of hospi-
tal stay (Abraham 2013; Balldin 1983; Bansal 2011; Barreda
2009; Berling 1994; Besselink 2008; Bredkjaer 1988; Buchler
1993; Debas 1980; Delcenserie 1996; Dürr 1978; Ebbehøj 1985;
Finch 1976; Garcia-Barrasa 2009; Gjørup 1992; Goebell 1979;
Guo 2015; Hansky 1969; Hejtmankova 2003; Isenmann 2004;
Johnson 2001; Luengo 1994; Luiten 1995; Martinez 1984;
McKay 1997a; McKay 1997b; Ohair 1993; Olah 2007; Paran
1995; Pettila 2010; Rokke 2007; Sainio 1995; Sateesh 2009;
Sharma 2011; Siriwardena 2007; Spicak 2002; Spicak 2003; Uhl
1999; Vege 2015; Wang 2011; Wang 2013c; Wang 2016; Xue
2009; Yang 2012). Since most trials did not report the mean and
standard deviation, we reported this outcome inTable 3. As seen in
the table, none of the interventions consistently decreased length
of hospital stay.
Length of intensive care unit stay
Thirteen trials (N = 1188) reported the length of intensive care
unit (ICU) stay (Berling 1994; Besselink 2008; Garcia-Barrasa
2009; Isenmann 2004; Johnson 2001; Nordback 2001; Rokke
2007; Sainio 1995; Sharma 2011; Siriwardena 2007; Spicak 2002;
Vege 2015;Wang 2011). Since most trials did not report themean
and standard deviation, we reported the ICU stay in Table 4. As
seen in the table, none of the interventions consistently decreased
length of ICU stay.
Requirement for additional invasive intervention
A total of 32 studies (N = 3495) reported requirement for
additional invasive intervention (Barreda 2009; Berling 1994;
Besselink 2008; Buchler 1993; Chen 2000; Delcenserie 1996;
Dürr 1978; Garcia-Barrasa 2009; Gilsanz 1978; Goebell 1979;
Goebell 1988; Hejtmankova 2003; Isenmann 2004; Llukacaj
2012; Luengo 1994; Luiten 1995; Martinez 1984; MRC
Multicentre Trial 1977; Nordback 2001; Ohair 1993; Olah 2007;
Pederzoli 1993a; Pederzoli 1993b; Rokke 2007; Sainio 1995;
Sillero 1981; Spicak 2002; Spicak 2003; Tykka 1985; Uhl 1999;
Wang 2013c; Xue 2009). The proportion of people whoneeded an
additional invasive intervention was lower in the gabexate group
compared to control (OR 0.58, 95%CI 0.37 to 0.90; participants
= 426; studies = 3). There was no evidence of difference in any of
the remaining comparisons (Analysis 1.9).
Endoscopic or radiological drainage of collections
Three studies (N = 436) reported endoscopic or radiological
drainage of collections (Delcenserie 1996; Wang 2013c; Zhu
2014). As shown in Analysis 1.10, there was no evidence of dif-
ference in any of the comparisons.
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Time to return to normal activity
None of the trials reported this outcome.
Time to work
None of the trials reported this outcome.
Costs
None of the trials reported this outcome.
Subgroup analysis
Because of the paucity of data, we could only analyse a subgroup
of acute necrotising pancreatitis and severe acute pancreatitis par-
ticipants.
Acute necrotising pancreatitis
There was no evidence of difference in any of the outcomes (
Analysis 2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4; Analysis 2.5;
Analysis 2.6).
Severe acute pancreatitis
Short-term mortality was lower in the gabexate group versus con-
trol (OR 0.19, 95% CI 0.04 to 0.99; participants = 52; studies =
1) (Analysis 3.1)
There was no evidence of difference in the proportion of partic-
ipants experiencing serious adverse events in any of the compar-
isons (Analysis 3.2). The number of serious adverse events was
lower in the somatostatin plus omeprazole group (rate ratio 0.36,
95% CI 0.19 to 0.70; participants = 140; studies = 1) and the
somatostatin plus ulinastatin group (rate ratio 0.30, 95% CI 0.15
to 0.60; participants = 122; studies = 1) compared to control.
There were also fewer serious adverse events in the somatostatin
plus ulinastatin group versus somatostatin alone (rate ratio 0.28,
95% CI 0.15 to 0.56; participants = 123; studies = 1). There was
no evidence of differences in other comparisons (Analysis 3.3).
Organ failure was lower in the ulinastatin group than in control
(OR 0.05, 95% CI 0.01 to 0.21; participants = 67; studies = 1).
There was no evidence of differences between other comparisons
(Analysis 3.4). There was no evidence of differences in infected
pancreatic necrosis or sepsis in any of the comparisons (Analysis
3.5; Analysis 3.6).
Readers should keep in mind that all the comparisons in which
there was evidence of difference are based on single trials at high
risk of bias and with small sample size (i.e. random errors).
Sensitivity analysis
All the trials except one were at unclear or high risk of bias in one
or more domains (Wang 2016). Since most trials reported median
rather than mean for length of hospital stay and length of ICU
stay, we did not perform a meta-analysis by imputing mean and
standard deviation. So, we did not perform a sensitivity analysis
excluding trials in which either themean or the standard deviation
or both were imputed. We did not perform a sensitivity analysis
imputingmissing data based on different scenarios since the details
of the postrandomisation dropouts were not available from the
different trials in which there were postrandomisation dropouts.
Quality of evidence
Most of the comparisons in all the outcomes had low or very low
quality evidence because of the risk of bias in the trials (down-
graded by one level), imprecision (small sample size (downgraded
by one level), and/or overlap of confidence intervals with clinically
insignificant effect or no effect (downgraded by one level). There
was evidence of heterogeneity in some of the outcomes, which re-
sulted in further downgrading by one level for some comparisons.
Reporting bias
We evaluated the reporting bias for short-term mortality, seri-
ous adverse events (number), infected pancreatic necrosis, adverse
events (number), and the requirement for additional intervention
for antibiotics versus control, the only comparisons with at least
10 trials. There was no evidence of reporting bias either on visual
inspection or by Egger’s test for the short-term mortality, infected
pancreatic necrosis, and requirement for additional intervention
(Figure 4, P = 0.88; Figure 5, P = 0.74; and Figure 6, P = 0.98,
respectively). There was evidence of reporting bias both on visual
inspection and by Egger’s test for number of serious adverse events
(Figure 7; P = 0.021). There was evidence of reporting bias on
visual inspection but not by Egger’s test for number of adverse
events (Figure 8; P = 0.079).
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Figure 4. Funnel plot of short-term mortality indicating no evidence of reporting bias.
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Figure 5. Funnel plot of infected pancreatic necrosis indicating no evidence of reporting bias.
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Figure 6. Funnel plot of requirement for additional invasive intervention indicating no evidence of reporting
bias.
24Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 7. Funnel plot of serious adverse events (number) indicating that trials with lower precision favoured
antibiotics without matching trials with lower precision which showed no effect or favouring control.
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Figure 8. Funnel plot of adverse events (number) indicating that trials with lower precision favoured
antibiotics while trials with greater precision favoured control.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Pharmacological interventions for treatment of acute severe pancreatitis (other outcomes)
Patient or population: people with acute pancreat it is
Settings: secondary or tert iary sett ing
Intervention: various treatments
Control: inact ive control
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Inactive control Various treatments
Serious adverse events
(proportion)
Follow-up: up to 3 months
Antibiotics OR 0.65
(0.37 to 1.15)
304
(5 studies)
⊕©©©
Very lowa,b,c
147 per 1000 101 per 1000
(60 to 166)
Antioxidants OR 1.98
(0.48 to 8.13)
82
(2 studies)
⊕©©©
Very lowa,b,c
147 per 1000 255 per 1000
(77 to 584)
EDTA OR 0.52
(0.11 to 2.39)
64
(1 study)
⊕©©©
Very lowa,b,c
147 per 1000 83 per 1000
(19 to 292)
Gabexate OR 1.31
(0.31 to 5.60)
201
(2 studies)
⊕©©©
Very lowa,b,c
147 per 1000 185 per 1000
(51 to 492)
Glucagon OR 0.29
(0.01 to 7.46)
127
(2 studies)
⊕©©©
Very lowa,b,c
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147 per 1000 48 per 1000
(2 to 563)
Octreotide OR 1.73
(0.61 to 4.93)
58
(1 study)
⊕©©©
Very lowa,b,c,d
147 per 1000 230 per 1000
(95 to 460)
Somatostatin OR 1.07
(0.35 to 3.27)
111
(2 studies)
⊕©©©
Very lowa,b,c,d
147 per 1000 156 per 1000
(57 to 361)
Serious adverse events
(number)
Follow-up: up to 3 months
Antibiotics Rate rat io0.86
(0.68 to 1.07)
716
(12 studies)
⊕©©©
Very lowa,b,c
437 per 1000 374 per 1000
(298 to 469)
Antioxidants Rate rat io0.22
(0.02 to 2.21)
71
(2 studies)
⊕©©©
Very lowa,b,c
437 per 1000 94 per 1000
(9 to 967)
Aprotinin Rate rat io0.79
(0.49 to 1.29)
264
(3 studies)
⊕©©©
Very lowa,b,c
437 per 1000 345 per 1000
(212 to 562)
Cimetidine Rate rat io1.00
(0.20 to 4.95)
60
(1 study)
⊕©©©
Very lowa,b,c
437 per 1000 437 per 1000
(88 to 2165)
EDTA Rate rat io0.94
(0.19 to 4.65)
64
(1 study)
⊕©©©
Very lowa,b,c
437 per 1000 411 per 1000
(83 to 2034)
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Gabexate Rate rat io0.86
(0.64 to 1.15)
375
(3 studies)
⊕©©©
Very lowa,b,c
437 per 1000 375 per 1000
(279 to 503)
Glucagon Rate rat io1.00
(0.02 to 50.40)
68
(1 study)
⊕©©©
Very lowa,b,c
437 per 1000 437 per 1000
(9 to 22027)
Lexipafant rate rat io0.67
(0.46 to 0.96)
290
(1 study)
⊕©©©
Very lowa,b,c
437 per 1000 292 per 1000
(203 to 420)
Octreotide Rate rat io0.74
(0.60 to 0.89)
770
(5 studies)
⊕©©©
Very lowa,b,c
437 per 1000 321 per 1000
(264 to 391)
Probiotics Rate rat io0.94
(0.65 to 1.36)
397
(3 studies)
⊕©©©
Very lowa,b,c,d
437 per 1000 412 per 1000
(286 to 595)
Somatostatin Rate rat io1.03
(0.66 to 1.59)
257
(3 studies)
⊕©©©
Very lowa,b,c
437 per 1000 449 per 1000
(290 to 695)
Somatostatin plus omeprazole Rate rat io0.36
(0.19 to 0.70)
140
(1 study)
⊕⊕©©
Lowa,b
437 per 1000 159 per 1000
(82 to 308)
Somatostatin plus ulinastatin Rate rat io0.30
(0.15 to 0.60)
122
(1 study)
⊕⊕©©
Lowa,b
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437 per 1000 133 per 1000
(68 to 262)
Organ failure
Follow-up: up to 3 months
Antibiotics OR 0.78
(0.44 to 1.38)
258
(5 studies)
⊕©©©
Very lowa,b,c
289 per 1000 241 per 1000
(152 to 360)
Antioxidants OR 0.92
(0.39 to 2.12)
163
(4 studies)
⊕©©©
Very lowa,b,c
289 per 1000 271 per 1000
(138 to 463)
Gabexate OR 0.32
(0.01 to 8.25)
50
(1 study)
⊕©©©
Very lowa,b,c
289 per 1000 115 per 1000
(5 to 770)
Lexipafant OR 0.68
(0.36 to 1.27)
340
(2 studies)
⊕©©©
Very lowa,b,c
289 per 1000 216 per 1000
(128 to 341)
Octreotide OR 0.51
(0.27 to 0.97)
430
(3 studies)
⊕©©©
Very lowa,b,c,d
289 per 1000 173 per 1000
(99 to 284)
Probiotics OR 0.80
(0.26 to 2.47)
358
(2 studies)
⊕©©©
Very lowa,b,c,d
289 per 1000 246 per 1000
(95 to 501)
Ulinastatin OR 0.27
(0.01 to 6.67)
129
(2 studies)
⊕©©©
Very lowa,b,c,d
289 per 1000 100 per 1000
(5 to 731)
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Infected pancreatic necro-
sis
Follow-up: up to 3 months
Antibiotics OR 0.82
(0.53 to 1.25)
714
(11 studies)
⊕©©©
Very lowa,b,c
140 per 1000 118 per 1000
(80 to 169)
Octreotide OR 0.52
(0.04 to 6.06)
58
(1 study)
⊕©©©
Very lowa,b,c
140 per 1000 78 per 1000
(7 to 497)
Probiotics OR 1.10
(0.62 to 1.96)
397
(3 studies)
⊕©©©
Very lowa,b,c
140 per 1000 152 per 1000
(92 to 243)
Sepsis
Follow-up: up to 3 months
Antibiotics OR 0.42
(0.11 to 1.60)
60
(1 study)
⊕©©©
Very lowa,b,c
122 per 1000 56 per 1000
(15 to 182)
Aprotinin OR 1.84
(0.49 to 6.96)
103
(2 studies)
⊕©©©
Very lowa,b,c
122 per 1000 204 per 1000
(63 to 492)
Gabexate OR 1.10
(0.55 to 2.19)
373
(3 studies)
⊕©©©
Very lowa,b,c
122 per 1000 133 per 1000
(71 to 233)
Lexipafant OR 0.26
(0.08 to 0.83)
290
(1 study)
⊕©©©
Very lowa,b,c
122 per 1000 35 per 1000
(12 to 103)
Octreotide OR 0.40
(0.05 to 3.53)
340
(2 studies)
⊕©©©
Very lowa,b,c,d
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122 per 1000 53 per 1000
(6 to 329)
Probiotics OR 0.36
(0.10 to 1.36)
62
(1 study)
⊕©©©
Very lowa,b,c
122 per 1000 48 per 1000
(13 to 159)
Health- related quality of
life
None of the trials reported this outcome.
* The basis for the assumed risk is the average control group proport ion across all comparisons. The corresponding risk (and its 95% conf idence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence intervals; OR = odds rat io; EDTA = ethylenediaminetetraacet ic acid
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aRisk of bias: downgraded by one level.
bImprecision: downgraded one level for wide conf idence intervals.
cImprecision: downgraded one level for small sample size.
dHeterogeneity: downgraded one level for lack of overlap of conf idence intervals and high I².
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D I S C U S S I O N
Summary of main results
A total of 7366 participants in 78 trials contributed to one or
more outcomes for this review. The treatments assessed in these 78
trials included antibiotics, antioxidants, aprotinin, atropine, calci-
tonin, cimetidine, EDTA, gabexate, glucagon, iniprol, lexipafant,
NSAID, octreotide, oxyphenonium, probiotics, activated protein
C, somatostatin, somatostatin plus omeprazole, somatostatin plus
ulinastatin, thymosin, ulinastatin, and inactive control.
Despite the number of trials included, network meta-analysis was
not performed because of major concerns about the transitivity
assumption, that is, whether all participants in the network were
sufficiently similar and therefore had an equal chance of receiving
any of the treatments in the network . In particular, we highlight
the fact that a total of 18 trials were included in the compari-
son under antibiotics versus inactive control (Delcenserie 1996;
Delcenserie 2001; Dellinger 2007; Finch 1976; Garcia-Barrasa
2009;Hejtmankova 2003; Isenmann 2004; Llukacaj 2012; Luiten
1995; Nordback 2001; Pederzoli 1993a; Poropat 2015; Rokke
2007; Sainio 1995; Spicak 2002; Spicak 2003; Xue 2009). Ten
of these trials included only participants with acute necrotising
pancreatitis (Barreda 2009; Delcenserie 2001; Dellinger 2007;
Garcia-Barrasa 2009; Llukacaj 2012 Nordback 2001; Pederzoli
1993a; Rokke 2007; Sainio 1995; Xue 2009). Just two other trials
that included only participants with acute necrotising pancreati-
tis were featured in all the other comparisons put together (Chen
2002b; Frulloni 1994). Thus, there is some clinical heterogene-
ity in the type of participants that were included in the different
comparisons. As a result, we performed direct comparison only.
There was no evidence of difference in short-term mortality be-
tween the groups in any of the comparisons. However, the confi-
dence intervals were wide and consistent with significant benefits
or harms of interventions. Because of the number of outcomes re-
ported in the different trials, it is reasonable to expect that the ben-
eficial effect is consistent across clinical outcomes. Interventions
with at least two clinical benefits were: lexipafant, which was asso-
ciated with fewer adverse events (and severe adverse events) and a
lower proportion of people with sepsis; octreotide, which was as-
sociated with fewer serious adverse events and a lower proportion
of people with organ failure; and gabexate, which was associated
with fewer adverse events and a lower proportion of people requir-
ing an additional invasive intervention compared to inactive inter-
vention. However, because of the number of analyses performed
(’Potential biases in the review process’), concerns about the avail-
ability of the drug (’Overall completeness and applicability of
evidence’), and the quality of evidence (’Quality of the evidence’),
further trials are required before recommending any of the inter-
ventions routinely.
Only one trial reported mortality beyond six months (Gilsanz
1978). The follow-up in the remaining trials was three months
in six trials (Besselink 2008; Buchler 1993; Chen 2000; Frulloni
1994; Goebell 1988; Pederzoli 1993b), while in the rest it was
less than six weeks. A three-month follow-up would identify all
the complications related to acute pancreatitis and most deaths
related to these complications. However, a period less than three
months is likely to miss a considerable proportion. None of the
trials reported health-related quality of life, costs, or other impor-
tant socioeconomic measures such as return to work. Health-re-
lated quality of life continues to improve between three months
and one year after necrotising pancreatitis, although some impair-
ment in quality of life may remain beyond then (Wright 2009).
The quality of life after acute severe pancreatitis also appears to
be impaired even several years after the acute pancreatitis episode
(Hochman 2006; Pendharkar 2014). Future trials on acute pan-
creatitis should assess the health-related quality of life for at least
3 months to 12 months and report socioeconomic measures so
that it is possible to understand whether the treatments are cost-
effective.
We can only speculate on why no intervention showed any con-
sistent benefit. One possible reason is that the trials were not pow-
ered to measure differences in short-term mortality. The short-
term mortality in the inactive control group was 12% overall and
17.4% (102/586) in the subgroup of acute severe pancreatitis. To
measure a 20% relative risk reduction in short-term mortality us-
ing an alpha error of 5% and a beta error of 20%, 3422 partic-
ipants are required. Clearly, the trials included only a small pro-
portion of the required sample size, so the lack of evidence of dif-
ference may be due to random error. The complications related to
mild pancreatitis are very infrequent, which means that an even
greater sample size than 3422 is required to demonstrate a differ-
ence in clinical benefits. On the other hand, if the interventions
are targeted against patients with severe pancreatitis, then it can
take several hours or even days for the full picture of severe acute
pancreatitis to develop. By this time, the damage may be too much
for any treatment (other than supportive treatment including or-
gan support) to make a difference. Several prognostic indexes ex-
ist for predicting whether the pancreatitis is mild or severe before
the clinical picture fully emerges. However, these indexes have a
modest sensitivity and specificity in predicting severe acute pan-
creatitis (Gao 2015a), so it may be reasonable to administer the
treatment in all patients with acute pancreatitis and accept that
only a proportion will benefit. The proportion of patients with se-
vere pancreatitis in trials that included both mild and severe acute
pancreatitis in this review ranged between 17% and 87% (median
35%). The sample size of the trial may have to be estimated on
the basis that only the subgroup of severe acute pancreatitis will
benefit. It is unlikely that trials powered to measure differences
in mortality can be conducted in patients with acute pancreatitis.
Using outcomes such as health-related quality of life or clinically
significant complications may allow clinically meaningful trials to
be conducted in this population.
Overall completeness and applicability of
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evidence
This review included all pharmacological interventions without
restriction by the year of publication of the trials or whether the
drugs are currently licensed. The European Agency for the Evalu-
ation of Medicinal Products (EMEA) had refused marketing au-
thorisation for lexipafant in 1998 after reviewing the data submit-
ted by the company (WHO 2001). Some of the reasons for this
refusal included concerns about not having a functional indepen-
dent data monitoring committee tomonitor the results and allega-
tions of financial misconduct by the company that manufactured
lexipafant (Hampton 2000; Masood 1998).
Apart from the trials comparing antibiotics versus control, most of
the remaining trials did not clearly statewhether they includedpar-
ticipants with necrotising pancreatitis. So, it is not clear whether
this evidence is applicable to patients with acute necrotising pan-
creatitis. Most trials included a totality or at least a significant
proportion of participants with severe acute pancreatitis, so the
results of the review are applicable to patients with severe acute
pancreatitis in addition to those with mild acute pancreatitis.
This review is only about pharmacological interventions for acute
pancreatitis. We have not included any nutritional interventions
or interventions on fluid management in this review. We are un-
able to comment on whether any of the above are effective in the
treatment of acute pancreatitis based on the results of this review.
We have only reviewed treatment of acute pancreatitis and not
prophylaxis. Thus, our review is applicable only in people with
acute pancreatitis.
Quality of the evidence
We assessed the quality of the evidence formally only for short-
termmortality, probably the most important outcome for patients
with acute pancreatitis. This was low for most of the comparisons.
The reason for this is that the risk of bias was unclear or high and
because the results were imprecise. Overall, there was not much
heterogeneity within each comparison or across comparisons as
demonstrated by the I² andChi² values within comparisons. There
was no evidence of publication bias in the one comparison we
could assess for short-term mortality (antibiotics versus control).
However, there was evidence of publication bias in serious adverse
events (number).There was no indirectness in the short-termmor-
tality because of the nature of the outcome.
Although we did not undertake a formal assessment of the quality
of evidence for the remaining outcomes, the quality of evidence
is similarly low because of the issues discussed above, or possibly
even lower (i.e. very low) because of having a smaller overall sam-
ple size. In addition, there appeared to be reporting bias for the
number of both serious adverse events and all adverse events for
the comparison antibiotics versus control, although Egger’s test
was statistically significant only for the number of serious adverse
events.
Potential biases in the review process
We followed the Cochrane Handbook for Systematic Reviews of In-
terventions for the conduct of the direct comparison of the review.
Two review authors selected studies and extracted data, reducing
the errors in data collection. We used formal search strategies to
identify the trials. While the likelihood of missing trials from the
identified references was low, the review included the time frame
before the mandatory trial registration era, and it was possible that
some trials were not reported in journals because of their results.
However, one has to be pragmatic and accept that this is the best
level of evidence that is currently available.
Network meta-analysis has its advantages in combining direct and
indirect evidence (resulting in more precise evidence); however,
when providing effect estimates in the absence of direct compar-
ison and calculating the probability that an intervention is the
best treatment, one has to be wary about the transitivity assump-
tion (i.e. whether similar participants were included in the trials
across all the comparisons and thus had an equal chance of be-
ing randomised to each treatment). As mentioned above, there is
some clinical heterogeneity in the type of participants who were
included in ’antibiotics versus control’ (a high proportion of tri-
als included only participants with acute necrotising pancreatitis)
compared to other comparisons (only a very low proportion of
trials included only participants with acute necrotising pancreati-
tis). In the presence of such heterogeneity, it is not appropriate to
conduct a network meta-analysis. In addition to the differences
in the presence or absence of necrotising pancreatitis, the type of
participants included in the trials were also different in terms of
the severity of pancreatitis. We are not able to assess this fully since
the definitions used in the trials were not the current definition of
severe acute pancreatitis. So, there is likely to be heterogeneity in
the type of participants included in the trials. In addition to the
clinical heterogeneity in the type of participants included, there
were variations in the treatments used in the trials; the definitions
used for the different outcomes were not clear or were different in
different trials. We did not find any systematic differences in the
definitions used for specific comparisons; nevertheless, the lack of
uniform definitions used in the trials along with other heterogene-
ity mentioned above is another potential bias in this review.
We included a number of outcomes to assess effectiveness. Al-
though the outcomes are clinically significant, the outcomes re-
ported in different trials were different. While we found evidence
of reporting bias only in a few outcomes where it was possible to
formally assess the reporting bias by funnel plots, there is a signifi-
cant possibility that the outcomes reported in the trials were based
on the results of the outcome. Examining a lot of outcomes can
also lead to false positives because of multiplicity issues. However,
we have decreased the impact of this by focusing on the most im-
portant outcome in acute pancreatitis, that is, mortality.
We were not able to obtain full texts for two references (Hansen
1966; Perez 1980). From the title, it appears that Perez 1980 was
an abstract of an included trial (Perezdeoteyza 1980). The second
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reference was published 50 years ago and may or may not be a
randomised controlled trial (Hansen 1966), but even if it were, it
is unlikely to alter our conclusions.
Agreements and disagreements with other
studies or reviews
This is the first attempted network meta-analysis on this topic.
We agree with Villatoro 2010 and Jiang 2012 in that there is no
evidence that antibiotics decrease mortality or infected pancreatic
necrosis in patients with acute pancreatitis.
Of the systematic reviews on other interventions, we agree with
Xu 2013 that octreotide does not appear to be beneficial in major
clinical outcomes related to acute pancreatitis and with Messori
1995 that gabexate might decrease the complications without af-
fecting mortality. We disagree with Andriulli 1998 that somato-
statin and octreotide decrease mortality. The differences in con-
clusions between Andriulli 1998 and this review may be due to
the inclusion of non-randomised studies and the publication of
new trials subsequent to the conduct of the systematic review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Very low-quality evidence suggests that no pharmacological treat-
ment leads to a decrease in short-term mortality in people with
acute pancreatitis. However, the confidence intervals were wide
and consistent with an increase or decrease in short-termmortality.
We did not find consistent clinical benefits with any intervention.
Implications for research
Because of the limitations in the prognostic scoring systems and
because damage to organs may occur in acute pancreatitis before
they are clinically manifest, future trials should consider includ-
ing pancreatitis of all severity but power the study to measure the
differences in the subgroup of people with severe acute pancre-
atitis. It may be difficult to power the studies based on mortality.
Future trials in patients with acute pancreatitis should consider
other outcomes such as complications or health-related quality of
life as primary outcomes. Such trials should include health-related
quality of life, costs, and return to work as outcomes and should
follow patients for at least three months (preferably for at least one
year).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abraham 2013
Methods Randomised clinical trial
Participants Country: India
Number randomised: 135
Postrandomisation dropouts: 6 (4.4%)
Revised sample size: 129
Average age: 39 years
Women: 13 (10.1%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 62 (48.1%)
Moderate pancreatitis: not stated
Severe pancreatitis: 67 (51.9%)
Persistent organ failure: not stated
Infected pancreatitis: 0
Inclusion criteria
1. Adults (18-70 years)
2. Acute pancreatitis (mild or severe)
3. Elevated C-reactive protein
Interventions Group 1: ulinastatin (n = 30), 200,000 IU twice daily for 5 days
Group 2: placebo (n = 32)
Outcomes Mortality, adverse events, organ failure, hospital stay
Follow-up: until discharge or maximum of 22 days
Notes Reasons for postrandomisation dropouts: withdrew consent, screening error, died
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[r]andomized, double-blind, placebo-controlled,
multi-centre trial across 15 centres in India”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[r]andomized, double-blind, placebo-controlled,
multi-centre trial across 15 centres in India”
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Abraham 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Balldin 1983
Methods Randomised clinical trial
Participants Country: Sweden
Number randomised: 55
Postrandomisation dropouts: not stated
Revised sample size: 55
Average age: not stated
Women: 15 (27.3%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 55 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: acute pancreatitis undergoing peritoneal lavage
Interventions Group 1: aprotinin (n = 26), 500,000 KIU in lavage fluid every 2 h for an average of 2.
7 days
Group 2: no intervention (n = 29)
Outcomes Mortality, serious adverse events, adverse events, sepsis, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Balldin 1983 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias High risk Comment: supported by grants from the ….Bayer AG….
Other bias Low risk Comment: no other risk of bias
Bansal 2011
Methods Randomised clinical trial
Participants Country: India
Number randomised: 44
Postrandomisation dropouts: 5 (11.4%)
Revised sample size: 39
Average age: 39 years
Women: 9 (23.1%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis within 96 h of onset of symptoms
Exclusion criteria
1. Age <18 or >75 years
2. Pregnancy
3. Acute pancreatitis secondary to surgery, trauma, or malignancy
4. Psychosis (except alcoholic delirium)
5. Need for urgent therapeutic intervention (endoscopic papillotomy,
cholecystectomy, and/or choledochotomy)
6. Those enrolled in any other trial
7. People with serious diseases of the heart, brain, liver, or kidney
8. Peptic ulcer
9. Autoimmune disease
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Bansal 2011 (Continued)
Interventions Group 1: antioxidants (n = 19): vitamin A, C, E - initially parenterally and then orally
when the participant could consume orally for a total of 14 days
Group 2: no intervention (n = 20)
Outcomes Mortality, serious adverse events, adverse events, organ failure, hospital stay
Follow-up: until discharge
Notes Reasons for postrandomisation dropouts: lost to follow-up, withdrew consent
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “[t]his was a single-center, prospective randomized,
open-label with blinded endpoint assessment study of an-
tioxidant therapy”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[t]his was a single-center, prospective randomized,
open-label with blinded endpoint assessment study of an-
tioxidant therapy”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Low risk Quote: “[s]ource of support: Nil”.
Other bias Low risk Comment: no other risk of bias.
Barreda 2009
Methods Randomised clinical trial
Participants Country: Peru
Number randomised: 80
Postrandomisation dropouts: 22 (27.5%)
Revised sample size: 58
Average age: 50 years
Women: 24 (41.4%)
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 58 (100%)
Mild pancreatitis: not stated
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Barreda 2009 (Continued)
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with necrotising pancreatitis
Exclusion criteria
1. Treated in other institutions for more than 4 days
2. Received other prophylactic antibiotics
Interventions Group 1: antibiotics (n = 24): imipenem 500 mg 4 times daily for 14 days
Group 2: no intervention (n = 34)
Outcomes Mortality, serious adverse events, adverse events, infected pancreatic necrosis, require-
ment for additional intervention, length of hospital stay
Follow-up: 2 months
Notes Reasons for postrandomisation dropouts: protocol violations
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “sealed envelopes”.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
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Berling 1994
Methods Randomised clinical trial
Participants Country: multicentric, international
Number randomised: 48
Postrandomisation dropouts: not stated
Revised sample size: 48
Average age: 56 years
Women: 17 (35.4%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 48 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: participantswith acute severe pancreatitiswith circulatory insufficiency
or peritonitis
Exclusion criteria
1. People who had several surgeries before
2. Renal failure
3. Previous allergy to aprotinin or history of severe allergies
4. Age < 15 years
5. Pregnant women
Interventions Group 1: aprotinin (n = 22), 20 million KIU in 7 lavages over 30 h
Group 2: no intervention (n = 26)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, sepsis, hospital
stay, ICU stay
Follow-up: 1 month
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “[t]he Bayer . . . and was also responsible for coding
the bottles.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “prospective double-blind randomized multicenter
trial”
Blinding of outcome assessment (detection
bias)
Low risk Quote: “prospective double-blind randomized multicenter
trial”
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Berling 1994 (Continued)
All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias High risk Quote: “[t]his study was supported by grants from Bayer
AG”.
Other bias Low risk Comment: no other risk of bias
Besselink 2008
Methods Randomised clinical trial
Participants Country: Netherlands
Number randomised: 298
Postrandomisation dropouts: 2 (0.7%)
Revised sample size: 296
Average age: 60 years
Women: 122 (41.2%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with predicted severe acute pancreatitis
Interventions Group 1: probiotics (n = 152): ecologic 641 (maximum of 28 days or until development
of pancreatic necrosis or fluid collection)
Group 2: placebo (n = 144)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, organ failure,
infected pancreatic necrosis, hospital stay, ICU stay
Follow-up: 3 months
Notes Reasons for postrandomisation dropouts: did not receive drug, wrong diagnosis of acute
pancreatitis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “[r]andomisation was done with a computer-gener-
ated permuted-block sequence.”
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Besselink 2008 (Continued)
Allocation concealment (selection bias) Low risk Quote: “[b]oth the probiotic and placebo preparations were
packaged in identical, numbered sachets that were stored in
identical, numbered containers.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[a]ll doctors, nurses, research staff , and patients
involved remained unaware of the actual product adminis-
tered during the entire study period.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[a]ll doctors, nurses, research staff , and patients
involved remained unaware of the actual product adminis-
tered during the entire study period.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias High risk Quote: “HMT is an employee of Winclove Bio Industries,
Amsterdam”
Other bias Low risk Comment: no other risk of bias
Birk 1994
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 20
Postrandomisation dropouts: not stated
Revised sample size: 20
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 20 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with severe acute pancreatitis
Interventions Group 1: antioxidants (n = 10): sodium selenite 600 µg/day for 8 days
Group 2: no intervention (n = 10)
Outcomes None of the outcomes of interest were reported.
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
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Birk 1994 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias.
Bredkjaer 1988
Methods Randomised clinical trial
Participants Country: Denmark
Number randomised: 66
Postrandomisation dropouts: 9 (13.6%)
Revised sample size: 57
Average age: not stated
Women: 26 (45.6%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Exclusion criteria:
1. Chronic pancreatitis
2. Previous pseudocyst
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Bredkjaer 1988 (Continued)
3. Malignancy
4. Gastroduodenal ulcer
5. Coagulation disease
Interventions Group 1: NSAID (n = 27): indomethacin 100 mg rectal for 7 days
Group 2: placebo (n = 30)
Outcomes The outcomes reported were: hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: chronic pancreatitis, wrong diagnosis, death
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Buchler 1993
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 223
Postrandomisation dropouts: not stated
Revised sample size: 223
Average age: 50 years
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Buchler 1993 (Continued)
Women: 87 (39%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with moderate or severe acute pancreatitis
Exclusion criteria
1. Pre-existing renal insufficiency
2. Age < 18 years
3. Pregnancy
4. Psychosis
5. Previous treatment with aprotinin, glucagon, calcitonin, or somatostatin
6. Previous participation in the study
Interventions Group 1: gabexate mesilate (n = 115), 53 mg/kg/day for 7 days
Group 2: placebo (n = 108)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, sepsis, hospital
stay
Follow-up: 3 months
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “[a] randomization list was applied to get a random
sequence of GM and placebos for increasing package num-
bers.”
Allocation concealment (selection bias) Low risk Quote: “[t]he drug packages for each hospital were num-
bered sequentially and the package number was used as pa-
tient number”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “randomized, double-blind trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “randomized, double-blind trial”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
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Buchler 1993 (Continued)
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Chen 2000
Methods Randomised clinical trial
Participants Country: Taiwan
Number randomised: 52
Postrandomisation dropouts: not stated
Revised sample size: 52
Average age: 44 years
Women: 15 (28.8%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 0 (0%)
Persistent organ failure: 52 (100%)
Infected pancreatitis: not stated
Inclusion criteria: people with severe acute pancreatitis with organ failure
Interventions Group 1: gabexate mesilate (n = 26), 100 mg/h for 7 days
Group 2: placebo (n = 26)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery
Follow-up: 3 months
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
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Chen 2000 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Unclear risk Comment: this information was not available.
Chen 2002a
Methods Randomised clinical trial
Participants Country: China
Number randomised: 68
Postrandomisation dropouts: 6 (8.8%)
Revised sample size: 62
Average age: 53 years
Women: 33 (53.2%)
Acute interstitial oedematous pancreatitis: 62 (100%)
Necrotising pancreatitis: 0 (0%)
Mild pancreatitis: 62 (100%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 0 (0%)
Persistent organ failure: 0 (0%)
Infected pancreatitis: not stated
Inclusion criteria: people with mild pancreatitis
Interventions Group 1: ulinastatin (n = 48), 50,000 IU twice daily for 3 days followed by once daily
for 5 days
Group 2: gabexate mesilate (n = 14), 100 mg twice daily for 3 days followed by once
daily for 5 days
Outcomes Serious adverse events, adverse events
Follow-up: not stated (probably 2 weeks)
Notes Reasons for postrandomisation dropouts: recent or current treatment with other drugs
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
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Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Chen 2002b
Methods Randomised clinical trial
Participants Country: China
Number randomised: 26
Postrandomisation dropouts: 1 (3.8%)
Revised sample size: 25
Average age: 59 years
Women: 12 (48%)
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 15 (60%)
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 25 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with severe necrotising pancreatitis
Interventions Group 1: ulinastatin (n = 14), 100,000 IU twice daily for 3 days followed by 50,000 IU
once daily for 5-10 days
Group 2: octreotide (n = 11), 0.3 mg twice daily for 3 days followed by 0.1 mg once
daily for 5 days
Outcomes Adverse events
Follow-up: not stated (probably 2 weeks)
Notes Reasons for postrandomisation dropouts: death after starting treatment
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Choi 1989
Methods Randomised clinical trial
Participants Country: Hong Kong, China
Number randomised: 71
Postrandomisation dropouts: not stated
Revised sample size: 71
Average age: 61 years
Women: 39 (54.9%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 15 (21.1%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Exclusion criteria: people with acute pancreatitis caused by trauma, iatrogenic, or ma-
lignancy
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Interventions Group 1: somatostatin (n = 35), 250 µg bolus followed by 100 µg/h for 48 h
Group 2: no intervention (n = 36)
Outcomes Mortality, serious adverse events, adverse events
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “[r]andomisation was done by drawing sealed en-
velopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Chooklin 2007
Methods Randomised clinical trial
Participants Country: Ukraine
Number randomised: 34
Postrandomisation dropouts: not stated
Revised sample size: 34
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
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Moderate pancreatitis: not stated
Severe pancreatitis: 34 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: antioxidants (N-acetyl cysteine, unspecified dose and duration) plus corticos-
teroids (dexamethasone, unspecified dose and duration) (n = 16)
Group 2: no intervention (n = 18)
Outcomes None of the outcomes of interest were reported.
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Unclear risk Comment: no other risk of bias
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Debas 1980
Methods Randomised clinical trial
Participants Country: Canada
Number randomised: 66
Postrandomisation dropouts: not stated
Revised sample size: 66
Average age: 53 years
Women: 25 (37.9%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: glucagon (n = 33), 1 mg every 3 h (duration not stated)
Group 2: placebo (n = 33)
Outcomes Mortality, serious adverse events, adverse events, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “[o]nce we decided to enter a patient into the study,
the hospital pharmacy randomly assigned…”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[p]rospective randomized double-blind study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[p]rospective randomized double-blind study”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
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Other bias Low risk Comment: no other risk of bias
Delcenserie 1996
Methods Randomised clinical trial
Participants Country: France
Number randomised: 23
Postrandomisation dropouts: 0 (0%)
Revised sample size: 23
Average age: 43 years
Women: 2 (8.7%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: 23 (100%)
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with severe acute pancreatitis (alcoholic)
2. No previous pancreatic disease
3. No previous antibiotic treatment
4. Admission within 48 h of onset
Exclusion criteria
1. Age <18 years
2. Antibiotic allergy
3. Need to carry out ERCP
Interventions Group 1: antibiotics (n = 11), ceftazidime 2 g IV 3 times daily; amikacin 7.5 mg/kg IV
BD; and metronidazole 0.5 g IV 3 times daily for 10 days
Group 2: no intervention (n = 12)
Outcomes Mortality, serious adverse events, requirement for surgery, requirement for endoscopic
or radiological drainage, organ failure, infected pancreatic necrosis, hospital stay
Follow-up: not stated (probably until discharge)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random-number table”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Delcenserie 2001
Methods Randomised clinical trial
Participants Country: France
Number randomised: 81
Postrandomisation dropouts: not stated
Revised sample size: 81
Average age: 47 years
Women: 14 (17.3%)
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 81 (100%)
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with acute necrotising pancreatitis
2. Within 48 h of onset of symptoms
3. No previous antibiotic treatment
Interventions Group 1: antibiotics (n = 53): ciprofloxacin for 7 days or 21 days (random choice); dose
not stated
Group 2: no intervention (n = 28)
Outcomes Mortality, serious adverse events
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Dellinger 2007
Methods Randomised clinical trial
Participants Country: multicentric, international
Number randomised: 100
Postrandomisation dropouts: 0 (0%)
Revised sample size: 100
Average age: 50 years
Women: 30 (30%)
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 100 (100%)
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 100 (100%)
Persistent organ failure: not stated
Infected pancreatitis: 0
Inclusion criteria
1. People with necrotising pancreatitis
2. Within 5 days of onset of symptoms
Exclusion criteria
1. People with concurrent pancreatic or peripancreatic infection
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2. Received meropenem within previous 30 days
3. Antimicrobial therapy in previous 48 h
4. Allergy to beta-lactam antibiotics
5. Received or likely to receive probenecid
6. Pregnancy or lactation
7. Neutropenia
8. Decompensated cirrhosis
Interventions Group 1: antibiotics (n = 50): meropenem 1 g IV 3 times daily for 7-21 days (recom-
mended duration: 14 days)
Group 2: placebo (n = 50)
Outcomes Mortality, serious adverse events, adverse events, infected pancreatic necrosis
Follow-up: 1.5 months
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “[t]he treatment given to each patient was deter-
mined by a random scheme prepared by the Biostatistics
group at AstraZeneca (Wilmington, DE), using computer
software that incorporates a standard procedure for gener-
ating random numbers”
Allocation concealment (selection bias) Low risk Quote: “[t]he treatment given to each patient was deter-
mined by a random scheme prepared by the Biostatistics
group at AstraZeneca (Wilmington, DE), using computer
software that incorporates a standard procedure for gener-
ating random numbers”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[r]andomized, double-blind, placebo-controlled
study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[r]andomized, double-blind, placebo-controlled
study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias High risk Quote: “[s]upported by a grant from AstraZeneca Pharma-
ceuticals”
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Other bias Low risk Comment: no other risk of bias
Dürr 1978
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 69
Postrandomisation dropouts: not stated
Revised sample size: 69
Average age: 49 years
Women: 27 (39.1%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: glucagon (n = 33), 10 mg daily until surgery or at least 5 days in those who
did not undergo surgery
Group 2: placebo (n = 36)
Outcomes Mortality, requirement for surgery, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Ebbehøj 1985
Methods Randomised clinical trial
Participants Country: Denmark
Number randomised: 30
Postrandomisation dropouts: 0 (0%)
Revised sample size: 30
Average age: 55 years
Women: 10 (33.3%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: NSAID (n = 14), indomethacin 50 mg PR twice daily for 7 days
Group 2: placebo (n = 16)
Outcomes Hospital stay
Follow-up: not stated (probably until discharge)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[c]ontrolled double-blind trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[c]ontrolled double-blind trial”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias High risk Quote: “[i]ndomethacin (Confortid) and placebo were gen-
erously supplied by Dumex Ltd, Denmark”
Other bias Low risk Comment: no other risk of bias
Finch 1976
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 62
Postrandomisation dropouts: 4 (6.5%)
Revised sample size: 58
Average age: 36 years
Women: 24 (41.4%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Exclusion criteria
1. History of blunt trauma
2. Previous history compatible with gallstones
3. Medications: steroids, thorazine, thiaziole diuretics
4. Parathyroid disease
5. Duodenal peptic ulcer disease
6. A source of fever, independent of the pancreatitis
7. Ancillary antibiotic coverage
Interventions Group 1: antibiotics (n = 31): ampicillin 500 mg to 1 g 4 times daily for 7 days (keflin
1 g 4 times daily for 7 days in people allergic to penicillin)
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Group 2: no intervention (n = 27)
Outcomes Mortality, adverse events, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: required surgery, developed pneumonia, went
home against medical advice, malignancy
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “[o]n a randomized pre-selected basis a card was
drawn to determine in which group (antibiotic treatment or
non-antibiotic treatment) the patient was to be included.”
Comment: further details on whether the card was an open
or held by a researcher not involved in recruitment are not
available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Freise 1986
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 50
Postrandomisation dropouts: not stated
Revised sample size: 50
Average age: not stated
Women: 17 (34%)
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Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Exclusion criteria
1. Duration of symptoms more than 48 h
2. < 18 years
3. Pregnancy
4. Chronic renal insufficiency
Interventions Group 1: gabexate mesilate (n = 25), 150 mg IV 3 times daily for 7 days
Group 2: placebo (n = 25)
Outcomes Mortality, serious adverse events, adverse events, organ failure, sepsis
Follow-up: not stated
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Comment: the drug code was concealed by third party.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
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Frulloni 1994
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 116
Postrandomisation dropouts: not stated
Revised sample size: 116
Average age: 57 years
Women: 49 (42.2%)
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 116 (100%)
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with acute necrotising pancreatitis
2. Within 72 h of onset of symptoms
3. No skin sensitivity to aprotinin
Interventions Group 1: gabexate mesilate (n = 65), 3 g/day for 7 days
Group 2: aprotinin (n = 51), 1.5 million KIU/day for 7 days
Outcomes Mortality, serious adverse events, adverse events, sepsis
Follow-up: 3 months
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
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For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Garcia-Barrasa 2009
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 46
Postrandomisation dropouts: 5 (10.9%)
Revised sample size: 41
Average age: 63 years
Women: 12 (29.3%)
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 41 (100%)
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 41 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute necrotising pancreatitis
Interventions Group 1: antibiotics (n = 22): ciprofloxacin 300 mg twice daily for 10 days
Group 2: placebo (n = 19)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, organ failure,
infected pancreatic necrosis, hospital stay, ICU stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: 3 - no confirmed necrosis; 2 fulminant pan-
creatitis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[p]rospective, randomized, placebo-controlled,
double-blind study”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[p]rospective, randomized, placebo-controlled,
double-blind study”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Low risk Quote: “[t]his study was promoted by the “Bellvitge Hos-
pital” and has not received any grant or payment from the
pharmaceutical industry”
Other bias Low risk Comment: no other risk of bias
Gilsanz 1978
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 62.
Postrandomisation dropouts: not stated
Revised sample size: 62
Average age: 52 years
Women: 44 (71%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: 48 (77.4%)
Severe pancreatitis: 14 (22.6%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Exclusion criteria
1. Post-traumatic pancreatitis
2. Postsurgical pancreatitis
3. Previous pancreatitic bouts
Interventions Group 1: glucagon (n = 31), 1 mg IV every 4 h (duration - not stated)
Group 2: oxyphenonium gromomethylate (n = 31), 1 mg IV every 4 h (duration - not
stated)
Outcomes Mortality, adverse events, requirement for surgery
Follow-up: 24 months
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “sealed envelope”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Gjørup 1992
Methods Randomised clinical trial
Participants Country: Denmark
Number randomised: 63
Postrandomisation dropouts: not stated
Revised sample size: 63
Average age: 49 years
Women: 22 (34.9%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with first attack of acute pancreatitis
2. Within 24 h of onset of symptoms
Interventions Group 1: somatostatin (n = 33), 250 µg/h for 3 days
Group 2: placebo (n = 30)
80Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gjørup 1992 (Continued)
Outcomes Mortality, serious adverse events, adverse events, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “by selecting sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blinded trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blinded trial”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Goebell 1979
Methods Randomised clinical trial
Participants Country: multicentric, international
Number randomised: 94
Postrandomisation dropouts: not stated
Revised sample size: 94
Average age: 55 years
Women: 37 (39.4%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 29 (30.9%)
Moderate pancreatitis: 49 (52.1%)
Severe pancreatitis: 16 (17%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
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Inclusion criteria: people with acute pancreatitis
Exclusion criteria
1. Serum creatinine levels above 5 mg/100 ml
2. Post-operative acute pancreatitis
Interventions Group 1: calcitonin (n = 50), synthetic salmon calcitonin 20 µg 3 times daily for 6 days
Group 2: placebo (n = 44)
Outcomes Mortality, adverse events, requirement for surgery, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Goebell 1988
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 162
Postrandomisation dropouts: 11 (6.8%)
Revised sample size: 151
Average age: not stated
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Goebell 1988 (Continued)
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with moderate or severe pancreatitis
Interventions Group 1: gabexate mesilate (n = 76), 150 mg every 2 h followed by 0.5 mg/kg/h for 7
days
Group 2: placebo (n = 75)
Outcomes Mortality, serious adverse events, requirement for surgery
Follow-up: 3 months
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
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Grupo Español 1996
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 70
Postrandomisation dropouts: 9 (12.9%)
Revised sample size: 61
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 61 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with severe acute pancreatitis
Interventions Group 1: somatostatin (n = 30), 250 µg/h for 5 days
Group 2: placebo (n = 31)
Outcomes Mortality
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: did not complete the study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[r]andomized, double-blind, placebo-controlled,
multi-centre trial across 15 centres in India”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[r]andomized, double-blind, placebo-controlled,
multi-centre trial across 15 centres in India”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
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Grupo Español 1996 (Continued)
Other bias Low risk Comment: no other risk of bias
Guo 2015
Methods Randomised clinical trial
Participants Country: China
Number randomised: 120
Postrandomisation dropouts: not stated
Revised sample size: 120
Average age: 46 years
Women: 58 (48.3%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 120 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with severe acute pancreatitis
Interventions Group 1: octerotide plus ulinastatin (n = 60), 0.1 mg SC 3 times daily for 7-14 days
Group 2: octreotide (n = 60), 10 million units IV continuous for 7-14 days
Outcomes Mortality, serious adverse events, adverse events, length of hospital stay
Follow-up: not stated (probably until discharge)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
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Guo 2015 (Continued)
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Hansky 1969
Methods Randomised clinical trial
Participants Country: Australia
Number randomised: 24
Postrandomisation dropouts: not stated
Revised sample size: 24
Average age: not stated
Women: 7 (29.2%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 3 (12.5%)
Moderate pancreatitis: 15 (62.5%)
Severe pancreatitis: 6 (25%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: iniprol (n = 15), single IV dose of 1 million units, followed by 500,000 units
IV 4 times daily for 4-8 days depending upon clinical course
Group 2: no intervention (n = 9)
Outcomes Mortality, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “[t]he drugwas not evaluated in a double-blindman-
ner”
86Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hansky 1969 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “[t]he drugwas not evaluated in a double-blindman-
ner”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias High risk Quote: “I am grateful to Difrex (Australia) laboratories for
supplying . . .”
Other bias Low risk Comment: no other risk of bias
Hejtmankova 2003
Methods Randomised clinical trial
Participants Country: not stated
Number randomised: 41
Postrandomisation dropouts: not stated
Revised sample size: 41
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 41 (100%).
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with severe acute pancreatitis
Interventions Group 1: antibiotics (n = 20): meropenem 500 mg 3 times daily for 10 days
Group 2: no intervention (n = 21)
Outcomes Mortality, adverse events, requirement for surgery, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
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Hejtmankova 2003 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Imrie 1978
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 161
Postrandomisation dropouts: not stated
Revised sample size: 161
Average age: 51 years
Women: 92 (57.1%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 60 (37.3%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Exclusion criteria
1. Post-traumatic pancreatitis
2. Postsurgical pancreatitis
3. Previous pancreatitic bouts
Interventions Group 1: aprotinin (n = 80), 500 000 KIU bolus followed by 200 000 KIU 4 times daily
for 5 days
Group 2: placebo (n = 81)
Outcomes Mortality, serious adverse events, adverse events
Follow-up: not stated (probably until discharge)
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Imrie 1978 (Continued)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “sealed envelope”.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind trial”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind trial”.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias High risk Quote: “[i]n addition to providing both Trasylol and
placebo, Bayer Pharmaceuticals contributed the financial
support of a research assistant”
Other bias Low risk Comment: no other risk of bias
Imrie 1980
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 50
Postrandomisation dropouts: not stated
Revised sample size: 50
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 29 (58%)
Moderate pancreatitis: not stated
Severe pancreatitis: 21 (42%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
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Imrie 1980 (Continued)
Interventions Group 1: aprotinin (n = 25), 2 million units KIU bolus followed by 400,000 KIU 4 h
later
Group 2: placebo (n = 25)
Outcomes Mortality
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind trial”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Isenmann 2004
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 119
Postrandomisation dropouts: 5 (4.2%)
Revised sample size: 114
Average age: 47 years
Women: 27 (23.7%)
Acute interstitial oedematous pancreatitis: 38 (33.3%)
Necrotising pancreatitis: 76 (66.7%)
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Isenmann 2004 (Continued)
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with predicted severe pancreatitis
Interventions Group 1: antibiotics (n = 58): metronidazole 500 mg twice daily and ciprofloxacin 400
mg twice daily (duration not reported)
Group 2: placebo (n = 56)
Outcomes Serious adverse events, adverse events, requirement for surgery, infected pancreatic necro-
sis, hospital stay, ICU stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: lost to follow-up, withdrawn from study prior
to medication
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “[s]tudy medication for each patient (verum or
placebo) was packed in identical vials and labelled with con-
secutive patient numbers according to the randomization
sequence”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind trial”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind trial”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias High risk Quote: “[s]upported by study medication provided from
Bayer Vital and Ratiopharm as well as a financial grant from
Bayer Vital”
Other bias Low risk Comment: no other risk of bias
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Johnson 2001
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 291
Postrandomisation dropouts: 1 (0.3%)
Revised sample size: 290
Average age: 63 years
Women: 124 (42.8%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with predicted severe acute pancreatitis
2. Premenopausal women in whom pregnancy could not be excluded
3. Pancreatitis secondary to trauma, surgery, malignancy, or ERCP
4. Person unsuitable for ventilation
5. Other investigational agents in the last 3 years
6. People receiving oral anti-coagulant therapy
7. People who had received lexipafant previously
Exclusion criteria: age < 18 or > 80 years
Interventions Group 1: lexipafant (n = 151), 100 mg daily for 7 days
Group 2: placebo (n = 139)
Outcomes Mortality, serious adverse events, adverse events, organ failure, sepsis, hospital stay, ICU
stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: withdrew from the study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind, placebo controlled, randomised, par-
allel group”
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Johnson 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind, placebo controlled, randomised, par-
allel group”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias High risk Quote: “[t]his study was funded by British Biotech Pharma-
ceuticals Ltd, Oxford, UK”
Other bias Low risk Comment: no other risk of bias
Kalima 1980
Methods Randomised clinical trial
Participants Country: Finland
Number randomised: 80
Postrandomisation dropouts: 9 (11.3%)
Revised sample size: 71
Average age: 46 years
Women: 28 (39.4%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: glucagon (n = 32), 7.5 mg twice daily for 4-5 days
Group 2: placebo (n = 29)
Outcomes Mortality, serious adverse events, adverse events
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: underwent surgery, wrong diagnosis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
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Kalima 1980 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although placebowas used, therewas nomention
of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although placebowas used, therewas nomention
of blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported
For profit-bias Unclear risk Comment: this information was not available
Other bias Low risk Comment: no other risk of bias
Kingsnorth 1995
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 83
Postrandomisation dropouts: not stated
Revised sample size: 83
Average age: 59 years
Women: 41 (49.4%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 54 (65.1%)
Moderate pancreatitis: not stated
Severe pancreatitis: 29 (34.9%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis within 48 h of onset of symptoms
Exclusion criteria
1. Age < 18 years
2. Unsterilised premenopausal women
3. Concomitant anticoagulant therapy
Interventions Group 1: lexipafant (n = 42), 15 mg 4 times daily for 3 days
Group 2: placebo (n = 41)
Outcomes Mortality, adverse events
Follow-up: 1 week
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Kingsnorth 1995 (Continued)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias High risk Quote: “S.W.G. was supported by British Biotech, Oxford,
UK”
Other bias Low risk Comment: no other risk of bias
Kirsch 1978
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 150
Postrandomisation dropouts: not stated
Revised sample size: 150
Average age: 53 years
Women: 78 (52%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 35 (23.3%)
Moderate pancreatitis: 61 (40.7%)
Severe pancreatitis: 54 (36%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
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Kirsch 1978 (Continued)
Interventions Group 1: glucagon (n = 75), 10 mg/day for 4 days
Group 2: atropine (n = 75), 4 days (dose not stated)
Outcomes Mortality, serious adverse events, adverse events
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Kronborg 1980
Methods Randomised clinical trial
Participants Country: Denmark
Number randomised: 22
Postrandomisation dropouts: not stated
Revised sample size: 22
Average age: not stated
Women: 4 (18.2%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: 11 (50%)
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
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Kronborg 1980 (Continued)
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with acute pancreatitis (first attack only)
2. Deteriorating clinical condition or in shock
3. No suspected biliary disease
Interventions Group 1: glucagon (n = 10), 1 mg IV followed by 6 mg/day for 3 days
Group 2: placebo (n = 12)
Outcomes Mortality, adverse events
Follow-up: until discharge
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: although authors stated they did not exclude any
participants for wrong diagnosis, it was not clear whether
they excluded participants for other reasons
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
97Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Llukacaj 2012
Methods Randomised clinical trial
Participants Country: Albania
Number randomised: 80
Postrandomisation dropouts: not stated
Revised sample size: 80
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 80 (100%)
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: 0
Inclusion criteria: people with non-infected necrotising pancreatitis
Interventions Group 1: antibiotics (n = 40): imipenem 750 mg IV twice daily for 7 days
Group 2: placebo (n = 40)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, infected pan-
creatic necrosis
Follow-up: 1 month
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: although authors stated they did not exclude any
participants for wrong diagnosis, it was not clear whether
they excluded participants for other reasons
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
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Llukacaj 2012 (Continued)
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Luengo 1994
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 100
Postrandomisation dropouts: not stated
Revised sample size: 100
Average age: 55 years
Women: 39 (39%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 78 (78%)
Moderate pancreatitis: not stated
Severe pancreatitis: 22 (22%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Exclusion criteria
1. Pancreatitis following trauma, surgery, endoscopy, malignancy, drugs, or
pregnancy
2. Allergy to one of the antibiotics
3. < 18 years of age
4. Postoperative pancreatitis
5. Infected pancreatic necrosis
Interventions Group 1: somatostatin (n = 50), 250 µg/h for 48 h following a 250 µg bolus
Group 2: no intervention (n = 50)
Outcomes Mortality, requirement for surgery, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “[p]atients were randomly divided by means of the
sealed-envelope method and grouped according to therapy”
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Luengo 1994 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: although authors stated they did not exclude any
participants for wrong diagnosis, it was not clear whether
they excluded participants for other reasons
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Luiten 1995
Methods Randomised clinical trial
Participants Country: the Netherlands
Number randomised: 109
Postrandomisation dropouts: 7 (6.4%)
Revised sample size: 102
Average age: 55 years
Women: 42 (41.2%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 102 (100%)
Persistent organ failure: not stated
Infected pancreatitis: 0
Inclusion criteria: people with severe pancreatitis
Interventions Group 1: antibiotics (n = 50): selective digestive decontamination using colistin 200 mg,
amphotericin 500 mg, and norfloxacin 50 mg 4 times daily orally and as rectal enema
along with short course of cefotaxime 500 mg IV 3 times daily until gram-negative
bacteria were eliminated from oral cavity and rectum. Total duration of treatment: until
patient was extubated and taking oral feeds
Group 2: no intervention (n = 52)
Outcomes Mortality, adverse events, requirement for surgery, hospital stay
Follow-up: until discharge
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Luiten 1995 (Continued)
Notes Reasons for postrandomisation dropouts: perioperatively proven infected pancreatic
necrosis or wrong clinical diagnosis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “[a] 24-hour randomization service was available to
randomize patients with stratification per center”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Marek 1999
Methods Randomised clinical trial
Participants Country: Poland
Number randomised: 73
Postrandomisation dropouts: 0 (0%)
Revised sample size: 73
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 56 (76.7%)
Moderate pancreatitis: not stated
Severe pancreatitis: 17 (23.3%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
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Marek 1999 (Continued)
Interventions Group 1: antioxidants (n = 35): vitamin C 500 mg IV 3 times daily for 5 days
Group 2: placebo (n = 38)
Outcomes None of the outcomes of interest were reported.
Follow-up: not stated (probably until discharge)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although a placebo was used, it was not clear
blinding was performed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebo was used, it was not clear
blinding was performed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Martinez 1984
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 31
Postrandomisation dropouts: 0 (0%)
Revised sample size: 31
Average age: 48 years
Women: 6 (19.4%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 0 (0%)
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Martinez 1984 (Continued)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 31 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with severe acute pancreatitis
Interventions Group 1: calcitonin (n = 14), synthetic salmon calcitonin 100 MRC units (equivalent
to 100 IU) IV 3 times daily for 5 days or more
Group 2: placebo (n = 17)
Outcomes Mortality, requirement for surgery, hospital stay
Follow-up: not stated (probably until discharge)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: although some participants were excluded from
hospital stay, they were included for mortality and require-
ment of surgical intervention
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
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McKay 1997a
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 58
Postrandomisation dropouts: 0 (0%)
Revised sample size: 58
Average age: 69 years
Women: 32 (55.2%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with moderate or severe pancreatitis
Exclusion criteria
1. < 18 years of age
2. Women in whom pregnancy could not be excluded
3. People with acute pancreatitis following pregnancy
Interventions Group 1: octreotide (n = 28), 1 mg/day IV for 5 days
Group 2: placebo (n = 30)
Outcomes Mortality, serious adverse events, adverse events, organ failure, infected pancreatic necro-
sis, hospital stay
Follow-up: not stated (probably until discharge)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “[r]andomization was by the use of sequentially
numbered treatment packs containing either octreotide or
placebo as determined by a computer-generated random
code.”
Allocation concealment (selection bias) Low risk Quote: “[r]andomization was by the use of sequentially
numbered treatment packs containing either octreotide or
placebo as determined by a computer-generated random
code.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[p]atients, investigators, and medical staff were
blinded regarding the nature of the trial infusion”
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McKay 1997a (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[p]atients, investigators, and medical staff were
blinded regarding the nature of the trial infusion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
McKay 1997b
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 51
Postrandomisation dropouts: 1 (2%)
Revised sample size: 50
Average age: 65 years
Women: 21 (42%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with predicted severe pancreatitis
Exclusion criteria
1. Pregnancy
2. ERCP induced pancreatitis
3. Oral anticoagulant use
4. Other trial drugs within 3 months of study
5. Previous use of lexipafant
Interventions Group 1: lexipafant (n = 26), 4 mg bolus IV followed by 4 mg/h by continuous infusion
for 5-7 days
Group 2: placebo (n = 24)
Outcomes Mortality, organ failure, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: incorrect diagnosis
Risk of bias Risk of bias
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McKay 1997b (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “[p]acks were numbered sequentially and prepared
in advance by British Biotech (Oxford, UK)”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[i]nvestigators and patients were unaware of the
nature of the trial infusion.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[i]nvestigators and patients were unaware of the
nature of the trial infusion.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias High risk Quote: “[t]his study was supported by a grant from British
Biotech”
Other bias Low risk Comment: no other risk of bias
Moreau 1986
Methods Randomised clinical trial
Participants Country: France
Number randomised: 87
Postrandomisation dropouts: 3 (3.4%)
Revised sample size: 84
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Exclusion criteria
1. Acute pancreatitis following surgery or ERCP
2. Duration of symptoms for more than 48 h
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Moreau 1986 (Continued)
Interventions Group 1: somatostatin (n = 44), 400 µg for first 3 days, tapered and stopped on 4th day
Group 2: placebo (n = 41)
Outcomes None of the outcomes of interest were reported.
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias High risk Quote: “Sonafi, kindly donated”
Other bias Low risk Comment: no other risk of bias
MRC Multicentre Trial 1977
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 264
Postrandomisation dropouts: 7 (2.7%)
Revised sample size: 257
Average age: not stated
Women: 153 (59.5%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
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MRC Multicentre Trial 1977 (Continued)
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: aprotinin (n = 66), 500,000 IU IV followed by 300,000 units every 6 h for 5
days
Group 2: glucagon (n = 68), 2 mg IV followed by 2 mg every 6 h for 5 days
Group 3: placebo (n = 123)
Outcomes Mortality, requirement for surgery
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: initial amylase was too low
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[r]andomized, double-blind, placebo-controlled,
multi-centre trial across 15 centres in India”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[r]andomized, double-blind, placebo-controlled,
multi-centre trial across 15 centres in India”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias High risk Comment: the drugs and placebowere supplied by the phar-
maceutical company
Other bias Low risk Comment: no other risk of bias
108Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nordback 2001
Methods Randomised clinical trial
Participants Country: Finland
Number randomised: 90
Postrandomisation dropouts: 32 (35.6%)
Revised sample size: 58
Average age: 46 years
Women: 7 (12.1%)
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 58 (100%)
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: 0 (0%)
Infected pancreatitis: not stated
Inclusion criteria: people with acute necrotising pancreatitis
Exclusion criteria
1. People who had already been started on antibiotics
2. Those admitted to intensive care unit with multiorgan failure
3. Suspected to have a reaction to study drugs
Interventions Group 1: antibiotics (n = 25): imipenem 1 g plus cilastatin IV 3 times daily; duration
not stated
Group 2: placebo (n = 33)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, ICU stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: older than 70 years of age, did not begin
antibiotic as scheduled, criteria for pancreatic necrosis not fulfilled
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although a placebo was used, it was not clear
blinding was performed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebo was used, it was not clear
blinding was performed
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Nordback 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Ohair 1993
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 180
Postrandomisation dropouts: not stated
Revised sample size: 180
Average age: 37 years
Women: 41 (22.8%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: octreotide (n = 90), 100 µg 3 times daily SC for duration of hospital stay
Group 2: placebo (n = 90)
Outcomes Requirement for surgery, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although a placebo was used, it was not clear
blinding was performed
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Ohair 1993 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebo was used, it was not clear
blinding was performed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Olah 2007
Methods Randomised clinical trial
Participants Country: Hungary
Number randomised: 83
Postrandomisation dropouts: 21 (25.3%)
Revised sample size: 62
Average age: 47 years
Women: 10 (16.1%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 62 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with severe acute pancreatitis
Exclusion criteria: people with acute exacerbation of chronic pancreatitis
Interventions Group 1: probiotics (n = 33): Synbiotic 2000 once daily for at least 1 week
Group 2: no intervention (n = 29)
Both groups received prebiotics (an intervention not of interest for this review)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, organ failure,
sepsis, infected pancreatic necrosis, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: because they were not severe acute pancreatitis
after 48 h, did not tolerate jejunal feeding, participant removed the feeding tube
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Olah 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Paran 1995
Methods Randomised clinical trial
Participants Country: Israel
Number randomised: 51
Postrandomisation dropouts: 13 (25.5%)
Revised sample size: 38
Average age: 61 years
Women: 18 (47.4%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: octreotide (n = 19), 01. mg SC 3 times daily for 14 days
Group 2: no intervention (n = 19)
Outcomes Mortality, serious adverse events, adverse events, sepsis, hospital stay
Follow-up: not stated (probably until discharge)
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Paran 1995 (Continued)
Notes Reasons for postrandomisation dropouts: failure to meet inclusion criteria, incomplete
data, incorrect diagnosis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “[a]s placebo vials were not available to us, the study
was double blinded”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “[a]s placebo vials were not available to us, the study
was double blinded”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Pederzoli 1993a
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 74
Postrandomisation dropouts: not stated
Revised sample size: 74
Average age: 52 years
Women: 30 (40.5%)
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 74 (100%)
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
113Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pederzoli 1993a (Continued)
Interventions Group 1: antibiotics (n = 41): imipenem 0.5 g every 8 h for 2 weeks
Group 2: no intervention (n = 33)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, organ failure,
infected pancreatic necrosis
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “casual numbers table”.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Pederzoli 1993b
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 199
Postrandomisation dropouts: 17 (8.5%)
Revised sample size: 182
Average age: 58 years
Women: 78 (42.9%)
Acute interstitial oedematous pancreatitis: 66 (36.3%)
Necrotising pancreatitis: 116 (63.7%)
Mild pancreatitis: 0 (0%)
114Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pederzoli 1993b (Continued)
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: gabexate mesilate (n = 91), 3 g/day for 7 days
Group 2: aprotinin (n = 91), 1,500,000 KIU/day for 7 days
Outcomes Mortality, adverse events, requirement for surgery
Follow-up: 3 months for mortality; all other complications - 2 weeks
Notes Reasons for postrandomisation dropouts: major protocol violations
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Perezdeoteyza 1980
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 40
Postrandomisation dropouts: not stated
Revised sample size: 40
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Perezdeoteyza 1980 (Continued)
Average age: 56 years
Women: 24 (60%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Exclusion criteria
1. Post-traumatic pancreatitis
2. Postsurgical pancreatitis
3. Previous pancreatitic bouts
Interventions Group 1: cimetidine (n = 20), 1200 mg IV for 4-5 days followed by 1000 mg oral for
10 days
Group 2: placebo (n = 20)
Outcomes Mortality
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “[r]andomisation code was held by pharmacy”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
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Perezdeoteyza 1980 (Continued)
Other bias Low risk Comment: no other risk of bias
Pettila 2010
Methods Randomised clinical trial
Participants Country: Finland
Number randomised: 32
Postrandomisation dropouts: 0 (0%)
Revised sample size: 32
Average age: 45 years
Women: 3 (9.4%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 32 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with acute severe pancreatitis
2. Admitted to hospital < 4 days of onset of pain
3. At least one organ dysfunction
4. < 48 h from the first organ dysfunction
Interventions Group 1: activated protein C (n = 16): drotrecogin alpha activated 24 µg/kg/h for 96 h
Group 2: placebo (n = 16)
Outcomes Mortality, hospital stay
Follow-up: not stated (probably 2 weeks)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “[t]he code for studymedicationwas concealed using
sealed envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
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Pettila 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias High risk Quote: “Eli Lilly in part provided the study drug for this
investigator-initiated study”
Other bias Low risk Comment: no other risk of bias
Plaudis 2010
Methods Randomised clinical trial
Participants Country: Latvia
Number randomised: 90
Postrandomisation dropouts: not stated
Revised sample size: 58
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 58 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute severe pancreatitis
Interventions Group 1: probiotics (n = 30): 4 bioactive lactic acid bacteria
Group 2: no intervention (n = 28)
Both groups received prebiotics (an intervention not of interest for this review)
Outcomes None of the outcomes of interest were reported.
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Plaudis 2010 (Continued)
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Poropat 2015
Methods Randomised clinical trial
Participants Country: Croatia
Number randomised: 43
Postrandomisation dropouts: 0 (0%)
Revised sample size: 43
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with acute pancreatitis
2. APACHE II score ≥ 8
Interventions Group 1: antibiotics (n = 23): imipenem 500 mg IV 3 times daily for 10 days
Group 2: no intervention (n = 24)
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Poropat 2015 (Continued)
Outcomes Mortality, serious adverse events, adverse events, infected pancreatic necrosis, and organ
failure
Follow-up: not stated (probably until discharge)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Rokke 2007
Methods Randomised clinical trial
Participants Country: Norway
Number randomised: 73
Postrandomisation dropouts: 0 (0%)
Revised sample size: 73
Average age: 58 years
Women: 24 (32.9%)
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 73 (100%)
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 73 (100%)
Persistent organ failure: not stated
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Rokke 2007 (Continued)
Infected pancreatitis: not stated
Inclusion criteria
1. People with acute necrotising pancreatitis
2. Duration of symptoms < 72 h
Exclusion criteria
1. Age < 18 years
2. Ongoing antibiotic treatment
3. Previous episodes of acute pancreatitis
4. Post-ERCP pancreatitis
5. Concomitant bacterial infection
6. Allergy to imipenem
7. Pregnancy
Interventions Group 1: antibiotics (n = 36): imipenem 0.5 g every 8 h for 5-7 days
Group 2: no intervention (n = 37)
Outcomes Mortality, adverse events, requirement for surgery, organ failure, infected pancreatic
necrosis, hospital stay, ICU stay
Follow-up: not stated (probably 2 weeks)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “[t]he study was unblinded to all attending physi-
cians”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “[t]he study was unblinded to all attending physi-
cians”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias High risk Quote: “[w]e are grateful to the pharmaceutical company
MSD for economic support in organizing meetings for the
Steering Committee”
Other bias Low risk Comment: no other risk of bias
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Sainio 1995
Methods Randomised clinical trial
Participants Country: Finland
Number randomised: 60
Postrandomisation dropouts: 0 (0%)
Revised sample size: 60
Average age: 41 years
Women: 7 (11.7%)
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 60 (100%)
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with alcohol-induced necrotising pancreatitis
Exclusion criteria
1. Treatment elsewhere for more than 48 h of onset of symptoms
2. Continuing antimicrobial treatment
3. Previous severe episode of pancreatitis
4. Aetiology other than alcohol and no history of alcohol intake prior to admission
Interventions Group 1: antibiotics (n = 30): cefuroxime 1.5 g IV 3 times daily continued until clinical
recovery and fall to normal level of C-reactive protein, after which oral administration
of 250 mg twice daily until 14 days
Group 2: no intervention (n = 30)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, sepsis, hospital
stay, ICU stay
Follow-up: not stated (probably until discharge)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Sateesh 2009
Methods Randomised clinical trial
Participants Country: India
Number randomised: 56
Postrandomisation dropouts: 3 (5.4%)
Revised sample size: 53
Average age: 39 years
Women: 33 (62.3%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 10 (18.9%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with acute pancreatitis
2. < 72 h of onset of symptoms
Exclusion criteria
1. Acute exacerbation of chronic pancreatitis
2. Prior antioxidant therapy
3. Delayed presentation to the ward
4. Severe comorbidity
5. Pregnancy
Interventions Group 1: antioxidants (n = 23): vitamin C 500 mg once daily, N-acteyl cysteine 200 mg
3 times daily, Antoxyl Forte 1 capsule 3 times daily); duration not stated
Group 2: no intervention (n = 30)
Outcomes Mortality, adverse events, organ failure, hospital stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: did not receive allocated treatment, discontin-
ued medication
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “according to a computer generated randomnumber
table”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “[t]he study was unblinded”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “[t]he study was unblinded”.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Sharma 2011
Methods Randomised clinical trial
Participants Country: India
Number randomised: 50
Postrandomisation dropouts: 0 (0%)
Revised sample size: 50
Average age: 41 years
Women: 27 (54%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 28 (56%)
Moderate pancreatitis: not stated
Severe pancreatitis: 22 (44%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with acute pancreatitis
2. < 72 h of onset of symptoms or had not been taking anything orally for up to 5
days
Exclusion criteria
1. Malignancy
2. Infection or sepsis related to source other than pancreatic bed
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3. Intra-oeprative diagnosis of acute pancreatitis
4. Immunodeficiency
5. Earlier use of probiotics or prebiotics
6. Pregnant women
Interventions Group 1: probiotics (n = 24): 2.5 billion bacteria per sachet and 25 mg of fructo-
oligosaccharide every day for 7 days
Group 2: placebo (n = 26)
Outcomes Hospital stay, ICU stay
Follow-up: not stated (probably until discharge)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “[t]he method of allocation concealment was se-
quentially numbered sealed opaque envelopes technique”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias High risk Quote: “[t]he authors disclose that Alkem provided the pro-
biotics and placebo on complimentary basis.”
Other bias Low risk Comment: no other risk of bias
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Sillero 1981
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 60
Postrandomisation dropouts: not stated
Revised sample size: 60
Average age: 52 years
Women: 36 (60%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: cimetidine (n = 30): 1200 mg IV for 4 days followed by 1000 mg oral for 10
days
Group 2: placebo (n = 30)
Outcomes Serious adverse events, adverse events, requirement for surgery
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “table of random numbers”
Allocation concealment (selection bias) Low risk Quote: “sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: although a placebo was used, it was not clear
blinding was performed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: although a placebo was used, it was not clear
blinding was performed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
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Sillero 1981 (Continued)
For profit-bias Unclear risk Comment: this information was not available
Other bias Low risk Comment: no other risk of bias
Siriwardena 2007
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 43
Postrandomisation dropouts: 0 (0%)
Revised sample size: 43
Average age: 67 years
Women: 28 (65.1%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with predicted severe pancreatitis
2. Within 72 h of admission to hospital
3. 16 years of older
4. Not enrolled in other trials
5. No history of allergy to intravenous antioxidant therapy
6. Enrolled in the trial with a previous episode of pancreatitis
Interventions Group 1: antioxidants (n = 22) selenium started with 1000 mg and then tapered to 200
mg/day for a total duration of 7 days; vitamin C started with 2000 mg and then tapered
to 1000 mg/day for a total duration of 7 days; N-acetyl cysteine started with 300 mg
and then tapered to 75 mg/day for a total duration of 7 days
Group 2: placebo (n = 21)
Outcomes Mortality, serious adverse events, organ failure, hospital stay, ICU stay
Follow-up: until discharge
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random number generation”
Comment: probably computer-generated
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Siriwardena 2007 (Continued)
Allocation concealment (selection bias) Low risk Quote: “[t]he pharmacy administered the randomisation
and storage of therapeutics for all participating centres”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Unclear risk Comment: mortality and adverse events were reported.
For profit-bias High risk Quote: “the costs of antioxidants and placebo were met by
Pharmanord UK”
Other bias Low risk Comment: no other risk of bias
Spicak 2002
Methods Randomised clinical trial
Participants Country: Czech Republic
Number randomised: 63
Postrandomisation dropouts: not stated
Revised sample size: 63
Average age: 55 years
Women: 25 (39.7%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 63 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with severe acute pancreatitis
2. Within 4 days of onset of symptoms
Exclusion criteria
1. < 18 years of age
2. More than 48 h from onset of symptoms
3. Iatrogenic pancreatitis
4. Infectious complications
5. Already receiving antibiotics for previous 2 weeks
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Spicak 2002 (Continued)
Interventions Group 1: antibiotics (n = 33): metronidazole 500 mg 3 times daily and ciprofloxacin
200 mg twice daily for 2 weeks
Group 2: no intervention (n = 30)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, infected pan-
creatic necrosis, hospital stay, ICU stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Spicak 2003
Methods Randomised clinical trial
Participants Country: Czech Republic
Number randomised: 41
Postrandomisation dropouts: not stated
Revised sample size: 41
Average age: 58 years
Women: 10 (24.4%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
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Mild pancreatitis: 0 (0%).
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 41 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Exclusion criteria
1. < 18 years of age
2. More than 48 h from onset of symptoms
3. Pancreatitis following surgery or ERCP
4. Infectious complications
5. Already receiving antibiotics for previous 2 weeks
Interventions Group 1: antibiotics (n = 20): meropenem 0.5 mg 3 times daily for 10 days
Group 2: no intervention (n = 21)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, infected pan-
creatic necrosis, hospital stay
Follow-up: not stated
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This information was not available.
Allocation concealment (selection bias) Unclear risk This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk This information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk This information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk This information was not available.
Other bias Low risk Comment: no other risk of bias
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Storck 1968
Methods Randomised clinical trial
Participants Country: Sweden
Number randomised: 43
Postrandomisation dropouts: not stated
Revised sample size: 43
Average age: 59 years
Women: 28 (65.1%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: aprotinin (n = 21), first half of the trial - 50,000 to 100,000 units per day and
then dose doubled for an average of 12 days
Group 2: placebo (n = 22)
Outcomes Mortality
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “[s]ealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
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Storck 1968 (Continued)
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Trapnell 1974
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 105
Postrandomisation dropouts: not stated
Revised sample size: 105
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with first attack of acute pancreatitis
2. Aetiology: gallstones or idiopathic pancreatitis
Interventions Group 1: aprotinin (n = 53), 200,000 units IV stat followed by 200,000 units IV 4 times
daily for 5 days
Group 2: placebo (n = 52)
Outcomes Mortality
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “random numbers”
Allocation concealment (selection bias) Low risk Quote: “[t]he envelopes of allotment were placed in a rec-
ognized position in each hospital together with the packs of
Trasylol”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
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Trapnell 1974 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias High risk Quote: “[w]e are particularly indebted to Dr Brian Allen of
Bayer Pharmaceuticals for the supplies of Trasylol and the
preparation of the A and B ampoules”
Other bias Unclear risk Comment: no other risk of bias
Tykka 1985
Methods Randomised clinical trial
Participants Country: Finland
Number randomised: 64
Postrandomisation dropouts: 0 (0%)
Revised sample size: 64
Average age: 51 years
Women: 23 (35.9%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Exclusion criteria
1. Post-traumatic pancreatitis
2. Postsurgical pancreatitis
Interventions Group 1: EDTA (n = 33), dose and duration not reported
Group 2: placebo (n = 31)
Follow-up: not stated (probably until discharge)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery
Notes -
Risk of bias Risk of bias
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Tykka 1985 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias High risk Quote: “[w]e are also grateful for the drugs and support from
Sinclair Pharmaceutical Limited, England.”
Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Uhl 1999
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 302
Postrandomisation dropouts: 0 (0%)
Revised sample size: 302
Average age: 50 years
Women: 104 (34.4%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: 108 (35.8%)
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with moderate to severe acute pancreatitis
2. Duration of symptoms < 4 days
Exclusion criteria
1. Known chronic renal failure
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2. < 18 years of age
3. Pregnancy
4. Psychosis (except alcoholic delirium)
5. Previous treatment with aprotinin, glucagon, calcitonin, pirenzepine, atropine, or
native somatostatin
6. Previous included in the study (i.e. relapse after previous inclusion in the study)
Interventions Group 1: octreotide (n = 199), 100 µg or 200 µg (randomised) SC 3 times daily for 7
days
Group 2: placebo (n = 103)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, sepsis, hospital
stay
Follow-up: not stated (probably until discharge)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Low risk Quote: “[t]he packages were used sequentially as the patients
were enrolled in the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias High risk Quote: “[t]he preparation, randomisation, and delivery of
the study medication, as well as the monitoring of the study
centres by checking the information in the CRFs, were car-
ried out by Novartis (formerly Sandoz), Nuremberg (Ger-
many)”
Other bias Low risk Comment: no other risk of bias
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Usadel 1985
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 77
Postrandomisation dropouts: not stated
Revised sample size: 77
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: somatostain (n = 36), 250 ng/h for 7 days
Group 2: placebo (n = 41)
Outcomes Mortality
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
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Other bias Low risk Comment: no other risk of bias
Valderrama 1992
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 105
Postrandomisation dropouts: 5 (4.8%)
Revised sample size: 100
Average age: 57 years
Women: 53 (53%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
Interventions Group 1: gabexate mesilate (n = 51), 12 mg/kg/day continuous IV for 4-12 days based
on disappearance of abdominal pain or requirement for surgery
Group 2: placebo (n = 49)
Outcomes Mortality, serious adverse events, adverse events, sepsis
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: protocol violations
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer generated”
Allocation concealment (selection bias) Low risk Quote: “consecutively numbered boxes containing FOY or
placebo”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
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Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias High risk Quote: “[t]he authors thank Laboratorio Dr Esteve SA for
supplies of gabexate mesylate (FOY)”
Other bias Low risk Comment: no other risk of bias
Vege 2015
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 28
Postrandomisation dropouts: not stated
Revised sample size: 28
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with predicted severe acute pancreatitis
2. < 72 h of onset of symptoms
Interventions Group 1: antioxidant (n = 14): pentoxifylline 400 mg oral 3 times daily for 3 days
Group 2: placebo (n = 14)
Outcomes Mortality, serious adverse events, organ failure, hospital stay, ICU stay
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Vege 2015 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Wang 2011
Methods Randomised clinical trial
Participants Country: China
Number randomised: 24
Postrandomisation dropouts: not stated
Revised sample size: 24
Average age: 46 years
Women: 15 (62.5%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 24 (100%).
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with severe acute pancreatitis.
Interventions Group 1: thymosin alpha (n = 12), 3.2 mg twice daily for 7 days
Group 2: placebo (n = 12)
Outcomes Mortality, hospital stay, ICU stay
Follow-up: 1 month
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Wang 2011 (Continued)
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Wang 2013a
Methods Randomised clinical trial
Participants Country: China
Number randomised: 183
Postrandomisation dropouts: not stated
Revised sample size: 183
Average age: 42 years
Women: 89 (48.6%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 159 (86.9%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with severe acute pancreatitis
2. Age: 18 to 45 years
3. < 2 days from onset of symptoms
4. Presence of gastrointestinal ileus or distension
Exclusion criteria
1. History of renal dysfunction
2. Pregnant or lactating
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3. Expected to receive extracorporeal removal
4. Inflammatory bowel disease
5. Infections at the time of hospital admission
6. Received recent NSAID
Interventions Group 1: somatostatin plus ulinastatin (n = 62)
Group 2: somatostatin (n = 61)
Group 3: no intervention (n = 60)
Somatostatin: 250 µg/h IV for 10 days.
Ulinastatin: 10,000 units IV twice daily for 10 days
Outcomes Mortality, serious adverse events
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Low risk Quote: “[t]he authors have no direct relationship with any
of the companies mentioned in this article, either by em-
ployment or by receiving research grants”
Other bias Low risk Comment: no other risk of bias
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Wang 2013b
Methods Randomised clinical trial
Participants Country: China
Number randomised: 354
Postrandomisation dropouts: not stated
Revised sample size: 354
Average age: not stated
Women: not stated
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with predicted severe acute pancreatitis
Interventions Group 1: octreotide plus NSAID (n = not reported)
Group 2: octreotide (n = not reported)
Octreotide: 50 µg/h for first 3 days followed by 25 µg/h for next 4 days
NSAID: celecoxib 200 mg twice daily for 7 days
Outcomes None of the outcomes of interest were reported.
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
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Wang 2013b (Continued)
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Wang 2013c
Methods Randomised clinical trial
Participants Country: China
Number randomised: 372
Postrandomisation dropouts: not stated
Revised sample size: 372
Average age: 45 years
Women: 174 (46.8%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 0 (0%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with predicted severe acute pancreatitis or acute pancreatitis
2. Age 18 to 70 years
3. Admission in < 48 h of onset of symptoms
4. No other severe diseases such as cirrhosis, chronic obstructive airway disease,
chronic renal insufficiency, malignant tumours
Exclusion criteria: people with alcohol dependence
Interventions Group 1: octreotide (n = 157), 50 µg/h for first 3 days followed by 25 µg/h for next 4
days or 25 µg/h for 7 days (randomised)
Group 2: no intervention (n = 79)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, requirement
for endoscopic or radiological drainage, organ failure, hospital stay
Follow-up: some outcomes were measured on 8th day and others at 1 month
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated randomization numbers”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
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Wang 2013c (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “[t]he physicians and nurses who managed the pa-
tients were blinded so that they did not know the patient has
been allocated to and what treatment they had received”.
Comment: there is no mention of participant blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[t]he physicians and nurses who managed the pa-
tients were blinded so that they did not know the patient
has been allocated to and what treatment they had received”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Low risk Quote: “[t]his study was supported by a Key Grant #
30330270 from the Natural Science Fund of China and the
National Ministry of Health Fund for the Public Welfare 2-
13”
Other bias Low risk Comment: no other risk of bias
Wang 2016
Methods Randomised clinical trial
Participants Country: China
Number randomised: 492
Postrandomisation dropouts: not stated
Revised sample size: 492
Average age: 41 years
Women: 238 (48.4%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 492 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with severe acute pancreatitis
Exclusion criteria
1. Evidence or a known history of renal dysfunction
2. Pregnancy
3. Malignancy
4. Immunodeficiency
5. Pre-existing chronic kidney diseases requiring regular hemodialysis
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Wang 2016 (Continued)
Interventions Group 1: somatostatin plus ulinastatin plus gabexate (n = 116)
Group 2: somatostatin plus ulinastatin (n = 124)
Group 3: somatostatin plus gabexate (n = 130)
Group 4: somatostatin (n = 122)
Somatostatin: 3 mg IV for 10 days
Ulinastatin: 10,000 units IV twice daily for 10 days
Gabexate: 0.1 g IV 3 times daily for 10 days
Outcomes Mortality, adverse events, organ failure, length of hospital stay
Follow-up: not stated (probably until discharge)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “[a]ccording to a computerized random number
generation . . .”
Allocation concealment (selection bias) Low risk Quote: “sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “[t]his was a prospective and double-blind study”
Comment: a placebo was used to achieve blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “[t]his was a prospective and double-blind study”
Comment: a placebo was used to achieve blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Low risk Quote: “[t]his work was supported by National Natural Sci-
ence Foundation of China, China (81360080, 81071594)
and the Science Foundation of Science and Technology Hall
of Jiangxi Province, China (20091391308000).”
Other bias Low risk Comment: no other risk of bias
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Xia 2014
Methods Randomised clinical trial
Participants Country: China
Number randomised: 140
Postrandomisation dropouts: not stated
Revised sample size: 140
Average age: 43 years
Women: 48 (34.3%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: 140 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with severe acute pancreatitis
2. No associated severe liver disease or biliary diseases
3. Pancreatitis not resulting from trauma, malignancy
4. No contraindications or allergies to somatostatin
5. No treatment with other drugs which could affect the results of this study
Interventions Group 1: somatostatin (3 mg IV twice daily for 7 days) plus omeprazole (40 mg IV twice
daily for 7 days) (n = 70)
Group 2: no intervention (n = 70)
Outcomes Mortality, serious adverse events, adverse events
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
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Xia 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Xue 2009
Methods Randomised clinical trial
Participants Country: China
Number randomised: 59
Postrandomisation dropouts: 3 (5.1%)
Revised sample size: 56
Average age: 48 years
Women: 28 (50%)
Acute interstitial oedematous pancreatitis: 0 (0%)
Necrotising pancreatitis: 56 (100%)
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 56 (100%)
Persistent organ failure: not stated
Infected pancreatitis: 0
Inclusion criteria
1. People with acute necrotising pancreatitis and identified as severe acute
pancreatitis
2. Within 3 days of onset of symptoms
3. Age at least 18 years
Exclusion criteria
1. Concurrent sepsis or peripancreatic infection
2. Direct transfer to ICU for multiorgan failure
3. Pancreatitis secondary to trauma, ERCP, or operation
4. Recurrent pancreatitis
5. Pregnancy, malignancy, or immunodeficiency
6. History of antibiotic administration within 48 h prior to enrolment
7. Possible death within 48 h after enrolment
Interventions Group 1: antibiotics (n = 29): imipenem-cilastatin 0.5 g every 8 h for 7-14 days
Group 2: no intervention (n = 27)
Outcomes Mortality, serious adverse events, adverse events, requirement for surgery, hospital stay
Follow-up: 1 month
Notes Reasons for postrandomisation dropouts: death after starting treatment, transferred to
operation
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Xue 2009 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-derived random number sequence”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: mortality and adverse events were reported.
For profit-bias Low risk Quote: “[w]e thank Sichuan Province Science and Technol-
ogy Tackling Key Project (no. 05SG011-021-1) for provid-
ing financial support for the trial and the publication of the
paper”
Other bias Low risk Comment: no other risk of bias
Yang 1999
Methods Randomised clinical trial
Participants Country: China
Number randomised: 48
Postrandomisation dropouts: not stated
Revised sample size: 48
Average age: 45 years
Women: 26 (54.2%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: not stated
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria: people with acute pancreatitis
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Yang 1999 (Continued)
Interventions Group 1: somatostatin (n = 25), 250 µg/h for 3-4 days
Group 2: no intervention (n = 23)
Outcomes Serious adverse events, adverse events
Follow-up: not stated (probably until discharge)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
Yang 2012
Methods Randomised clinical trial
Participants Country: China
Number randomised: 163
Postrandomisation dropouts: 6 (3.7%)
Revised sample size: 157
Average age: 46 years
Women: 71 (45.2%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 157 (100%)
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Yang 2012 (Continued)
Moderate pancreatitis: not stated
Severe pancreatitis: not stated
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with mild pancreatitis
2. Aged between 18 and 70 years
3. < 48 h of symptoms
4. People with a BMI > 25 kg/m²
Exclusion criteria
1. People with alcohol dependence
2. Pregnancy
3. Drug abuse
4. Psychosis
5. Cirrhosis
6. Chronic obstructive pulmonary disease
7. Chronic renal insufficiency
8. Malignancy
Interventions Group 1: octreotide (n = 80), 50 µg/h for 3 days
Group 2: no intervention (n = 77)
Outcomes Mortality, hospital stay
Follow-up: 1 month
Notes Reasons for postrandomisation dropouts: loss to follow-up; lack of data
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated randomization numbers”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
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Yang 2012 (Continued)
For profit-bias Low risk Quote: “[t]his study was supported by Key Grant #
30330270 of the Natural Science Fund of China and the
National Ministry of Health Fund for Public Welfare 2-13.
”
Other bias Low risk Comment: no other risk of bias
Zhu 2014
Methods Randomised clinical trial
Participants Country: China
Number randomised: 39
Postrandomisation dropouts: not stated
Revised sample size: 39
Average age: 43 years
Women: 18 (46.2%)
Acute interstitial oedematous pancreatitis: not stated
Necrotising pancreatitis: not stated
Mild pancreatitis: 0 (0%)
Moderate pancreatitis: 0 (0%)
Severe pancreatitis: 39 (100%)
Persistent organ failure: not stated
Infected pancreatitis: not stated
Inclusion criteria
1. People with severe acute pancreatitis
2. < 48 h from onset of symptoms
3. < 65 years of age
Exclusion criteria
1. Chronic pancreatitis
2. Associated with primary infection, tumours, low immunity
Interventions Group 1: probiotics (n = 20), 2 tablets twice daily for 14 days (Japanese preparation)
Group 2: placebo (n = 19)
Outcomes Serious adverse events, adverse events, requirement for endoscopic or radiological
drainage, infected pancreatic necrosis
Follow-up: not stated (probably 2 weeks)
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
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Zhu 2014 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality or adverse events were not re-
ported
For profit-bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other risk of bias
ERCP: endoscopic retrograde cholangiopancreatography; ICU: intensive care unit; IU: international unit; IV: intravenous; KIU:
kallikrein inhibitor units; MRC: Medical Research Council (1 MRC = 1 IU); PR: per rectum; SC: subcutaneous.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akzhigitov 1968 Not an RCT
Akzhigitov 1969 Not an RCT
Al-Leswas 2013a Comparison of 2 different antioxidants
Al-Leswas 2013b Comparison of 2 different antioxidants
Al-Leswas 2013c Comparison of 2 different antioxidants
Al-Leswas 2013d Comparison of 2 different antioxidants
Al-Leswas 2013e Comparison of 2 different antioxidants
Al-Leswas 2013f Comparison of 2 different antioxidants
Al-Leswas 2013g Comparison of 2 different antioxidants
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Amundsen 1972 Not conducted in humans
Andersson 2008 Not a primary research study (commentary)
Baden 1967 Quasi-RCT (allocation based on birth date) comparing 2 different preparations of aprotinin
Baden 1969 Quasi-RCT (allocation based on birth date) comparing 2 different preparations of aprotinin
Bai 2013 Not an RCT
Bassi 1998 Comparison of 2 different antibiotic regimens
Beechey-Newman 1991 Not an RCT
Beechey-Newman 1993 Not an RCT
Beger 2001 Not a primary research study (commentary)
Bender 1992 Not an RCT
Binder 1993 Comparison of different doses of octreotide
Binder 1994 Comparison of different doses of octreotide
Brown 2004 Not a primary research study (editorial)
Buchler 1988 Not an RCT
Cameron 1979 Quasi-randomised study (allocation by patient number)
Cheng 2008 There was no control group for pharmacological intervention
Cullimore 2008 Not a primary research study (letter to editor)
Curtis 1997 Not a primary research study (review)
D’Amico 1990 Not an RCT
Da Silvereira 2002 Not a primary research study (commentary)
De Vries 2007 Not a primary research study (systematic review)
Dikkenberg 2008 Not a primary research study (commentary)
Dreiling 1977 Not an RCT
Du 2002 Comparison of 2 doses of vitamin C
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Du 2003 Comparison of 2 doses of vitamin C
Dürr 1985 Quasi-RCT (allocation by alternation)
Freise 1985 Not an RCT
Friess 1994 Not a primary research study (review)
Gabryelewicz 1968 Not in humans
Gabryelewicz 1976 Not an RCT
Gao 2015b Not a pharmacological intervention
Garcia 2005 Comparison of 2 variations of probiotics
Gostishchev 1977 Not a primary research study (review)
Guo 2013 Comparison of different doses of octreotide
Hajdu 2012 Variations in nutritional supplementation
Harinath 2002 Prophylactic intervention (not in people with acute pancreatitis)
Hart 2008 Not a primary research study (review)
He 2004 Not a pharmacological intervention
Helton 2001 Not a primary research study (comment)
Hoekstra 2008 Not a primary research study (letter to editor)
Holub 1974 Not a primary research study (letter to editor)
Howard 2007 Not a primary research study (editorial)
Howes 1975 Quasi-RCT (allocation by hospital number)
Huang 2008 Variations in different types of nutritional supplementation
Issekutz 2002 No suitable control (3 groups were: probiotics + fibre versus inactivated lactobacilli + fibre versus standard
nutrition; it is not possible to obtain the effect estimate of probiotics alone from this comparison)
Ivanov 2002 Not an RCT
Jiang 1988 Not an RCT
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(Continued)
Karakan 2007 Not a pharmacological intervention (fibre supplementation only)
Karakoyunlar 1999 Not an RCT
Karavanov 1966 Not an RCT
Lasztity 2005a Variations in fatty acids used in enteral nutrition
Lasztity 2005b Variations in fatty acids used in enteral nutrition
Lasztity 2006 Variations in fatty acids used in enteral nutrition
Lata 1998 Not an RCT
Lata 2010 This started as a RCT but was converted to a cohort study after publication of negative results
Lim 2015 Not a primary research study (review)
Lu 2006 Not a pharmacological intervention (variations in parenteral nutrition)
Lu 2008 Intervention includes a non-pharmacological treatment in addition to antioxidant
Manes 2003 Comparison of 2 different antibiotics
Manes 2006 Comparison of 2 different antibiotic regimens
McClave 2009 Not a primary research study (editorial)
Mercadier 1973 Not an RCT
Niu 2014 Comparison of 2 different fats
Pearce 2006 Variations in composition of enteral feeds
Pederzoli 1995 Not primary research (review)
Pezzilli 1997 Comparison of two doses of gabexate mesilate
Pezzilli 1999 Comparison of 2 doses of gabexate mesilate
Pezzilli 2001 Comparison of 2 doses of gabexate mesilate
Piascik 2010 In addition to the difference in the groups in terms of whether the patients received protease inhibitor, the
antibiotic regimen differed between the groups
Plaudis 2012 Not an RCT
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Rahman 2003 Not a primary research study (letter to editor)
Ranson 1976 Not an RCT
Reddy 2008 Not a primary research study (letter to editor)
Santen 2008 Not primary research (letter to editor)
Singer 1966 No mention about randomisation
Skyring 1965 No mention about randomisation
Tanaka 1979 There were 2 trials reported in this publication. Of these, 1 was a quasi-RCT (alternate allocation) and it
was not clear whether the second trial was an RCT
Tang 2005 Only the control group received Chinese medicines
Tang 2007 Not an RCT
Ukai 2015 Not a primary research study (review)
Usadel 1980 Not a primary research study (letter to editor)
Venkatesan 2008 Not a primary research study (commentary)
Villatoro 2010 Not primary research (review)
Wang 2008 Variations in composition of parenteral nutrition
Wang 2009 Variations in composition of parenteral nutrition
Weismann 2010 Not a primary research study (commentary)
Wyncoll 1998 Not a primary research study (letter to editor)
Xiong 2009 Variations in parenteral nutrition
Xu 2012 Variations in parenteral nutrition
Yang 2008a Not an RCT
Yang 2008b Variations in total parenteral nutrition
Yang 2009 Chinese medicines were given to the control group but not the intervention group
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Zapater 2000 The co-interventions in the groups varied apart from the drug being evaluated (nasogastric suction was
used only in the control group)
RCT = randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Hansen 1966
Methods Awaiting full text
Participants -
Interventions -
Outcomes -
Notes -
Perez 1980
Methods Awaiting full text
Participants -
Interventions -
Outcomes -
Notes -
Characteristics of ongoing studies [ordered by study ID]
ChiCTR-IPR-16008301
Trial name or title The effect of proton pump inhibitors on acute pancreatitis--a randomly prospective control study
Methods Randomised controlled trial
Participants Adults with acute pancreatitis
Interventions Proton pump inhibitor (omeprazole) versus placebo
Outcomes Duration of hospital stay, gastrointestinal bleeding, and hospital costs
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ChiCTR-IPR-16008301 (Continued)
Starting date September 2016
Contact information Xiao Ma (mxiao 9101@163.com)
Notes -
EUCTR2014-004844-37-ES
Trial name or title Trial of indomethacin in pancreatitis
Methods Randomised controlled trial
Participants Adults with acute pancreatitis
Interventions Non-steroidal anti-inflammatory drugs (indomethacin) versus placebo
Outcomes Mortality and organ failure
Starting date May 2015
Contact information Enrique de Madaria Pascual (madaria@hotmail.com)
Notes ChiCTR-IPR-16008301, NCT02692391
NCT01132521
Trial name or title Ulinastatin in severe acute pancreatitis
Methods Randomised controlled trial
Participants Adults with severe acute pancreatitis
Interventions Ulinastatin versus placebo
Outcomes mortality, organ failure, requirement for additional invasive intervention, hospital stay, intensive care unit
stay
Starting date June 2010
Contact information Chunyou Wang (Wuhan Union Hospital, China)
Notes The study is currently suspended.
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NCT02025049
Trial name or title DP-b99 in the treatment of acute high-risk pancreatitis
Methods Randomised controlled trial
Participants Adults with predicted severe acute pancreatitis
Interventions DP-b99 versus placebo
Outcomes Complications
Starting date December 2013
Contact information Gilad Rosenberg (Wuhan Union Hospital, China)
Notes The University Hospital Brno, Gastroenterology Clinic, Brno, Czech Republic, 62500
NCT02212392
Trial name or title Comparing the outcome in patients of acute pancreatitis, with and without prophylactic antibiotics
Methods Randomised controlled trial
Participants Adults with acute pancreatitis
Interventions Antibiotics (meropenem) versus no intervention
Outcomes Infections and hospital stay
Starting date Jan 2013
Contact information Fazal H Shah (Benazir Bhutto Hospital, Rawalpindi, Punjab, Pakistan, 46000)
Notes -
NCT02692391
Trial name or title A randomized controlled pilot trial of indomethacin in acute pancreatitis
Methods Randomised controlled trial
Participants Adults with acute pancreatitis
Interventions Non-steroidal anti-inflammatory drugs (indomethacin) versus placebo
Outcomes Mortality and organ failure
Starting date April 2014
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NCT02692391 (Continued)
Contact information Georgios I Papachristou (papachri@pitt.edu)
Notes -
NCT02885441
Trial name or title Treatment of acute pancreatitis with ketorolac
Methods Randomised controlled trial
Participants Adults with predicted severe acute pancreatitis
Interventions Non-steroidal anti-inflammatory drugs (ketorolac) versus placebo
Outcomes New onset organ failure, pancreatic necrosis, and duration of hospital stay
Starting date September 2016
Contact information Shaahin Shahbazi (mdkabe@gmail.com)
Notes -
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D A T A A N D A N A L Y S E S
Comparison 1. Acute pancreatitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Short-term mortality 67 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Antibiotics versus control 17 1058 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.57, 1.15]
1.2 Antioxidants versus
control
4 163 Odds Ratio (M-H, Fixed, 95% CI) 2.01 [0.53, 7.56]
1.3 Aprotinin versus control 7 651 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.40, 1.14]
1.4 Calcitonin versus control 2 125 Odds Ratio (M-H, Fixed, 95% CI) 0.55 [0.15, 2.00]
1.5 Cimetidine versus control 1 40 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 17.18]
1.6 EDTA versus control 1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.12, 7.08]
1.7 Gabexate versus control 5 576 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.48, 1.30]
1.8 Glucagon versus control 5 409 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.51, 1.87]
1.9 Iniprol versus control 1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 1.67]
1.10 Lexipafant versus control 3 423 Odds Ratio (M-H, Fixed, 95% CI) 0.55 [0.30, 1.01]
1.11 Octreotide versus control 5 927 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.47, 1.23]
1.12 Probiotics versus control 2 358 Odds Ratio (M-H, Fixed, 95% CI) 1.70 [0.87, 3.30]
1.13 Activated protein C
versus control
1 32 Odds Ratio (M-H, Fixed, 95% CI) 8.56 [0.41, 180.52]
1.14 Somatostatin versus
control
6 493 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.29, 1.10]
1.15 Somatostatin plus
omeprazole versus control
1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.05, 1.11]
1.16 Somatostatin plus
ulinastatin versus control
1 122 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.15, 1.23]
1.17 Thymosin versus control 1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.18 Ulinastatin versus
control
1 132 Odds Ratio (M-H, Fixed, 95% CI) 0.45 [0.12, 1.72]
1.19 Gabexate versus
aprotinin
2 298 Odds Ratio (M-H, Fixed, 95% CI) 0.62 [0.32, 1.20]
1.20 Glucagon versus
aprotinin
1 134 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.44, 4.08]
1.21 Glucagon versus atropine 1 150 Odds Ratio (M-H, Fixed, 95% CI) 4.17 [0.45, 38.21]
1.22 Octreotide plus
ulinastatin versus octreotide
1 120 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.06, 1.60]
1.23 Somatostatin plus
gabexate versus somatostatin
1 252 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.37, 2.33]
1.24 Somatostatin plus
ulinastatin versus somatostatin
2 369 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.34, 1.56]
1.25 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin
1 238 Odds Ratio (M-H, Fixed, 95% CI) 0.61 [0.21, 1.74]
1.26 Somatostatin plus
ulinastatin versus somatostatin
plus gabexate
1 254 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.26, 1.95]
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1.27 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin plus gabexate
1 246 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.23, 1.86]
1.28 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin plus ulinastatin
1 240 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.30, 2.80]
2 Serious adverse events
(proportion)
17 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Antibiotics versus control 5 304 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.37, 1.15]
2.2 Antioxidants versus
control
2 82 Odds Ratio (M-H, Fixed, 95% CI) 1.98 [0.48, 8.13]
2.3 EDTA versus control 1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.52 [0.11, 2.39]
2.4 Gabexate versus control 2 201 Odds Ratio (M-H, Fixed, 95% CI) 1.31 [0.31, 5.60]
2.5 Glucagon versus control 2 127 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 7.46]
2.6 Octreotide versus control 1 58 Odds Ratio (M-H, Fixed, 95% CI) 1.73 [0.61, 4.93]
2.7 Somatostatin versus
control
2 111 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.35, 3.27]
2.8 Gabexate versus aprotinin 1 116 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.22, 4.91]
2.9 Ulinastatin versus
gabexate
1 62 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Serious adverse events (number) 37 Rate Ratio (Fixed, 95% CI) Subtotals only
3.1 Antibiotics versus control 12 716 Rate Ratio (Fixed, 95% CI) 0.86 [0.68, 1.07]
3.2 Antioxidants versus
control
2 71 Rate Ratio (Fixed, 95% CI) 0.22 [0.02, 2.21]
3.3 Aprotinin versus control 3 264 Rate Ratio (Fixed, 95% CI) 0.79 [0.49, 1.29]
3.4 Cimetidine versus control 1 60 Rate Ratio (Fixed, 95% CI) 1.0 [0.20, 4.95]
3.5 EDTA versus control 1 64 Rate Ratio (Fixed, 95% CI) 0.94 [0.19, 4.65]
3.6 Gabexate versus control 3 375 Rate Ratio (Fixed, 95% CI) 0.86 [0.64, 1.15]
3.7 Glucagon versus control 1 68 Rate Ratio (Fixed, 95% CI) 1.0 [0.02, 50.40]
3.8 Lexipafant versus control 1 290 Rate Ratio (Fixed, 95% CI) 0.67 [0.46, 0.96]
3.9 Octreotide versus control 4 770 Rate Ratio (Fixed, 95% CI) 0.74 [0.60, 0.89]
3.10 Probiotics versus control 3 397 Rate Ratio (Fixed, 95% CI) 0.94 [0.65, 1.36]
3.11 Somatostatin versus
control
3 257 Rate Ratio (Fixed, 95% CI) 1.03 [0.66, 1.59]
3.12 Somatostatin plus
omeprazole versus control
1 140 Rate Ratio (Fixed, 95% CI) 0.36 [0.19, 0.70]
3.13 Somatostatin plus
ulinastatin versus control
1 122 Rate Ratio (Fixed, 95% CI) 0.30 [0.15, 0.60]
3.14 Glucagon versus atropine 1 150 Rate Ratio (Fixed, 95% CI) 0.33 [0.03, 3.20]
3.15 Octreotide plus
ulinastatin versus octreotide
1 120 Rate Ratio (Fixed, 95% CI) 0.30 [0.17, 0.51]
3.16 Somatostatin plus
ulinastatin versus somatostatin
1 123 Rate Ratio (Fixed, 95% CI) 0.28 [0.15, 0.56]
4 Organ failure 18 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Antibiotics versus control 5 258 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.44, 1.38]
4.2 Antioxidants versus
control
4 163 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.39, 2.12]
4.3 Gabexate versus control 1 50 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.01, 8.25]
4.4 Lexipafant versus control 2 340 Odds Ratio (M-H, Random, 95% CI) 0.68 [0.36, 1.27]
4.5 Octreotide versus control 2 430 Odds Ratio (M-H, Random, 95% CI) 0.51 [0.27, 0.97]
4.6 Probiotics versus control 2 358 Odds Ratio (M-H, Random, 95% CI) 0.80 [0.26, 2.47]
4.7 Ulinastatin versus control 1 129 Odds Ratio (M-H, Random, 95% CI) 0.27 [0.01, 6.67]
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4.8 Somatostatin plus
gabexate versus somatostatin
1 252 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.33, 1.80]
4.9 Somatostatin plus
ulinastatin versus somatostatin
1 246 Odds Ratio (M-H, Random, 95% CI) 0.58 [0.23, 1.45]
4.10 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin
1 238 Odds Ratio (M-H, Random, 95% CI) 0.46 [0.17, 1.25]
4.11 Somatostatin plus
ulinastatin versus somatostatin
plus gabexate
1 254 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.29, 1.92]
4.12 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin plus gabexate
1 246 Odds Ratio (M-H, Random, 95% CI) 0.59 [0.21, 1.65]
4.13 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin plus ulinastatin
1 240 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.27, 2.35]
5 Infected pancreatic necrosis 15 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Antibiotics versus control 11 714 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.53, 1.25]
5.2 Octreotide versus control 1 58 Odds Ratio (M-H, Fixed, 95% CI) 0.52 [0.04, 6.06]
5.3 Probiotics versus control 3 397 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.62, 1.96]
6 Sepsis 11 Odds Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Antibiotics versus control 1 60 Odds Ratio (M-H, Random, 95% CI) 0.42 [0.11, 1.60]
6.2 Aprotinin versus control 2 103 Odds Ratio (M-H, Random, 95% CI) 1.84 [0.49, 6.96]
6.3 Gabexate versus control 3 373 Odds Ratio (M-H, Random, 95% CI) 1.10 [0.55, 2.19]
6.4 Lexipafant versus control 1 290 Odds Ratio (M-H, Random, 95% CI) 0.26 [0.08, 0.83]
6.5 Octreotide versus control 2 340 Odds Ratio (M-H, Random, 95% CI) 0.40 [0.05, 3.53]
6.6 Probiotics versus control 1 62 Odds Ratio (M-H, Random, 95% CI) 0.36 [0.10, 1.36]
6.7 Gabexate versus aprotinin 1 116 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.22, 4.91]
7 Adverse events (proportion) 27 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Antibiotics versus control 6 429 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.32, 0.80]
7.2 Antioxidants versus
control
1 39 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Calcitonin versus control 1 94 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.12, 6.49]
7.4 EDTA versus control 1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.27, 2.31]
7.5 Gabexate versus control 3 373 Odds Ratio (M-H, Fixed, 95% CI) 0.83 [0.54, 1.27]
7.6 Glucagon versus control 2 127 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.00, 1.69]
7.7 Lexipafant versus control 1 83 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.16, 1.12]
7.8 Octreotide versus control 3 398 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.65, 1.55]
7.9 Probiotics versus control 1 62 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.12, 1.01]
7.10 Somatostatin versus
control
2 111 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.19, 1.02]
7.11 Somatostatin plus
omeprazole versus control
1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.00 [0.00, 0.04]
7.12 Gabexate versus
aprotinin
2 298 Odds Ratio (M-H, Fixed, 95% CI) 0.41 [0.23, 0.70]
7.13 Ulinastatin versus
gabexate
1 62 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.14 Ulinastatin versus
octreotide
1 25 Odds Ratio (M-H, Fixed, 95% CI) 2.33 [0.46, 11.81]
7.15 Somatostatin plus
gabexate versus somatostatin
1 252 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.44, 1.95]
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7.16 Somatostatin plus
ulinastatin versus somatostatin
1 246 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.25, 1.34]
7.17 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin
1 238 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.20, 1.20]
7.18 Somatostatin plus
ulinastatin versus somatostatin
plus gabexate
1 254 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.27, 1.44]
7.19 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin plus gabexate
1 246 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.22, 1.28]
7.20 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin plus ulinastatin
1 240 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.32, 2.22]
8 Adverse events (number) 40 Rate Ratio (Random, 95% CI) Subtotals only
8.1 Antibiotics versus control 12 755 Rate Ratio (Random, 95% CI) 0.75 [0.58, 0.95]
8.2 Antioxidants versus
control
2 94 Rate Ratio (Random, 95% CI) 0.82 [0.38, 1.79]
8.3 Aprotinin versus control 3 264 Rate Ratio (Random, 95% CI) 0.98 [0.69, 1.39]
8.4 Calcitonin versus control 1 94 Rate Ratio (Random, 95% CI) 0.88 [0.12, 6.25]
8.5 Cimetidine versus control 1 60 Rate Ratio (Random, 95% CI) 1.14 [0.64, 2.02]
8.6 EDTA versus control 1 64 Rate Ratio (Random, 95% CI) 0.63 [0.28, 1.39]
8.7 Gabexate versus control 3 375 Rate Ratio (Random, 95% CI) 0.76 [0.61, 0.95]
8.8 Glucagon versus control 2 90 Rate Ratio (Random, 95% CI) 1.19 [0.51, 2.80]
8.9 Lexipafant versus control 1 290 Rate Ratio (Random, 95% CI) 0.61 [0.44, 0.85]
8.10 Octreotide versus control 4 634 Rate Ratio (Random, 95% CI) 0.78 [0.58, 1.05]
8.11 Probiotics versus control 3 397 Rate Ratio (Random, 95% CI) 0.84 [0.52, 1.36]
8.12 Somatostatin versus
control
2 134 Rate Ratio (Random, 95% CI) 0.75 [0.26, 2.18]
8.13 Ulinastatin versus
control
1 129 Rate Ratio (Random, 95% CI) 0.69 [0.32, 1.46]
8.14 Gabexate versus
aprotinin
1 182 Rate Ratio (Random, 95% CI) 0.66 [0.38, 1.14]
8.15 Glucagon versus atropine 1 150 Rate Ratio (Random, 95% CI) 0.79 [0.36, 1.73]
8.16 Oxyphenonium versus
glucagon
1 62 Rate Ratio (Random, 95% CI) 0.93 [0.65, 1.34]
8.17 Octreotide plus
ulinastatin versus octreotide
1 120 Rate Ratio (Random, 95% CI) 0.29 [0.17, 0.48]
9 Requirement for additional
invasive intervention
32 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Antibiotics versus control 14 884 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.59, 1.13]
9.2 Aprotinin versus control 2 237 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.23, 1.47]
9.3 Calcitonin versus control 2 125 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.08, 1.16]
9.4 Cimetidine versus control 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.61]
9.5 EDTA versus control 1 64 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.14, 3.29]
9.6 Gabexate versus control 3 426 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.37, 0.90]
9.7 Glucagon versus control 2 260 Odds Ratio (M-H, Fixed, 95% CI) 1.26 [0.58, 2.77]
9.8 Octreotide versus control 3 854 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.48, 1.21]
9.9 Probiotics versus control 2 358 Odds Ratio (M-H, Fixed, 95% CI) 1.50 [0.83, 2.71]
9.10 Somatostatin versus
control
1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.11, 1.38]
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9.11 Gabexate versus
aprotinin
1 182 Odds Ratio (M-H, Fixed, 95% CI) 0.5 [0.19, 1.32]
9.12 Glucagon versus
aprotinin
1 134 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.44, 4.08]
9.13 Oxyphenonium versus
glucagon
1 62 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.13, 7.59]
10 Endoscopic or radiological
drainage of collections
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Antibiotics versus control 1 23 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 9.07]
10.2 Octreotide versus control 1 372 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.40, 1.96]
10.3 Probiotics versus control 1 39 Odds Ratio (M-H, Fixed, 95% CI) 0.94 [0.20, 4.44]
Comparison 2. Acute necrotising pancreatitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Short-term mortality 11 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Antibiotics versus control 10 683 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.52, 1.30]
1.2 Gabexate versus aprotinin 1 116 Odds Ratio (M-H, Fixed, 95% CI) 0.52 [0.20, 1.36]
2 Serious adverse events
(proportion)
5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Antibiotics versus control 4 281 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.46, 1.54]
2.2 Gabexate versus aprotinin 1 116 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.22, 4.91]
3 Serious adverse events (number) 7 Rate Ratio (Fixed, 95% CI) Subtotals only
3.1 Antibiotics versus control 7 Rate Ratio (Fixed, 95% CI) 0.79 [0.59, 1.06]
4 Organ failure 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Antibiotics versus control 4 211 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.42, 1.45]
5 Infected pancreatic necrosis 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Antibiotics versus control 6 426 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.51, 1.42]
6 Sepsis 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Antibiotics versus control 1 60 Odds Ratio (M-H, Random, 95% CI) 0.42 [0.11, 1.60]
6.2 Gabexate versus aprotinin 1 116 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.22, 4.91]
Comparison 3. Severe acute pancreatitis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Short-term mortality 22 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Antibiotics versus control 9 542 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.53, 1.27]
1.2 Aprotinin versus control 2 103 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.19, 2.30]
1.3 Calcitonin versus control 1 31 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.11, 5.46]
1.4 Gabexate versus control 1 52 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.04, 0.99]
1.5 Probiotics versus control 1 62 Odds Ratio (M-H, Fixed, 95% CI) 0.25 [0.05, 1.34]
1.6 Activated protein C versus
control
1 32 Odds Ratio (M-H, Fixed, 95% CI) 8.56 [0.41, 180.52]
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1.7 Somatostatin versus
control
2 182 Odds Ratio (M-H, Fixed, 95% CI) 0.51 [0.21, 1.23]
1.8 Somatostatin plus
omeprazole versus control
1 140 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.05, 1.11]
1.9 Somatostatin plus
ulinastatin versus control
1 122 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.15, 1.23]
1.10 Thymosin versus control 1 24 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.11 Ulinastatin versus
control
1 70 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.04, 1.29]
1.12 Octreotide plus
ulinastatin versus octreotide
1 120 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.06, 1.60]
1.13 Somatostatin plus
gabexate versus somatostatin
1 252 Odds Ratio (M-H, Fixed, 95% CI) 0.93 [0.37, 2.33]
1.14 Somatostatin plus
ulinastatin versus somatostatin
2 369 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.34, 1.56]
1.15 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin
1 238 Odds Ratio (M-H, Fixed, 95% CI) 0.61 [0.21, 1.74]
1.16 Somatostatin plus
ulinastatin versus somatostatin
plus gabexate
1 254 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.26, 1.95]
1.17 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin plus gabexate
1 246 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.23, 1.86]
1.18 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin plus ulinastatin
1 240 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.30, 2.80]
2 Serious adverse events
(proportion)
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Antibiotics versus control 3 164 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.27, 1.18]
3 Serious adverse events (number) 13 Rate Ratio (Random, 95% CI) Subtotals only
3.1 Antibiotics versus control 5 Rate Ratio (Random, 95% CI) 0.81 [0.52, 1.25]
3.2 Aprotinin versus control 2 Rate Ratio (Random, 95% CI) 0.65 [0.25, 1.71]
3.3 Gabexate versus control 1 Rate Ratio (Random, 95% CI) 0.64 [0.37, 1.10]
3.4 Probiotics versus control 2 Rate Ratio (Random, 95% CI) 0.62 [0.24, 1.59]
3.5 Somatostatin versus
control
1 Rate Ratio (Random, 95% CI) 1.07 [0.67, 1.69]
3.6 Somatostatin plus
omeprazole versus control
1 Rate Ratio (Random, 95% CI) 0.36 [0.19, 0.70]
3.7 Somatostatin plus
ulinastatin versus control
1 Rate Ratio (Random, 95% CI) 0.30 [0.15, 0.60]
3.8 Octreotide plus ulinastatin
versus octreotide
1 Rate Ratio (Random, 95% CI) 0.30 [0.17, 0.51]
3.9 Somatostatin plus
ulinastatin versus somatostatin
1 Rate Ratio (Random, 95% CI) 0.28 [0.15, 0.56]
4 Organ failure 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Antibiotics versus control 3 137 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.40, 1.99]
4.2 Lexipafant versus control 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Probiotics versus control 1 62 Odds Ratio (M-H, Fixed, 95% CI) 0.40 [0.12, 1.36]
4.4 Ulinastatin versus control 1 67 Odds Ratio (M-H, Fixed, 95% CI) 0.05 [0.01, 0.21]
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4.5 Somatostatin plus
gabexate versus somatostatin
1 252 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.33, 1.80]
4.6 Somatostatin plus
ulinastatin versus somatostatin
1 246 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.23, 1.45]
4.7 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin
1 238 Odds Ratio (M-H, Fixed, 95% CI) 0.46 [0.17, 1.25]
4.8 Somatostatin plus
ulinastatin versus somatostatin
plus gabexate
1 254 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.29, 1.92]
4.9 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin plus gabexate
1 246 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.21, 1.65]
4.10 Somatostatin plus
ulinastatin plus gabexate versus
somatostatin plus ulinastatin
1 240 Odds Ratio (M-H, Fixed, 95% CI) 0.79 [0.27, 2.35]
5 Infected pancreatic necrosis 8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Antibiotics versus control 6 341 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.41, 1.33]
5.2 Probiotics versus control 2 101 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.22, 1.68]
6 Sepsis 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Aprotinin versus control 2 103 Odds Ratio (M-H, Fixed, 95% CI) 1.87 [0.50, 6.98]
6.2 Probiotics versus control 1 62 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.10, 1.36]
Analysis 1.1. Comparison 1 Acute pancreatitis, Outcome 1 Short-term mortality.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 1 Acute pancreatitis
Outcome: 1 Short-term mortality
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Barreda 2009 0/24 0/34 Not estimable
Delcenserie 1996 1/11 3/12 3.8 % 0.30 [ 0.03, 3.43 ]
Delcenserie 2001 6/53 3/28 5.0 % 1.06 [ 0.24, 4.62 ]
Dellinger 2007 10/50 9/50 10.4 % 1.14 [ 0.42, 3.10 ]
Finch 1976 1/31 0/27 0.7 % 2.70 [ 0.11, 69.19 ]
Garcia-Barrasa 2009 4/22 2/19 2.5 % 1.89 [ 0.31, 11.68 ]
Hejtmankova 2003 4/20 5/21 5.6 % 0.80 [ 0.18, 3.54 ]
Llukacaj 2012 8/40 6/40 6.9 % 1.42 [ 0.44, 4.53 ]
0.005 0.1 1 10 200
Favours intervention Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Luiten 1995 11/50 18/52 19.9 % 0.53 [ 0.22, 1.28 ]
Nordback 2001 2/25 5/33 5.7 % 0.49 [ 0.09, 2.75 ]
Pederzoli 1993a 3/41 4/33 5.9 % 0.57 [ 0.12, 2.76 ]
Poropat 2015 3/23 2/24 2.5 % 1.65 [ 0.25, 10.91 ]
Rokke 2007 3/36 4/37 5.2 % 0.75 [ 0.16, 3.62 ]
Sainio 1995 1/30 7/30 9.8 % 0.11 [ 0.01, 0.99 ]
Spicak 2002 5/33 3/30 3.9 % 1.61 [ 0.35, 7.39 ]
Spicak 2003 4/20 5/21 5.6 % 0.80 [ 0.18, 3.54 ]
Xue 2009 4/30 5/28 6.5 % 0.71 [ 0.17, 2.96 ]
Subtotal (95% CI) 539 519 100.0 % 0.81 [ 0.57, 1.15 ]
Total events: 70 (Intervention), 81 (Control)
Heterogeneity: Chi2 = 9.40, df = 15 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
2 Antioxidants versus control
Bansal 2011 0/19 2/20 74.4 % 0.19 [ 0.01, 4.22 ]
Sateesh 2009 1/23 0/30 12.8 % 4.07 [ 0.16, 104.53 ]
Siriwardena 2007 4/22 0/21 12.9 % 10.46 [ 0.53, 207.40 ]
Vege 2015 0/14 0/14 Not estimable
Subtotal (95% CI) 78 85 100.0 % 2.01 [ 0.53, 7.56 ]
Total events: 5 (Intervention), 2 (Control)
Heterogeneity: Chi2 = 3.58, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 1.03 (P = 0.30)
3 Aprotinin versus control
Balldin 1983 0/26 3/29 9.2 % 0.14 [ 0.01, 2.90 ]
Berling 1994 4/22 4/26 8.5 % 1.22 [ 0.27, 5.59 ]
Imrie 1978 7/80 7/81 18.0 % 1.01 [ 0.34, 3.03 ]
Imrie 1980 1/25 0/25 1.3 % 3.12 [ 0.12, 80.39 ]
MRC Multicentre Trial 1977 6/66 13/123 23.4 % 0.85 [ 0.31, 2.34 ]
Storck 1968 2/21 2/22 5.0 % 1.05 [ 0.13, 8.24 ]
Trapnell 1974 4/53 13/52 34.4 % 0.24 [ 0.07, 0.81 ]
Subtotal (95% CI) 293 358 100.0 % 0.68 [ 0.40, 1.14 ]
Total events: 24 (Intervention), 42 (Control)
Heterogeneity: Chi2 = 6.11, df = 6 (P = 0.41); I2 =2%
Test for overall effect: Z = 1.47 (P = 0.14)
4 Calcitonin versus control
Goebell 1979 2/50 4/44 63.8 % 0.42 [ 0.07, 2.39 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martinez 1984 2/14 3/17 36.2 % 0.78 [ 0.11, 5.46 ]
Subtotal (95% CI) 64 61 100.0 % 0.55 [ 0.15, 2.00 ]
Total events: 4 (Intervention), 7 (Control)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
5 Cimetidine versus control
Perezdeoteyza 1980 1/20 1/20 100.0 % 1.00 [ 0.06, 17.18 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.06, 17.18 ]
Total events: 1 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 EDTA versus control
Tykka 1985 2/33 2/31 100.0 % 0.94 [ 0.12, 7.08 ]
Subtotal (95% CI) 33 31 100.0 % 0.94 [ 0.12, 7.08 ]
Total events: 2 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
7 Gabexate versus control
Buchler 1993 18/115 16/108 39.4 % 1.07 [ 0.51, 2.22 ]
Chen 2000 2/26 8/26 20.9 % 0.19 [ 0.04, 0.99 ]
Freise 1986 5/25 2/25 4.5 % 2.88 [ 0.50, 16.48 ]
Goebell 1988 8/76 11/75 28.0 % 0.68 [ 0.26, 1.81 ]
Valderrama 1992 0/51 2/49 7.1 % 0.18 [ 0.01, 3.94 ]
Subtotal (95% CI) 293 283 100.0 % 0.79 [ 0.48, 1.30 ]
Total events: 33 (Intervention), 39 (Control)
Heterogeneity: Chi2 = 6.56, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 0.91 (P = 0.36)
8 Glucagon versus control
Debas 1980 3/33 1/33 4.9 % 3.20 [ 0.32, 32.48 ]
Du¨rr 1978 4/33 5/36 22.8 % 0.86 [ 0.21, 3.50 ]
Kalima 1980 0/32 1/29 8.4 % 0.29 [ 0.01, 7.46 ]
Kronborg 1980 5/10 8/12 19.7 % 0.50 [ 0.09, 2.81 ]
MRC Multicentre Trial 1977 8/68 13/123 44.2 % 1.13 [ 0.44, 2.87 ]
Subtotal (95% CI) 176 233 100.0 % 0.97 [ 0.51, 1.87 ]
Total events: 20 (Intervention), 28 (Control)
Heterogeneity: Chi2 = 2.24, df = 4 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
9 Iniprol versus control
Hansky 1969 1/15 3/9 100.0 % 0.14 [ 0.01, 1.67 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 15 9 100.0 % 0.14 [ 0.01, 1.67 ]
Total events: 1 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
10 Lexipafant versus control
Johnson 2001 15/151 23/139 74.3 % 0.56 [ 0.28, 1.12 ]
Kingsnorth 1995 2/42 2/41 6.6 % 0.98 [ 0.13, 7.27 ]
McKay 1997b 3/26 6/24 19.0 % 0.39 [ 0.09, 1.78 ]
Subtotal (95% CI) 219 204 100.0 % 0.55 [ 0.30, 1.01 ]
Total events: 20 (Intervention), 31 (Control)
Heterogeneity: Chi2 = 0.51, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.053)
11 Octreotide versus control
McKay 1997a 5/28 6/30 12.7 % 0.87 [ 0.23, 3.25 ]
Paran 1995 2/19 6/19 14.4 % 0.25 [ 0.04, 1.48 ]
Uhl 1999 27/199 16/103 48.7 % 0.85 [ 0.44, 1.67 ]
Wang 2013c 7/91 4/45 13.2 % 0.85 [ 0.24, 3.08 ]
Wang 2013c 4/157 2/79 6.9 % 1.01 [ 0.18, 5.62 ]
Yang 2012 0/80 1/77 4.1 % 0.32 [ 0.01, 7.90 ]
Subtotal (95% CI) 574 353 100.0 % 0.76 [ 0.47, 1.23 ]
Total events: 45 (Intervention), 35 (Control)
Heterogeneity: Chi2 = 2.06, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
12 Probiotics versus control
Besselink 2008 24/152 9/144 56.5 % 2.81 [ 1.26, 6.28 ]
Olah 2007 2/33 6/29 43.5 % 0.25 [ 0.05, 1.34 ]
Subtotal (95% CI) 185 173 100.0 % 1.70 [ 0.87, 3.30 ]
Total events: 26 (Intervention), 15 (Control)
Heterogeneity: Chi2 = 6.52, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 1.56 (P = 0.12)
13 Activated protein C versus control
Pettila 2010 3/16 0/16 100.0 % 8.56 [ 0.41, 180.52 ]
Subtotal (95% CI) 16 16 100.0 % 8.56 [ 0.41, 180.52 ]
Total events: 3 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
14 Somatostatin versus control
Choi 1989 1/35 2/36 7.9 % 0.50 [ 0.04, 5.78 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gj rup 1992 1/33 1/30 4.2 % 0.91 [ 0.05, 15.16 ]
Grupo Espa ol 1996 2/30 4/31 15.2 % 0.48 [ 0.08, 2.85 ]
Luengo 1994 1/50 1/50 4.1 % 1.00 [ 0.06, 16.44 ]
Usadel 1985 4/36 7/41 24.1 % 0.61 [ 0.16, 2.27 ]
Wang 2013a 7/61 12/60 44.4 % 0.52 [ 0.19, 1.42 ]
Subtotal (95% CI) 245 248 100.0 % 0.57 [ 0.29, 1.10 ]
Total events: 16 (Intervention), 27 (Control)
Heterogeneity: Chi2 = 0.35, df = 5 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
15 Somatostatin plus omeprazole versus control
Xia 2014 2/70 8/70 100.0 % 0.23 [ 0.05, 1.11 ]
Subtotal (95% CI) 70 70 100.0 % 0.23 [ 0.05, 1.11 ]
Total events: 2 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
16 Somatostatin plus ulinastatin versus control
Wang 2013a 6/62 12/60 100.0 % 0.43 [ 0.15, 1.23 ]
Subtotal (95% CI) 62 60 100.0 % 0.43 [ 0.15, 1.23 ]
Total events: 6 (Intervention), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
17 Thymosin versus control
Wang 2011 0/12 0/12 Not estimable
Subtotal (95% CI) 12 12 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
18 Ulinastatin versus control
Abraham 2013 2/38 6/32 93.1 % 0.24 [ 0.04, 1.29 ]
Abraham 2013 1/30 0/32 6.9 % 3.31 [ 0.13, 84.32 ]
Subtotal (95% CI) 68 64 100.0 % 0.45 [ 0.12, 1.72 ]
Total events: 3 (Intervention), 6 (Control)
Heterogeneity: Chi2 = 1.99, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 1.16 (P = 0.24)
19 Gabexate versus aprotinin
Frulloni 1994 9/65 12/51 51.7 % 0.52 [ 0.20, 1.36 ]
Pederzoli 1993b 9/91 12/91 48.3 % 0.72 [ 0.29, 1.81 ]
Subtotal (95% CI) 156 142 100.0 % 0.62 [ 0.32, 1.20 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 18 (Intervention), 24 (Control)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
20 Glucagon versus aprotinin
MRC Multicentre Trial 1977 8/68 6/66 100.0 % 1.33 [ 0.44, 4.08 ]
Subtotal (95% CI) 68 66 100.0 % 1.33 [ 0.44, 4.08 ]
Total events: 8 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.61)
21 Glucagon versus atropine
Kirsch 1978 4/75 1/75 100.0 % 4.17 [ 0.45, 38.21 ]
Subtotal (95% CI) 75 75 100.0 % 4.17 [ 0.45, 38.21 ]
Total events: 4 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
22 Octreotide plus ulinastatin versus octreotide
Guo 2015 2/60 6/60 100.0 % 0.31 [ 0.06, 1.60 ]
Subtotal (95% CI) 60 60 100.0 % 0.31 [ 0.06, 1.60 ]
Total events: 2 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
23 Somatostatin plus gabexate versus somatostatin
Wang 2016 10/130 10/122 100.0 % 0.93 [ 0.37, 2.33 ]
Subtotal (95% CI) 130 122 100.0 % 0.93 [ 0.37, 2.33 ]
Total events: 10 (Intervention), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
24 Somatostatin plus ulinastatin versus somatostatin
Wang 2013a 6/62 7/61 40.1 % 0.83 [ 0.26, 2.62 ]
Wang 2016 7/124 10/122 59.9 % 0.67 [ 0.25, 1.82 ]
Subtotal (95% CI) 186 183 100.0 % 0.73 [ 0.34, 1.56 ]
Total events: 13 (Intervention), 17 (Control)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
25 Somatostatin plus ulinastatin plus gabexate versus somatostatin
Wang 2016 6/116 10/122 100.0 % 0.61 [ 0.21, 1.74 ]
Subtotal (95% CI) 116 122 100.0 % 0.61 [ 0.21, 1.74 ]
Total events: 6 (Intervention), 10 (Control)
Heterogeneity: not applicable
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.92 (P = 0.36)
26 Somatostatin plus ulinastatin versus somatostatin plus gabexate
Wang 2016 7/124 10/130 100.0 % 0.72 [ 0.26, 1.95 ]
Subtotal (95% CI) 124 130 100.0 % 0.72 [ 0.26, 1.95 ]
Total events: 7 (Intervention), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
27 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus gabexate
Wang 2016 6/116 10/130 100.0 % 0.65 [ 0.23, 1.86 ]
Subtotal (95% CI) 116 130 100.0 % 0.65 [ 0.23, 1.86 ]
Total events: 6 (Intervention), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
28 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus ulinastatin
Wang 2016 6/116 7/124 100.0 % 0.91 [ 0.30, 2.80 ]
Subtotal (95% CI) 116 124 100.0 % 0.91 [ 0.30, 2.80 ]
Total events: 6 (Intervention), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
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Analysis 1.2. Comparison 1 Acute pancreatitis, Outcome 2 Serious adverse events (proportion).
Review: Pharmacological interventions for acute pancreatitis
Comparison: 1 Acute pancreatitis
Outcome: 2 Serious adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Delcenserie 1996 0/11 7/12 23.4 % 0.03 [ 0.00, 0.67 ]
Dellinger 2007 6/50 9/50 26.8 % 0.62 [ 0.20, 1.90 ]
Garcia-Barrasa 2009 13/22 10/19 14.9 % 1.30 [ 0.38, 4.48 ]
Llukacaj 2012 6/40 4/40 11.5 % 1.59 [ 0.41, 6.12 ]
Sainio 1995 4/30 8/30 23.5 % 0.42 [ 0.11, 1.60 ]
Subtotal (95% CI) 153 151 100.0 % 0.65 [ 0.37, 1.15 ]
Total events: 29 (Intervention), 38 (Control)
Heterogeneity: Chi2 = 7.08, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 1.49 (P = 0.14)
2 Antioxidants versus control
Bansal 2011 0/19 0/20 Not estimable
Siriwardena 2007 7/22 4/21 100.0 % 1.98 [ 0.48, 8.13 ]
Subtotal (95% CI) 41 41 100.0 % 1.98 [ 0.48, 8.13 ]
Total events: 7 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
3 EDTA versus control
Tykka 1985 3/33 5/31 100.0 % 0.52 [ 0.11, 2.39 ]
Subtotal (95% CI) 33 31 100.0 % 0.52 [ 0.11, 2.39 ]
Total events: 3 (Intervention), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
4 Gabexate versus control
Freise 1986 5/25 4/25 100.0 % 1.31 [ 0.31, 5.60 ]
Goebell 1988 0/76 0/75 Not estimable
Subtotal (95% CI) 101 100 100.0 % 1.31 [ 0.31, 5.60 ]
Total events: 5 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
5 Glucagon versus control
Debas 1980 0/33 0/33 Not estimable
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kalima 1980 0/32 1/29 100.0 % 0.29 [ 0.01, 7.46 ]
Subtotal (95% CI) 65 62 100.0 % 0.29 [ 0.01, 7.46 ]
Total events: 0 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
6 Octreotide versus control
McKay 1997a 14/28 11/30 100.0 % 1.73 [ 0.61, 4.93 ]
Subtotal (95% CI) 28 30 100.0 % 1.73 [ 0.61, 4.93 ]
Total events: 14 (Intervention), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
7 Somatostatin versus control
Gj rup 1992 4/33 0/30 7.6 % 9.31 [ 0.48, 180.52 ]
Yang 1999 3/25 6/23 92.4 % 0.39 [ 0.08, 1.77 ]
Subtotal (95% CI) 58 53 100.0 % 1.07 [ 0.35, 3.27 ]
Total events: 7 (Intervention), 6 (Control)
Heterogeneity: Chi2 = 3.76, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.11 (P = 0.91)
8 Gabexate versus aprotinin
Frulloni 1994 4/65 3/51 100.0 % 1.05 [ 0.22, 4.91 ]
Subtotal (95% CI) 65 51 100.0 % 1.05 [ 0.22, 4.91 ]
Total events: 4 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
9 Ulinastatin versus gabexate
Chen 2002a 0/48 0/14 Not estimable
Subtotal (95% CI) 48 14 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.3. Comparison 1 Acute pancreatitis, Outcome 3 Serious adverse events (number).
Review: Pharmacological interventions for acute pancreatitis
Comparison: 1 Acute pancreatitis
Outcome: 3 Serious adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Antibiotics versus control
Barreda 2009 24 34 0.28377 (0.3594) 10.3 % 1.33 [ 0.66, 2.69 ]
Delcenserie 1996 11 12 -1.99243 (1.06066) 1.2 % 0.14 [ 0.02, 1.09 ]
Delcenserie 2001 53 28 -0.33581 (0.319847) 13.0 % 0.71 [ 0.38, 1.34 ]
Garcia-Barrasa 2009 22 19 -0.36975 (0.474342) 5.9 % 0.69 [ 0.27, 1.75 ]
Isenmann 2004 58 56 0.14259 (0.225906) 26.0 % 1.15 [ 0.74, 1.80 ]
Nordback 2001 25 33 -0.5333 (0.600925) 3.7 % 0.59 [ 0.18, 1.91 ]
Pederzoli 1993a 41 33 -0.51935 (0.319847) 13.0 % 0.59 [ 0.32, 1.11 ]
Poropat 2015 23 24 -0.24512 (0.540062) 4.5 % 0.78 [ 0.27, 2.26 ]
Sainio 1995 30 30 -0.69315 (0.612372) 3.5 % 0.50 [ 0.15, 1.66 ]
Spicak 2002 33 30 -0.09531 (0.447214) 6.6 % 0.91 [ 0.38, 2.18 ]
Spicak 2003 20 21 -0.35667 (0.645497) 3.2 % 0.70 [ 0.20, 2.48 ]
Xue 2009 29 27 0.071642 (0.378932) 9.2 % 1.07 [ 0.51, 2.26 ]
Subtotal (95% CI) 369 347 100.0 % 0.86 [ 0.68, 1.07 ]
Heterogeneity: Chi2 = 9.72, df = 11 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
2 Antioxidants versus control
Bansal 2011 20 21 0.04879 (2) 35.3 % 1.05 [ 0.02, 52.92 ]
Vege 2015 15 15 -2.3979 (1.477098) 64.7 % 0.09 [ 0.01, 1.64 ]
Subtotal (95% CI) 35 36 100.0 % 0.22 [ 0.02, 2.21 ]
Heterogeneity: Chi2 = 0.97, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
3 Aprotinin versus control
Balldin 1983 26 29 -1.50024 (1.095445) 5.1 % 0.22 [ 0.03, 1.91 ]
Berling 1994 22 26 -0.20067 (0.306622) 65.6 % 0.82 [ 0.45, 1.49 ]
Imrie 1978 80 81 -0.09294 (0.459468) 29.2 % 0.91 [ 0.37, 2.24 ]
Subtotal (95% CI) 128 136 100.0 % 0.79 [ 0.49, 1.29 ]
Heterogeneity: Chi2 = 1.44, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
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Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
4 Cimetidine versus control
Sillero 1981 30 30 0 (0.816497) 100.0 % 1.00 [ 0.20, 4.95 ]
Subtotal (95% CI) 30 30 100.0 % 1.00 [ 0.20, 4.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 EDTA versus control
Tykka 1985 33 31 -0.06252 (0.816497) 100.0 % 0.94 [ 0.19, 4.65 ]
Subtotal (95% CI) 33 31 100.0 % 0.94 [ 0.19, 4.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
6 Gabexate versus control
Buchler 1993 115 108 -0.0628 (0.182574) 67.9 % 0.94 [ 0.66, 1.34 ]
Chen 2000 26 26 -0.45199 (0.279145) 29.1 % 0.64 [ 0.37, 1.10 ]
Valderrama 1992 51 49 0.653142 (0.866025) 3.0 % 1.92 [ 0.35, 10.49 ]
Subtotal (95% CI) 192 183 100.0 % 0.86 [ 0.64, 1.15 ]
Heterogeneity: Chi2 = 2.26, df = 2 (P = 0.32); I2 =11%
Test for overall effect: Z = 1.03 (P = 0.31)
7 Glucagon versus control
Debas 1980 34 34 0 (2) 100.0 % 1.00 [ 0.02, 50.40 ]
Subtotal (95% CI) 34 34 100.0 % 1.00 [ 0.02, 50.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
8 Lexipafant versus control
Johnson 2001 151 139 -0.40489 (0.185722) 100.0 % 0.67 [ 0.46, 0.96 ]
Subtotal (95% CI) 151 139 100.0 % 0.67 [ 0.46, 0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
9 Octreotide versus control
McKay 1997a 28 30 0.212094 (0.378932) 6.9 % 1.24 [ 0.59, 2.60 ]
Paran 1995 19 19 -0.72824 (0.32544) 9.4 % 0.48 [ 0.26, 0.91 ]
Uhl 1999 199 103 -0.09579 (0.186763) 28.6 % 0.91 [ 0.63, 1.31 ]
Wang 2013c 157 79 -0.47916 (0.186697) 28.6 % 0.62 [ 0.43, 0.89 ]
Wang 2013c 91 45 -0.33647 (0.193925) 26.5 % 0.71 [ 0.49, 1.04 ]
Subtotal (95% CI) 494 276 100.0 % 0.74 [ 0.60, 0.89 ]
Heterogeneity: Chi2 = 5.70, df = 4 (P = 0.22); I2 =30%
Test for overall effect: Z = 3.08 (P = 0.0021)
10 Probiotics versus control
Besselink 2008 152 144 0.241397 (0.233465) 64.3 % 1.27 [ 0.81, 2.01 ]
Olah 2007 33 29 -0.86681 (0.366589) 26.1 % 0.42 [ 0.20, 0.86 ]
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Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Zhu 2014 20 19 0.131028 (0.60553) 9.6 % 1.14 [ 0.35, 3.74 ]
Subtotal (95% CI) 205 192 100.0 % 0.94 [ 0.65, 1.36 ]
Heterogeneity: Chi2 = 6.61, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 0.31 (P = 0.76)
11 Somatostatin versus control
Choi 1989 35 36 -1.07044 (0.816497) 7.4 % 0.34 [ 0.07, 1.70 ]
Gj rup 1992 34 31 2.104851 (1.490712) 2.2 % 8.21 [ 0.44, 152.41 ]
Wang 2013a 61 60 0.065709 (0.23428) 90.3 % 1.07 [ 0.67, 1.69 ]
Subtotal (95% CI) 130 127 100.0 % 1.03 [ 0.66, 1.59 ]
Heterogeneity: Chi2 = 3.78, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.12 (P = 0.90)
12 Somatostatin plus omeprazole versus control
Xia 2014 70 70 -1.0116 (0.3371) 100.0 % 0.36 [ 0.19, 0.70 ]
Subtotal (95% CI) 70 70 100.0 % 0.36 [ 0.19, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
13 Somatostatin plus ulinastatin versus control
Wang 2013a 62 60 -1.19024 (0.34566) 100.0 % 0.30 [ 0.15, 0.60 ]
Subtotal (95% CI) 62 60 100.0 % 0.30 [ 0.15, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.44 (P = 0.00057)
14 Glucagon versus atropine
Kirsch 1978 75 75 -1.09861 (1.154701) 100.0 % 0.33 [ 0.03, 3.20 ]
Subtotal (95% CI) 75 75 100.0 % 0.33 [ 0.03, 3.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
15 Octreotide plus ulinastatin versus octreotide
Guo 2015 60 60 -1.20984 (0.27635) 100.0 % 0.30 [ 0.17, 0.51 ]
Subtotal (95% CI) 60 60 100.0 % 0.30 [ 0.17, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.38 (P = 0.000012)
16 Somatostatin plus ulinastatin versus somatostatin
Wang 2013a 62 61 -1.25595 (0.342381) 100.0 % 0.28 [ 0.15, 0.56 ]
Subtotal (95% CI) 62 61 100.0 % 0.28 [ 0.15, 0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.67 (P = 0.00024)
0.005 0.1 1 10 200
Favours intervention Favours control
178Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Acute pancreatitis, Outcome 4 Organ failure.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 1 Acute pancreatitis
Outcome: 4 Organ failure
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Antibiotics versus control
Delcenserie 1996 1/11 1/12 3.9 % 1.10 [ 0.06, 20.01 ]
Garcia-Barrasa 2009 13/22 10/19 21.4 % 1.30 [ 0.38, 4.48 ]
Pederzoli 1993a 12/41 13/33 34.8 % 0.64 [ 0.24, 1.68 ]
Poropat 2015 4/23 5/24 15.4 % 0.80 [ 0.19, 3.45 ]
Rokke 2007 6/36 9/37 24.6 % 0.62 [ 0.20, 1.97 ]
Subtotal (95% CI) 133 125 100.0 % 0.78 [ 0.44, 1.38 ]
Total events: 36 (Intervention), 38 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 4 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
2 Antioxidants versus control
Bansal 2011 7/19 8/20 38.7 % 0.88 [ 0.24, 3.18 ]
Sateesh 2009 2/23 4/30 21.0 % 0.62 [ 0.10, 3.72 ]
Siriwardena 2007 7/22 4/21 32.9 % 1.98 [ 0.48, 8.13 ]
Vege 2015 0/14 3/14 7.4 % 0.11 [ 0.01, 2.42 ]
Subtotal (95% CI) 78 85 100.0 % 0.92 [ 0.39, 2.12 ]
Total events: 16 (Intervention), 19 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 3.17, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 0.21 (P = 0.84)
3 Gabexate versus control
Freise 1986 0/25 1/25 100.0 % 0.32 [ 0.01, 8.25 ]
Subtotal (95% CI) 25 25 100.0 % 0.32 [ 0.01, 8.25 ]
Total events: 0 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
4 Lexipafant versus control
Johnson 2001 18/151 21/139 87.0 % 0.76 [ 0.39, 1.50 ]
McKay 1997b 2/26 5/24 13.0 % 0.32 [ 0.06, 1.82 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 177 163 100.0 % 0.68 [ 0.36, 1.27 ]
Total events: 20 (Intervention), 26 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
5 Octreotide versus control
McKay 1997a 12/28 11/30 23.3 % 1.30 [ 0.45, 3.72 ]
Wang 2013c 53/157 45/79 42.8 % 0.39 [ 0.22, 0.67 ]
Wang 2013c 40/91 30/45 34.0 % 0.39 [ 0.19, 0.83 ]
Subtotal (95% CI) 276 154 100.0 % 0.51 [ 0.27, 0.97 ]
Total events: 105 (Intervention), 86 (Control)
Heterogeneity: Tau2 = 0.17; Chi2 = 4.27, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 2.04 (P = 0.041)
6 Probiotics versus control
Besselink 2008 21/152 16/144 59.9 % 1.28 [ 0.64, 2.57 ]
Olah 2007 5/33 9/29 40.1 % 0.40 [ 0.12, 1.36 ]
Subtotal (95% CI) 185 173 100.0 % 0.80 [ 0.26, 2.47 ]
Total events: 26 (Intervention), 25 (Control)
Heterogeneity: Tau2 = 0.43; Chi2 = 2.63, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.39 (P = 0.70)
7 Ulinastatin versus control
Abraham 2013 12/35 29/32 50.1 % 0.05 [ 0.01, 0.21 ]
Abraham 2013 5/30 4/32 49.9 % 1.40 [ 0.34, 5.80 ]
Subtotal (95% CI) 65 64 100.0 % 0.27 [ 0.01, 6.67 ]
Total events: 17 (Intervention), 33 (Control)
Heterogeneity: Tau2 = 4.80; Chi2 = 10.41, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 0.80 (P = 0.43)
8 Somatostatin plus gabexate versus somatostatin
Wang 2016 11/130 13/122 100.0 % 0.78 [ 0.33, 1.80 ]
Subtotal (95% CI) 130 122 100.0 % 0.78 [ 0.33, 1.80 ]
Total events: 11 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
9 Somatostatin plus ulinastatin versus somatostatin
Wang 2016 8/124 13/122 100.0 % 0.58 [ 0.23, 1.45 ]
Subtotal (95% CI) 124 122 100.0 % 0.58 [ 0.23, 1.45 ]
Total events: 8 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
10 Somatostatin plus ulinastatin plus gabexate versus somatostatin
Wang 2016 6/116 13/122 100.0 % 0.46 [ 0.17, 1.25 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 116 122 100.0 % 0.46 [ 0.17, 1.25 ]
Total events: 6 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
11 Somatostatin plus ulinastatin versus somatostatin plus gabexate
Wang 2016 8/124 11/130 100.0 % 0.75 [ 0.29, 1.92 ]
Subtotal (95% CI) 124 130 100.0 % 0.75 [ 0.29, 1.92 ]
Total events: 8 (Intervention), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
12 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus gabexate
Wang 2016 6/116 11/130 100.0 % 0.59 [ 0.21, 1.65 ]
Subtotal (95% CI) 116 130 100.0 % 0.59 [ 0.21, 1.65 ]
Total events: 6 (Intervention), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
13 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus ulinastatin
Wang 2016 6/116 8/124 100.0 % 0.79 [ 0.27, 2.35 ]
Subtotal (95% CI) 116 124 100.0 % 0.79 [ 0.27, 2.35 ]
Total events: 6 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
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Analysis 1.5. Comparison 1 Acute pancreatitis, Outcome 5 Infected pancreatic necrosis.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 1 Acute pancreatitis
Outcome: 5 Infected pancreatic necrosis
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Barreda 2009 3/24 2/34 3.1 % 2.29 [ 0.35, 14.86 ]
Delcenserie 1996 0/11 3/12 6.8 % 0.12 [ 0.01, 2.58 ]
Dellinger 2007 9/50 6/50 10.4 % 1.61 [ 0.53, 4.92 ]
Garcia-Barrasa 2009 8/22 8/19 11.6 % 0.79 [ 0.22, 2.77 ]
Isenmann 2004 7/58 5/56 9.5 % 1.40 [ 0.42, 4.70 ]
Llukacaj 2012 6/40 4/40 7.2 % 1.59 [ 0.41, 6.12 ]
Pederzoli 1993a 5/41 10/33 20.6 % 0.32 [ 0.10, 1.05 ]
Poropat 2015 2/23 3/24 5.7 % 0.67 [ 0.10, 4.41 ]
Rokke 2007 3/36 7/37 13.4 % 0.39 [ 0.09, 1.64 ]
Spicak 2002 1/33 0/30 1.1 % 2.82 [ 0.11, 71.78 ]
Spicak 2003 3/20 6/21 10.6 % 0.44 [ 0.09, 2.08 ]
Subtotal (95% CI) 358 356 100.0 % 0.82 [ 0.53, 1.25 ]
Total events: 47 (Intervention), 54 (Control)
Heterogeneity: Chi2 = 10.39, df = 10 (P = 0.41); I2 =4%
Test for overall effect: Z = 0.93 (P = 0.35)
2 Octreotide versus control
McKay 1997a 1/28 2/30 100.0 % 0.52 [ 0.04, 6.06 ]
Subtotal (95% CI) 28 30 100.0 % 0.52 [ 0.04, 6.06 ]
Total events: 1 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
3 Probiotics versus control
Besselink 2008 21/152 14/144 56.4 % 1.49 [ 0.73, 3.05 ]
Olah 2007 2/33 6/29 27.3 % 0.25 [ 0.05, 1.34 ]
Zhu 2014 6/20 5/19 16.3 % 1.20 [ 0.30, 4.86 ]
Subtotal (95% CI) 205 192 100.0 % 1.10 [ 0.62, 1.96 ]
Total events: 29 (Intervention), 25 (Control)
Heterogeneity: Chi2 = 3.69, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 0.33 (P = 0.74)
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Analysis 1.6. Comparison 1 Acute pancreatitis, Outcome 6 Sepsis.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 1 Acute pancreatitis
Outcome: 6 Sepsis
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Antibiotics versus control
Sainio 1995 4/30 8/30 100.0 % 0.42 [ 0.11, 1.60 ]
Subtotal (95% CI) 30 30 100.0 % 0.42 [ 0.11, 1.60 ]
Total events: 4 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
2 Aprotinin versus control
Balldin 1983 1/26 0/29 16.8 % 3.47 [ 0.14, 88.99 ]
Berling 1994 5/22 4/26 83.2 % 1.62 [ 0.38, 6.96 ]
Subtotal (95% CI) 48 55 100.0 % 1.84 [ 0.49, 6.96 ]
Total events: 6 (Intervention), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
3 Gabexate versus control
Buchler 1993 18/115 17/108 90.9 % 0.99 [ 0.48, 2.04 ]
Freise 1986 1/25 0/25 4.5 % 3.12 [ 0.12, 80.39 ]
Valderrama 1992 1/51 0/49 4.6 % 2.94 [ 0.12, 73.93 ]
Subtotal (95% CI) 191 182 100.0 % 1.10 [ 0.55, 2.19 ]
Total events: 20 (Intervention), 17 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
4 Lexipafant versus control
Johnson 2001 4/151 13/139 100.0 % 0.26 [ 0.08, 0.83 ]
Subtotal (95% CI) 151 139 100.0 % 0.26 [ 0.08, 0.83 ]
Total events: 4 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
5 Octreotide versus control
Paran 1995 5/19 14/19 48.3 % 0.13 [ 0.03, 0.54 ]
Uhl 1999 9/199 4/103 51.7 % 1.17 [ 0.35, 3.90 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 218 122 100.0 % 0.40 [ 0.05, 3.53 ]
Total events: 14 (Intervention), 18 (Control)
Heterogeneity: Tau2 = 2.00; Chi2 = 5.35, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.82 (P = 0.41)
6 Probiotics versus control
Olah 2007 4/33 8/29 100.0 % 0.36 [ 0.10, 1.36 ]
Subtotal (95% CI) 33 29 100.0 % 0.36 [ 0.10, 1.36 ]
Total events: 4 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
7 Gabexate versus aprotinin
Frulloni 1994 4/65 3/51 100.0 % 1.05 [ 0.22, 4.91 ]
Subtotal (95% CI) 65 51 100.0 % 1.05 [ 0.22, 4.91 ]
Total events: 4 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
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Analysis 1.7. Comparison 1 Acute pancreatitis, Outcome 7 Adverse events (proportion).
Review: Pharmacological interventions for acute pancreatitis
Comparison: 1 Acute pancreatitis
Outcome: 7 Adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Dellinger 2007 32/50 42/50 28.4 % 0.34 [ 0.13, 0.88 ]
Finch 1976 6/31 5/27 8.1 % 1.06 [ 0.28, 3.94 ]
Llukacaj 2012 6/40 4/40 6.4 % 1.59 [ 0.41, 6.12 ]
Nordback 2001 5/25 11/33 14.3 % 0.50 [ 0.15, 1.69 ]
Rokke 2007 12/36 22/37 27.2 % 0.34 [ 0.13, 0.89 ]
Sainio 1995 20/30 25/30 15.7 % 0.40 [ 0.12, 1.36 ]
Subtotal (95% CI) 212 217 100.0 % 0.51 [ 0.32, 0.80 ]
Total events: 81 (Intervention), 109 (Control)
Heterogeneity: Chi2 = 5.44, df = 5 (P = 0.36); I2 =8%
Test for overall effect: Z = 2.92 (P = 0.0035)
2 Antioxidants versus control
Bansal 2011 0/19 0/20 Not estimable
Subtotal (95% CI) 19 20 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcitonin versus control
Goebell 1979 2/50 2/44 100.0 % 0.88 [ 0.12, 6.49 ]
Subtotal (95% CI) 50 44 100.0 % 0.88 [ 0.12, 6.49 ]
Total events: 2 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
4 EDTA versus control
Tykka 1985 9/33 10/31 100.0 % 0.79 [ 0.27, 2.31 ]
Subtotal (95% CI) 33 31 100.0 % 0.79 [ 0.27, 2.31 ]
Total events: 9 (Intervention), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
5 Gabexate versus control
Buchler 1993 74/115 68/108 52.8 % 1.06 [ 0.61, 1.83 ]
Freise 1986 7/25 16/25 24.3 % 0.22 [ 0.07, 0.72 ]
0.001 0.01 0.1 1 10 100 1000
Favours intervention Favours control
(Continued . . . )
185Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Valderrama 1992 15/51 15/49 22.8 % 0.94 [ 0.40, 2.22 ]
Subtotal (95% CI) 191 182 100.0 % 0.83 [ 0.54, 1.27 ]
Total events: 96 (Intervention), 99 (Control)
Heterogeneity: Chi2 = 5.65, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.87 (P = 0.39)
6 Glucagon versus control
Debas 1980 0/33 0/33 Not estimable
Kalima 1980 0/32 4/29 100.0 % 0.09 [ 0.00, 1.69 ]
Subtotal (95% CI) 65 62 100.0 % 0.09 [ 0.00, 1.69 ]
Total events: 0 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
7 Lexipafant versus control
Kingsnorth 1995 9/42 16/41 100.0 % 0.43 [ 0.16, 1.12 ]
Subtotal (95% CI) 42 41 100.0 % 0.43 [ 0.16, 1.12 ]
Total events: 9 (Intervention), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
8 Octreotide versus control
McKay 1997a 15/28 11/30 12.2 % 1.99 [ 0.70, 5.70 ]
Paran 1995 5/19 14/19 25.5 % 0.13 [ 0.03, 0.54 ]
Uhl 1999 147/199 73/103 62.2 % 1.16 [ 0.68, 1.97 ]
Subtotal (95% CI) 246 152 100.0 % 1.00 [ 0.65, 1.55 ]
Total events: 167 (Intervention), 98 (Control)
Heterogeneity: Chi2 = 9.78, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 0.00 (P = 1.0)
9 Probiotics versus control
Olah 2007 9/33 15/29 100.0 % 0.35 [ 0.12, 1.01 ]
Subtotal (95% CI) 33 29 100.0 % 0.35 [ 0.12, 1.01 ]
Total events: 9 (Intervention), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.052)
10 Somatostatin versus control
Gj rup 1992 19/33 21/30 56.0 % 0.58 [ 0.21, 1.65 ]
Yang 1999 3/25 8/23 44.0 % 0.26 [ 0.06, 1.12 ]
Subtotal (95% CI) 58 53 100.0 % 0.44 [ 0.19, 1.02 ]
Total events: 22 (Intervention), 29 (Control)
Heterogeneity: Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
11 Somatostatin plus omeprazole versus control
Xia 2014 18/70 70/70 100.0 % 0.00 [ 0.00, 0.04 ]
Subtotal (95% CI) 70 70 100.0 % 0.00 [ 0.00, 0.04 ]
Total events: 18 (Intervention), 70 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.15 (P = 0.000034)
12 Gabexate versus aprotinin
Frulloni 1994 13/65 23/51 50.4 % 0.30 [ 0.13, 0.69 ]
Pederzoli 1993b 14/91 24/91 49.6 % 0.51 [ 0.24, 1.06 ]
Subtotal (95% CI) 156 142 100.0 % 0.41 [ 0.23, 0.70 ]
Total events: 27 (Intervention), 47 (Control)
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 3.24 (P = 0.0012)
13 Ulinastatin versus gabexate
Chen 2002a 0/48 0/14 Not estimable
Subtotal (95% CI) 48 14 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
14 Ulinastatin versus octreotide
Chen 2002b 8/14 4/11 100.0 % 2.33 [ 0.46, 11.81 ]
Subtotal (95% CI) 14 11 100.0 % 2.33 [ 0.46, 11.81 ]
Total events: 8 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
15 Somatostatin plus gabexate versus somatostatin
Wang 2016 16/130 16/122 100.0 % 0.93 [ 0.44, 1.95 ]
Subtotal (95% CI) 130 122 100.0 % 0.93 [ 0.44, 1.95 ]
Total events: 16 (Intervention), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
16 Somatostatin plus ulinastatin versus somatostatin
Wang 2016 10/124 16/122 100.0 % 0.58 [ 0.25, 1.34 ]
Subtotal (95% CI) 124 122 100.0 % 0.58 [ 0.25, 1.34 ]
Total events: 10 (Intervention), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
17 Somatostatin plus ulinastatin plus gabexate versus somatostatin
Wang 2016 8/116 16/122 100.0 % 0.49 [ 0.20, 1.20 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 116 122 100.0 % 0.49 [ 0.20, 1.20 ]
Total events: 8 (Intervention), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
18 Somatostatin plus ulinastatin versus somatostatin plus gabexate
Wang 2016 10/124 16/130 100.0 % 0.63 [ 0.27, 1.44 ]
Subtotal (95% CI) 124 130 100.0 % 0.63 [ 0.27, 1.44 ]
Total events: 10 (Intervention), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
19 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus gabexate
Wang 2016 8/116 16/130 100.0 % 0.53 [ 0.22, 1.28 ]
Subtotal (95% CI) 116 130 100.0 % 0.53 [ 0.22, 1.28 ]
Total events: 8 (Intervention), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
20 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus ulinastatin
Wang 2016 8/116 10/124 100.0 % 0.84 [ 0.32, 2.22 ]
Subtotal (95% CI) 116 124 100.0 % 0.84 [ 0.32, 2.22 ]
Total events: 8 (Intervention), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
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Analysis 1.8. Comparison 1 Acute pancreatitis, Outcome 8 Adverse events (number).
Review: Pharmacological interventions for acute pancreatitis
Comparison: 1 Acute pancreatitis
Outcome: 8 Adverse events (number)
Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Antibiotics versus control
Barreda 2009 24 34 0.20723 (0.23795) 9.4 % 1.23 [ 0.77, 1.96 ]
Garcia-Barrasa 2009 22 19 -0.26439 (0.343592) 6.8 % 0.77 [ 0.39, 1.51 ]
Hejtmankova 2003 20 21 -0.23889 (0.288675) 8.1 % 0.79 [ 0.45, 1.39 ]
Isenmann 2004 58 56 0.046826 (0.153072) 11.7 % 1.05 [ 0.78, 1.41 ]
Luiten 1995 50 52 -1.08292 (0.307708) 7.6 % 0.34 [ 0.19, 0.62 ]
Nordback 2001 25 33 -0.99533 (0.427618) 5.3 % 0.37 [ 0.16, 0.85 ]
Pederzoli 1993a 41 33 -0.74513 (0.262905) 8.7 % 0.47 [ 0.28, 0.79 ]
Poropat 2015 23 24 -0.50749 (0.324235) 7.3 % 0.60 [ 0.32, 1.14 ]
Sainio 1995 30 30 -0.58779 (0.22771) 9.7 % 0.56 [ 0.36, 0.87 ]
Spicak 2002 33 30 -0.09531 (0.324443) 7.2 % 0.91 [ 0.48, 1.72 ]
Spicak 2003 20 21 0.107631 (0.242641) 9.2 % 1.11 [ 0.69, 1.79 ]
Xue 2009 29 27 0.122697 (0.255198) 8.9 % 1.13 [ 0.69, 1.86 ]
Subtotal (95% CI) 375 380 100.0 % 0.75 [ 0.58, 0.95 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 28.59, df = 11 (P = 0.003); I2 =62%
Test for overall effect: Z = 2.35 (P = 0.019)
2 Antioxidants versus control
Bansal 2011 20 21 0.04879 (2) 3.9 % 1.05 [ 0.02, 52.92 ]
Sateesh 2009 23 30 -0.2043 (0.403113) 96.1 % 0.82 [ 0.37, 1.80 ]
Subtotal (95% CI) 43 51 100.0 % 0.82 [ 0.38, 1.79 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
3 Aprotinin versus control
Balldin 1983 26 29 0.2523 (0.378932) 22.5 % 1.29 [ 0.61, 2.70 ]
Berling 1994 22 26 -0.09531 (0.242846) 54.9 % 0.91 [ 0.56, 1.46 ]
Imrie 1978 80 81 -0.13068 (0.378932) 22.5 % 0.88 [ 0.42, 1.84 ]
Subtotal (95% CI) 128 136 100.0 % 0.98 [ 0.69, 1.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
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Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
4 Calcitonin versus control
Goebell 1979 50 44 -0.12783 (1) 100.0 % 0.88 [ 0.12, 6.25 ]
Subtotal (95% CI) 50 44 100.0 % 0.88 [ 0.12, 6.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
5 Cimetidine versus control
Sillero 1981 30 30 0.127833 (0.292326) 100.0 % 1.14 [ 0.64, 2.02 ]
Subtotal (95% CI) 30 30 100.0 % 1.14 [ 0.64, 2.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
6 EDTA versus control
Tykka 1985 33 31 -0.46799 (0.408248) 100.0 % 0.63 [ 0.28, 1.39 ]
Subtotal (95% CI) 33 31 100.0 % 0.63 [ 0.28, 1.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
7 Gabexate versus control
Buchler 1993 115 108 -0.2035 (0.115949) 70.1 % 0.82 [ 0.65, 1.02 ]
Chen 2000 26 26 -0.62253 (0.264282) 17.0 % 0.54 [ 0.32, 0.90 ]
Valderrama 1992 51 49 -0.17977 (0.305742) 12.9 % 0.84 [ 0.46, 1.52 ]
Subtotal (95% CI) 192 183 100.0 % 0.76 [ 0.61, 0.95 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.19, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 2.41 (P = 0.016)
8 Glucagon versus control
Debas 1980 34 34 0 (2) 4.8 % 1.00 [ 0.02, 50.40 ]
Kronborg 1980 10 12 0.182322 (0.447214) 95.2 % 1.20 [ 0.50, 2.88 ]
Subtotal (95% CI) 44 46 100.0 % 1.19 [ 0.51, 2.80 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
9 Lexipafant versus control
Johnson 2001 151 139 -0.4997 (0.16913) 100.0 % 0.61 [ 0.44, 0.85 ]
Subtotal (95% CI) 151 139 100.0 % 0.61 [ 0.44, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.95 (P = 0.0031)
10 Octreotide versus control
McKay 1997a 28 30 0.202524 (0.365963) 12.2 % 1.22 [ 0.60, 2.51 ]
Paran 1995 19 19 -0.58192 (0.286432) 17.0 % 0.56 [ 0.32, 0.98 ]
Uhl 1999 199 103 -0.07273 (0.095133) 37.8 % 0.93 [ 0.77, 1.12 ]
Wang 2013c 157 79 -0.44778 (0.133694) 32.9 % 0.64 [ 0.49, 0.83 ]
Subtotal (95% CI) 403 231 100.0 % 0.78 [ 0.58, 1.05 ]
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Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.05; Chi2 = 8.20, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 1.66 (P = 0.097)
11 Probiotics versus control
Besselink 2008 152 144 0.113925 (0.106076) 45.0 % 1.12 [ 0.91, 1.38 ]
Olah 2007 33 29 -0.78314 (0.34194) 25.3 % 0.46 [ 0.23, 0.89 ]
Zhu 2014 20 19 -0.09212 (0.285774) 29.7 % 0.91 [ 0.52, 1.60 ]
Subtotal (95% CI) 205 192 100.0 % 0.84 [ 0.52, 1.36 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 6.45, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 0.70 (P = 0.48)
12 Somatostatin versus control
Choi 1989 35 36 -0.92734 (0.526235) 41.4 % 0.40 [ 0.14, 1.11 ]
Gj rup 1992 33 30 0.172954 (0.260525) 58.6 % 1.19 [ 0.71, 1.98 ]
Subtotal (95% CI) 68 66 100.0 % 0.75 [ 0.26, 2.18 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 3.51, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.52 (P = 0.60)
13 Ulinastatin versus control
Abraham 2013 30 32 0.005698 (0.242641) 50.6 % 1.01 [ 0.63, 1.62 ]
Abraham 2013 35 32 -0.76078 (0.256321) 49.4 % 0.47 [ 0.28, 0.77 ]
Subtotal (95% CI) 65 64 100.0 % 0.69 [ 0.32, 1.46 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 4.72, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.97 (P = 0.33)
14 Gabexate versus aprotinin
Pederzoli 1993b 91 91 -0.42121 (0.280836) 100.0 % 0.66 [ 0.38, 1.14 ]
Subtotal (95% CI) 91 91 100.0 % 0.66 [ 0.38, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
15 Glucagon versus atropine
Kirsch 1978 75 75 -0.24116 (0.402911) 100.0 % 0.79 [ 0.36, 1.73 ]
Subtotal (95% CI) 75 75 100.0 % 0.79 [ 0.36, 1.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
16 Oxyphenonium versus glucagon
Gilsanz 1978 31 31 -0.06899 (0.185806) 100.0 % 0.93 [ 0.65, 1.34 ]
Subtotal (95% CI) 31 31 100.0 % 0.93 [ 0.65, 1.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
17 Octreotide plus ulinastatin versus octreotide
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Study or subgroup Intervention Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Guo 2015 60 60 -1.25276 (0.26726) 100.0 % 0.29 [ 0.17, 0.48 ]
Subtotal (95% CI) 60 60 100.0 % 0.29 [ 0.17, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.69 (P < 0.00001)
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Analysis 1.9. Comparison 1 Acute pancreatitis, Outcome 9 Requirement for additional invasive
intervention.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 1 Acute pancreatitis
Outcome: 9 Requirement for additional invasive intervention
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Barreda 2009 4/24 2/34 1.7 % 3.20 [ 0.54, 19.11 ]
Delcenserie 1996 0/11 3/12 3.9 % 0.12 [ 0.01, 2.58 ]
Garcia-Barrasa 2009 11/22 8/19 5.2 % 1.38 [ 0.40, 4.73 ]
Hejtmankova 2003 4/20 5/21 4.7 % 0.80 [ 0.18, 3.54 ]
Isenmann 2004 10/58 6/56 6.1 % 1.74 [ 0.59, 5.15 ]
Llukacaj 2012 10/40 8/40 7.3 % 1.33 [ 0.46, 3.83 ]
Luiten 1995 16/50 24/52 19.4 % 0.55 [ 0.25, 1.23 ]
Nordback 2001 2/25 5/33 4.8 % 0.49 [ 0.09, 2.75 ]
Pederzoli 1993a 12/41 11/33 10.4 % 0.83 [ 0.31, 2.22 ]
Rokke 2007 3/36 3/37 3.3 % 1.03 [ 0.19, 5.48 ]
Sainio 1995 7/30 14/30 13.0 % 0.35 [ 0.11, 1.05 ]
Spicak 2002 6/33 7/30 7.3 % 0.73 [ 0.21, 2.48 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Spicak 2003 4/20 5/21 4.7 % 0.80 [ 0.18, 3.54 ]
Xue 2009 8/29 9/27 8.2 % 0.76 [ 0.24, 2.39 ]
Subtotal (95% CI) 439 445 100.0 % 0.82 [ 0.59, 1.13 ]
Total events: 97 (Intervention), 110 (Control)
Heterogeneity: Chi2 = 10.79, df = 13 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
2 Aprotinin versus control
Berling 1994 0/22 6/26 45.6 % 0.07 [ 0.00, 1.32 ]
MRC Multicentre Trial 1977 6/66 11/123 54.4 % 1.02 [ 0.36, 2.89 ]
Subtotal (95% CI) 88 149 100.0 % 0.59 [ 0.23, 1.47 ]
Total events: 6 (Intervention), 17 (Control)
Heterogeneity: Chi2 = 3.08, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 1.14 (P = 0.25)
3 Calcitonin versus control
Goebell 1979 2/50 5/44 60.4 % 0.33 [ 0.06, 1.77 ]
Martinez 1984 1/14 4/17 39.6 % 0.25 [ 0.02, 2.55 ]
Subtotal (95% CI) 64 61 100.0 % 0.30 [ 0.08, 1.16 ]
Total events: 3 (Intervention), 9 (Control)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.080)
4 Cimetidine versus control
Sillero 1981 0/30 3/30 100.0 % 0.13 [ 0.01, 2.61 ]
Subtotal (95% CI) 30 30 100.0 % 0.13 [ 0.01, 2.61 ]
Total events: 0 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
5 EDTA versus control
Tykka 1985 3/33 4/31 100.0 % 0.68 [ 0.14, 3.29 ]
Subtotal (95% CI) 33 31 100.0 % 0.68 [ 0.14, 3.29 ]
Total events: 3 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
6 Gabexate versus control
Buchler 1993 23/115 25/108 40.1 % 0.83 [ 0.44, 1.57 ]
Chen 2000 7/26 13/26 18.5 % 0.37 [ 0.12, 1.17 ]
Goebell 1988 14/76 26/75 41.5 % 0.43 [ 0.20, 0.90 ]
Subtotal (95% CI) 217 209 100.0 % 0.58 [ 0.37, 0.90 ]
Total events: 44 (Intervention), 64 (Control)
Heterogeneity: Chi2 = 2.45, df = 2 (P = 0.29); I2 =18%
Test for overall effect: Z = 2.43 (P = 0.015)
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
7 Glucagon versus control
Du¨rr 1978 5/33 5/36 37.0 % 1.11 [ 0.29, 4.23 ]
MRC Multicentre Trial 1977 8/68 11/123 63.0 % 1.36 [ 0.52, 3.56 ]
Subtotal (95% CI) 101 159 100.0 % 1.26 [ 0.58, 2.77 ]
Total events: 13 (Intervention), 16 (Control)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
8 Octreotide versus control
Ohair 1993 7/90 6/90 13.6 % 1.18 [ 0.38, 3.66 ]
Uhl 1999 27/199 19/103 53.4 % 0.69 [ 0.37, 1.32 ]
Wang 2013c 11/91 7/45 20.3 % 0.75 [ 0.27, 2.08 ]
Wang 2013c 5/157 4/79 12.7 % 0.62 [ 0.16, 2.36 ]
Subtotal (95% CI) 537 317 100.0 % 0.76 [ 0.48, 1.21 ]
Total events: 50 (Intervention), 36 (Control)
Heterogeneity: Chi2 = 0.75, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
9 Probiotics versus control
Besselink 2008 28/152 14/144 64.2 % 2.10 [ 1.05, 4.17 ]
Olah 2007 4/33 7/29 35.8 % 0.43 [ 0.11, 1.67 ]
Subtotal (95% CI) 185 173 100.0 % 1.50 [ 0.83, 2.71 ]
Total events: 32 (Intervention), 21 (Control)
Heterogeneity: Chi2 = 4.17, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.35 (P = 0.18)
10 Somatostatin versus control
Luengo 1994 4/50 9/50 100.0 % 0.40 [ 0.11, 1.38 ]
Subtotal (95% CI) 50 50 100.0 % 0.40 [ 0.11, 1.38 ]
Total events: 4 (Intervention), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
11 Gabexate versus aprotinin
Pederzoli 1993b 7/91 13/91 100.0 % 0.50 [ 0.19, 1.32 ]
Subtotal (95% CI) 91 91 100.0 % 0.50 [ 0.19, 1.32 ]
Total events: 7 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
12 Glucagon versus aprotinin
MRC Multicentre Trial 1977 8/68 6/66 100.0 % 1.33 [ 0.44, 4.08 ]
Subtotal (95% CI) 68 66 100.0 % 1.33 [ 0.44, 4.08 ]
Total events: 8 (Intervention), 6 (Control)
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.61)
13 Oxyphenonium versus glucagon
Gilsanz 1978 2/31 2/31 100.0 % 1.00 [ 0.13, 7.59 ]
Subtotal (95% CI) 31 31 100.0 % 1.00 [ 0.13, 7.59 ]
Total events: 2 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
0.005 0.1 1 10 200
Favours intervention Favours control
Analysis 1.10. Comparison 1 Acute pancreatitis, Outcome 10 Endoscopic or radiological drainage of
collections.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 1 Acute pancreatitis
Outcome: 10 Endoscopic or radiological drainage of collections
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Delcenserie 1996 0/11 1/12 100.0 % 0.33 [ 0.01, 9.07 ]
Subtotal (95% CI) 11 12 100.0 % 0.33 [ 0.01, 9.07 ]
Total events: 0 (Intervention), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
2 Octreotide versus control
Wang 2013c 6/157 3/79 29.8 % 1.01 [ 0.25, 4.14 ]
Wang 2013c 14/91 8/45 70.2 % 0.84 [ 0.32, 2.18 ]
Subtotal (95% CI) 248 124 100.0 % 0.89 [ 0.40, 1.96 ]
Total events: 20 (Intervention), 11 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
0.01 0.1 1 10 100
Favours intervention Favours control
(Continued . . . )
195Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.29 (P = 0.77)
3 Probiotics versus control
Zhu 2014 4/20 4/19 100.0 % 0.94 [ 0.20, 4.44 ]
Subtotal (95% CI) 20 19 100.0 % 0.94 [ 0.20, 4.44 ]
Total events: 4 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
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Analysis 2.1. Comparison 2 Acute necrotising pancreatitis, Outcome 1 Short-term mortality.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 2 Acute necrotising pancreatitis
Outcome: 1 Short-term mortality
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Barreda 2009 0/24 0/34 Not estimable
Delcenserie 2001 6/53 3/28 8.7 % 1.06 [ 0.24, 4.62 ]
Dellinger 2007 10/50 9/50 17.9 % 1.14 [ 0.42, 3.10 ]
Garcia-Barrasa 2009 4/22 2/19 4.4 % 1.89 [ 0.31, 11.68 ]
Llukacaj 2012 8/40 6/40 11.9 % 1.42 [ 0.44, 4.53 ]
Nordback 2001 2/25 5/33 9.9 % 0.49 [ 0.09, 2.75 ]
Pederzoli 1993a 3/41 4/33 10.2 % 0.57 [ 0.12, 2.76 ]
Rokke 2007 3/36 4/37 9.0 % 0.75 [ 0.16, 3.62 ]
Sainio 1995 1/30 7/30 16.8 % 0.11 [ 0.01, 0.99 ]
Xue 2009 4/30 5/28 11.2 % 0.71 [ 0.17, 2.96 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 351 332 100.0 % 0.82 [ 0.52, 1.30 ]
Total events: 41 (Intervention), 45 (Control)
Heterogeneity: Chi2 = 6.00, df = 8 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
2 Gabexate versus aprotinin
Frulloni 1994 9/65 12/51 100.0 % 0.52 [ 0.20, 1.36 ]
Subtotal (95% CI) 65 51 100.0 % 0.52 [ 0.20, 1.36 ]
Total events: 9 (Intervention), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
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Analysis 2.2. Comparison 2 Acute necrotising pancreatitis, Outcome 2 Serious adverse events (proportion).
Review: Pharmacological interventions for acute pancreatitis
Comparison: 2 Acute necrotising pancreatitis
Outcome: 2 Serious adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Dellinger 2007 6/50 9/50 35.0 % 0.62 [ 0.20, 1.90 ]
Garcia-Barrasa 2009 13/22 10/19 19.4 % 1.30 [ 0.38, 4.48 ]
Llukacaj 2012 6/40 4/40 15.0 % 1.59 [ 0.41, 6.12 ]
Sainio 1995 4/30 8/30 30.6 % 0.42 [ 0.11, 1.60 ]
Subtotal (95% CI) 142 139 100.0 % 0.84 [ 0.46, 1.54 ]
Total events: 29 (Intervention), 31 (Control)
Heterogeneity: Chi2 = 2.64, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Gabexate versus aprotinin
Frulloni 1994 4/65 3/51 100.0 % 1.05 [ 0.22, 4.91 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 65 51 100.0 % 1.05 [ 0.22, 4.91 ]
Total events: 4 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
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Analysis 2.3. Comparison 2 Acute necrotising pancreatitis, Outcome 3 Serious adverse events (number).
Review: Pharmacological interventions for acute pancreatitis
Comparison: 2 Acute necrotising pancreatitis
Outcome: 3 Serious adverse events (number)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Antibiotics versus control
Barreda 2009 0.28377 (0.3594) 17.5 % 1.33 [ 0.66, 2.69 ]
Delcenserie 2001 -0.33581 (0.319847) 22.1 % 0.71 [ 0.38, 1.34 ]
Garcia-Barrasa 2009 -0.36975 (0.474342) 10.1 % 0.69 [ 0.27, 1.75 ]
Nordback 2001 -0.5333 (0.600925) 6.3 % 0.59 [ 0.18, 1.91 ]
Pederzoli 1993a -0.51935 (0.319847) 22.1 % 0.59 [ 0.32, 1.11 ]
Sainio 1995 -0.69315 (0.612372) 6.0 % 0.50 [ 0.15, 1.66 ]
Xue 2009 0.071642 (0.378932) 15.8 % 1.07 [ 0.51, 2.26 ]
Subtotal (95% CI) 100.0 % 0.79 [ 0.59, 1.06 ]
Heterogeneity: Chi2 = 4.51, df = 6 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
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Analysis 2.4. Comparison 2 Acute necrotising pancreatitis, Outcome 4 Organ failure.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 2 Acute necrotising pancreatitis
Outcome: 4 Organ failure
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Antibiotics versus control
Delcenserie 1996 1/11 1/12 4.6 % 1.10 [ 0.06, 20.01 ]
Garcia-Barrasa 2009 13/22 10/19 25.2 % 1.30 [ 0.38, 4.48 ]
Pederzoli 1993a 12/41 13/33 41.1 % 0.64 [ 0.24, 1.68 ]
Rokke 2007 6/36 9/37 29.0 % 0.62 [ 0.20, 1.97 ]
Subtotal (95% CI) 110 101 100.0 % 0.78 [ 0.42, 1.45 ]
Total events: 32 (Intervention), 33 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
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Analysis 2.5. Comparison 2 Acute necrotising pancreatitis, Outcome 5 Infected pancreatic necrosis.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 2 Acute necrotising pancreatitis
Outcome: 5 Infected pancreatic necrosis
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Barreda 2009 3/24 2/34 4.6 % 2.29 [ 0.35, 14.86 ]
Dellinger 2007 9/50 6/50 15.7 % 1.61 [ 0.53, 4.92 ]
Garcia-Barrasa 2009 8/22 8/19 17.5 % 0.79 [ 0.22, 2.77 ]
Llukacaj 2012 6/40 4/40 10.9 % 1.59 [ 0.41, 6.12 ]
Pederzoli 1993a 5/41 10/33 31.1 % 0.32 [ 0.10, 1.05 ]
Rokke 2007 3/36 7/37 20.2 % 0.39 [ 0.09, 1.64 ]
Subtotal (95% CI) 213 213 100.0 % 0.85 [ 0.51, 1.42 ]
Total events: 34 (Intervention), 37 (Control)
Heterogeneity: Chi2 = 6.88, df = 5 (P = 0.23); I2 =27%
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 2.6. Comparison 2 Acute necrotising pancreatitis, Outcome 6 Sepsis.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 2 Acute necrotising pancreatitis
Outcome: 6 Sepsis
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Antibiotics versus control
Sainio 1995 4/30 8/30 100.0 % 0.42 [ 0.11, 1.60 ]
Subtotal (95% CI) 30 30 100.0 % 0.42 [ 0.11, 1.60 ]
Total events: 4 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
2 Gabexate versus aprotinin
Frulloni 1994 4/65 3/51 100.0 % 1.05 [ 0.22, 4.91 ]
Subtotal (95% CI) 65 51 100.0 % 1.05 [ 0.22, 4.91 ]
Total events: 4 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
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Analysis 3.1. Comparison 3 Severe acute pancreatitis, Outcome 1 Short-term mortality.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 3 Severe acute pancreatitis
Outcome: 1 Short-term mortality
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Delcenserie 1996 1/11 3/12 5.9 % 0.30 [ 0.03, 3.43 ]
Dellinger 2007 10/50 9/50 16.4 % 1.14 [ 0.42, 3.10 ]
Garcia-Barrasa 2009 4/22 2/19 4.0 % 1.89 [ 0.31, 11.68 ]
Hejtmankova 2003 4/20 5/21 8.9 % 0.80 [ 0.18, 3.54 ]
Luiten 1995 11/50 18/52 31.4 % 0.53 [ 0.22, 1.28 ]
Rokke 2007 3/36 4/37 8.2 % 0.75 [ 0.16, 3.62 ]
Spicak 2002 5/33 3/30 6.1 % 1.61 [ 0.35, 7.39 ]
Spicak 2003 4/20 5/21 8.9 % 0.80 [ 0.18, 3.54 ]
Xue 2009 4/30 5/28 10.2 % 0.71 [ 0.17, 2.96 ]
Subtotal (95% CI) 272 270 100.0 % 0.82 [ 0.53, 1.27 ]
Total events: 46 (Intervention), 54 (Control)
Heterogeneity: Chi2 = 3.60, df = 8 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
2 Aprotinin versus control
Balldin 1983 0/26 3/29 52.0 % 0.14 [ 0.01, 2.90 ]
Berling 1994 4/22 4/26 48.0 % 1.22 [ 0.27, 5.59 ]
Subtotal (95% CI) 48 55 100.0 % 0.66 [ 0.19, 2.30 ]
Total events: 4 (Intervention), 7 (Control)
Heterogeneity: Chi2 = 1.62, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.65 (P = 0.51)
3 Calcitonin versus control
Martinez 1984 2/14 3/17 100.0 % 0.78 [ 0.11, 5.46 ]
Subtotal (95% CI) 14 17 100.0 % 0.78 [ 0.11, 5.46 ]
Total events: 2 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
4 Gabexate versus control
Chen 2000 2/26 8/26 100.0 % 0.19 [ 0.04, 0.99 ]
Subtotal (95% CI) 26 26 100.0 % 0.19 [ 0.04, 0.99 ]
Total events: 2 (Intervention), 8 (Control)
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(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
5 Probiotics versus control
Olah 2007 2/33 6/29 100.0 % 0.25 [ 0.05, 1.34 ]
Subtotal (95% CI) 33 29 100.0 % 0.25 [ 0.05, 1.34 ]
Total events: 2 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
6 Activated protein C versus control
Pettila 2010 3/16 0/16 100.0 % 8.56 [ 0.41, 180.52 ]
Subtotal (95% CI) 16 16 100.0 % 8.56 [ 0.41, 180.52 ]
Total events: 3 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
7 Somatostatin versus control
Grupo Espa ol 1996 2/30 4/31 25.5 % 0.48 [ 0.08, 2.85 ]
Wang 2013a 7/61 12/60 74.5 % 0.52 [ 0.19, 1.42 ]
Subtotal (95% CI) 91 91 100.0 % 0.51 [ 0.21, 1.23 ]
Total events: 9 (Intervention), 16 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
8 Somatostatin plus omeprazole versus control
Xia 2014 2/70 8/70 100.0 % 0.23 [ 0.05, 1.11 ]
Subtotal (95% CI) 70 70 100.0 % 0.23 [ 0.05, 1.11 ]
Total events: 2 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
9 Somatostatin plus ulinastatin versus control
Wang 2013a 6/62 12/60 100.0 % 0.43 [ 0.15, 1.23 ]
Subtotal (95% CI) 62 60 100.0 % 0.43 [ 0.15, 1.23 ]
Total events: 6 (Intervention), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
10 Thymosin versus control
Wang 2011 0/12 0/12 Not estimable
Subtotal (95% CI) 12 12 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
11 Ulinastatin versus control
Abraham 2013 2/38 6/32 100.0 % 0.24 [ 0.04, 1.29 ]
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(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 38 32 100.0 % 0.24 [ 0.04, 1.29 ]
Total events: 2 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.096)
12 Octreotide plus ulinastatin versus octreotide
Guo 2015 2/60 6/60 100.0 % 0.31 [ 0.06, 1.60 ]
Subtotal (95% CI) 60 60 100.0 % 0.31 [ 0.06, 1.60 ]
Total events: 2 (Intervention), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
13 Somatostatin plus gabexate versus somatostatin
Wang 2016 10/130 10/122 100.0 % 0.93 [ 0.37, 2.33 ]
Subtotal (95% CI) 130 122 100.0 % 0.93 [ 0.37, 2.33 ]
Total events: 10 (Intervention), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
14 Somatostatin plus ulinastatin versus somatostatin
Wang 2013a 6/62 7/61 40.1 % 0.83 [ 0.26, 2.62 ]
Wang 2016 7/124 10/122 59.9 % 0.67 [ 0.25, 1.82 ]
Subtotal (95% CI) 186 183 100.0 % 0.73 [ 0.34, 1.56 ]
Total events: 13 (Intervention), 17 (Control)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
15 Somatostatin plus ulinastatin plus gabexate versus somatostatin
Wang 2016 6/116 10/122 100.0 % 0.61 [ 0.21, 1.74 ]
Subtotal (95% CI) 116 122 100.0 % 0.61 [ 0.21, 1.74 ]
Total events: 6 (Intervention), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
16 Somatostatin plus ulinastatin versus somatostatin plus gabexate
Wang 2016 7/124 10/130 100.0 % 0.72 [ 0.26, 1.95 ]
Subtotal (95% CI) 124 130 100.0 % 0.72 [ 0.26, 1.95 ]
Total events: 7 (Intervention), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
17 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus gabexate
Wang 2016 6/116 10/130 100.0 % 0.65 [ 0.23, 1.86 ]
Subtotal (95% CI) 116 130 100.0 % 0.65 [ 0.23, 1.86 ]
Total events: 6 (Intervention), 10 (Control)
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
18 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus ulinastatin
Wang 2016 6/116 7/124 100.0 % 0.91 [ 0.30, 2.80 ]
Subtotal (95% CI) 116 124 100.0 % 0.91 [ 0.30, 2.80 ]
Total events: 6 (Intervention), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
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Analysis 3.2. Comparison 3 Severe acute pancreatitis, Outcome 2 Serious adverse events (proportion).
Review: Pharmacological interventions for acute pancreatitis
Comparison: 3 Severe acute pancreatitis
Outcome: 2 Serious adverse events (proportion)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Delcenserie 1996 0/11 7/12 35.9 % 0.03 [ 0.00, 0.67 ]
Dellinger 2007 6/50 9/50 41.2 % 0.62 [ 0.20, 1.90 ]
Garcia-Barrasa 2009 13/22 10/19 22.9 % 1.30 [ 0.38, 4.48 ]
Subtotal (95% CI) 83 81 100.0 % 0.56 [ 0.27, 1.18 ]
Total events: 19 (Intervention), 26 (Control)
Heterogeneity: Chi2 = 5.21, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 1.53 (P = 0.13)
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Analysis 3.3. Comparison 3 Severe acute pancreatitis, Outcome 3 Serious adverse events (number).
Review: Pharmacological interventions for acute pancreatitis
Comparison: 3 Severe acute pancreatitis
Outcome: 3 Serious adverse events (number)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Antibiotics versus control
Delcenserie 1996 -1.99243 (1.06066) 4.5 % 0.14 [ 0.02, 1.09 ]
Garcia-Barrasa 2009 -0.36975 (0.474342) 22.6 % 0.69 [ 0.27, 1.75 ]
Spicak 2002 -0.09531 (0.447214) 25.4 % 0.91 [ 0.38, 2.18 ]
Spicak 2003 -0.35667 (0.645497) 12.2 % 0.70 [ 0.20, 2.48 ]
Xue 2009 0.071642 (0.378932) 35.4 % 1.07 [ 0.51, 2.26 ]
Subtotal (95% CI) 100.0 % 0.81 [ 0.52, 1.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.61, df = 4 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
2 Aprotinin versus control
Balldin 1983 -1.50024 (1.095445) 17.3 % 0.22 [ 0.03, 1.91 ]
Berling 1994 -0.20067 (0.306622) 82.7 % 0.82 [ 0.45, 1.49 ]
Subtotal (95% CI) 100.0 % 0.65 [ 0.25, 1.71 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 1.31, df = 1 (P = 0.25); I2 =23%
Test for overall effect: Z = 0.87 (P = 0.39)
3 Gabexate versus control
Chen 2000 -0.45199 (0.279145) 100.0 % 0.64 [ 0.37, 1.10 ]
Subtotal (95% CI) 100.0 % 0.64 [ 0.37, 1.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
4 Probiotics versus control
Olah 2007 -0.86681 (0.366589) 61.7 % 0.42 [ 0.20, 0.86 ]
Zhu 2014 0.131028 (0.60553) 38.3 % 1.14 [ 0.35, 3.74 ]
Subtotal (95% CI) 100.0 % 0.62 [ 0.24, 1.59 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 1.99, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 1.00 (P = 0.32)
5 Somatostatin versus control
Wang 2013a 0.065709 (0.23428) 100.0 % 1.07 [ 0.67, 1.69 ]
Subtotal (95% CI) 100.0 % 1.07 [ 0.67, 1.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
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Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
6 Somatostatin plus omeprazole versus control
Xia 2014 -1.0116 (0.3371) 100.0 % 0.36 [ 0.19, 0.70 ]
Subtotal (95% CI) 100.0 % 0.36 [ 0.19, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
7 Somatostatin plus ulinastatin versus control
Wang 2013a -1.19024 (0.34566) 100.0 % 0.30 [ 0.15, 0.60 ]
Subtotal (95% CI) 100.0 % 0.30 [ 0.15, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.44 (P = 0.00057)
8 Octreotide plus ulinastatin versus octreotide
Guo 2015 -1.20984 (0.27635) 100.0 % 0.30 [ 0.17, 0.51 ]
Subtotal (95% CI) 100.0 % 0.30 [ 0.17, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.38 (P = 0.000012)
9 Somatostatin plus ulinastatin versus somatostatin
Wang 2013a -1.25595 (0.342381) 100.0 % 0.28 [ 0.15, 0.56 ]
Subtotal (95% CI) 100.0 % 0.28 [ 0.15, 0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.67 (P = 0.00024)
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Analysis 3.4. Comparison 3 Severe acute pancreatitis, Outcome 4 Organ failure.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 3 Severe acute pancreatitis
Outcome: 4 Organ failure
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Delcenserie 1996 1/11 1/12 6.9 % 1.10 [ 0.06, 20.01 ]
Garcia-Barrasa 2009 13/22 10/19 34.7 % 1.30 [ 0.38, 4.48 ]
Rokke 2007 6/36 9/37 58.4 % 0.62 [ 0.20, 1.97 ]
Subtotal (95% CI) 69 68 100.0 % 0.89 [ 0.40, 1.99 ]
Total events: 20 (Intervention), 20 (Control)
Heterogeneity: Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
2 Lexipafant versus control
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Probiotics versus control
Olah 2007 5/33 9/29 100.0 % 0.40 [ 0.12, 1.36 ]
Subtotal (95% CI) 33 29 100.0 % 0.40 [ 0.12, 1.36 ]
Total events: 5 (Intervention), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
4 Ulinastatin versus control
Abraham 2013 12/35 29/32 100.0 % 0.05 [ 0.01, 0.21 ]
Subtotal (95% CI) 35 32 100.0 % 0.05 [ 0.01, 0.21 ]
Total events: 12 (Intervention), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.15 (P = 0.000033)
5 Somatostatin plus gabexate versus somatostatin
Wang 2016 11/130 13/122 100.0 % 0.78 [ 0.33, 1.80 ]
Subtotal (95% CI) 130 122 100.0 % 0.78 [ 0.33, 1.80 ]
Total events: 11 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
6 Somatostatin plus ulinastatin versus somatostatin
Wang 2016 8/124 13/122 100.0 % 0.58 [ 0.23, 1.45 ]
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Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 124 122 100.0 % 0.58 [ 0.23, 1.45 ]
Total events: 8 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
7 Somatostatin plus ulinastatin plus gabexate versus somatostatin
Wang 2016 6/116 13/122 100.0 % 0.46 [ 0.17, 1.25 ]
Subtotal (95% CI) 116 122 100.0 % 0.46 [ 0.17, 1.25 ]
Total events: 6 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
8 Somatostatin plus ulinastatin versus somatostatin plus gabexate
Wang 2016 8/124 11/130 100.0 % 0.75 [ 0.29, 1.92 ]
Subtotal (95% CI) 124 130 100.0 % 0.75 [ 0.29, 1.92 ]
Total events: 8 (Intervention), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
9 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus gabexate
Wang 2016 6/116 11/130 100.0 % 0.59 [ 0.21, 1.65 ]
Subtotal (95% CI) 116 130 100.0 % 0.59 [ 0.21, 1.65 ]
Total events: 6 (Intervention), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
10 Somatostatin plus ulinastatin plus gabexate versus somatostatin plus ulinastatin
Wang 2016 6/116 8/124 100.0 % 0.79 [ 0.27, 2.35 ]
Subtotal (95% CI) 116 124 100.0 % 0.79 [ 0.27, 2.35 ]
Total events: 6 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
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Analysis 3.5. Comparison 3 Severe acute pancreatitis, Outcome 5 Infected pancreatic necrosis.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 3 Severe acute pancreatitis
Outcome: 5 Infected pancreatic necrosis
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Antibiotics versus control
Delcenserie 1996 0/11 3/12 12.7 % 0.12 [ 0.01, 2.58 ]
Dellinger 2007 9/50 6/50 19.4 % 1.61 [ 0.53, 4.92 ]
Garcia-Barrasa 2009 8/22 8/19 21.5 % 0.79 [ 0.22, 2.77 ]
Rokke 2007 3/36 7/37 24.9 % 0.39 [ 0.09, 1.64 ]
Spicak 2002 1/33 0/30 2.0 % 2.82 [ 0.11, 71.78 ]
Spicak 2003 3/20 6/21 19.6 % 0.44 [ 0.09, 2.08 ]
Subtotal (95% CI) 172 169 100.0 % 0.73 [ 0.41, 1.33 ]
Total events: 24 (Intervention), 30 (Control)
Heterogeneity: Chi2 = 5.08, df = 5 (P = 0.41); I2 =2%
Test for overall effect: Z = 1.02 (P = 0.31)
2 Probiotics versus control
Olah 2007 2/33 6/29 62.6 % 0.25 [ 0.05, 1.34 ]
Zhu 2014 6/20 5/19 37.4 % 1.20 [ 0.30, 4.86 ]
Subtotal (95% CI) 53 48 100.0 % 0.60 [ 0.22, 1.68 ]
Total events: 8 (Intervention), 11 (Control)
Heterogeneity: Chi2 = 2.00, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 3.6. Comparison 3 Severe acute pancreatitis, Outcome 6 Sepsis.
Review: Pharmacological interventions for acute pancreatitis
Comparison: 3 Severe acute pancreatitis
Outcome: 6 Sepsis
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Aprotinin versus control
Balldin 1983 1/26 0/29 13.6 % 3.47 [ 0.14, 88.99 ]
Berling 1994 5/22 4/26 86.4 % 1.62 [ 0.38, 6.96 ]
Subtotal (95% CI) 48 55 100.0 % 1.87 [ 0.50, 6.98 ]
Total events: 6 (Intervention), 4 (Control)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
2 Probiotics versus control
Olah 2007 4/33 8/29 100.0 % 0.36 [ 0.10, 1.36 ]
Subtotal (95% CI) 33 29 100.0 % 0.36 [ 0.10, 1.36 ]
Total events: 4 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
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Table 1. Characteristics of included studies (ordered by comparisons)
Study
name
No
of partic-
ipants
ran-
domised
Postran-
domisa-
tion
dropouts
No of
partici-
pants for
whom
out-
comewas
reported
Treat-
ment 1
Treat-
ment 2
Selection
bias
Perfor-
mance
and
detection
bias
Attrition
bias
Selective
report-
ing bias
Other
bias
Pettila
2010
32 0 32 Activated
protein C
Placebo Unclear Low Low High High
Barreda
2009
80 22 58 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear High Low Unclear
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Table 1. Characteristics of included studies (ordered by comparisons) (Continued)
Del-
censerie
1996
23 0 23 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear Low Low Unclear
Del-
censerie
2001
81 Not
stated
81 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear Unclear Low Unclear
Dellinger
2007
100 0 100 Antibi-
otics
Placebo Low Low Low Low High
Finch
1976
62 4 58 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear High Low Unclear
Garcia-
Barrasa
2009
46 5 41 Antibi-
otics
Placebo Unclear Low High Low Low
Hejt-
mankova
2003
41 Not
stated
41 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear Unclear Low Unclear
Isen-
mann
2004
119 5 114 Antibi-
otics
Placebo Unclear Low High High High
Llukacaj
2012
80 Not
stated
80 Antibi-
otics
Placebo Unclear Low Unclear High Unclear
Luiten
1995
109 7 102 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear High Low Unclear
Nord-
back
2001
90 32 58 Antibi-
otics
Placebo Unclear Unclear High Low Unclear
Poropat
2015
47 0 47 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear Low Low Unclear
Pederzoli
1993a
74 Not
stated
74 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear Low Low Unclear
Rokke
2007
73 0 73 Antibi-
otics
No ac-
tive inter-
vention
Unclear High Low Low High
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Table 1. Characteristics of included studies (ordered by comparisons) (Continued)
Sainio
1995
60 0 60 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear Low Low Unclear
Spicak
2002
63 Not
stated
63 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear Unclear Low Unclear
Spicak
2003
41 Not
stated
41 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear Unclear Low Unclear
Xue 2009 59 3 56 Antibi-
otics
No ac-
tive inter-
vention
Unclear Unclear High Low Low
Bansal
2011
44 5 39 Antioxi-
dants
No ac-
tive inter-
vention
Unclear High High Low Low
Birk 1994 20 Not
stated
20 Antioxi-
dants
No ac-
tive inter-
vention
Unclear Unclear Unclear High Unclear
Marek
1999
73 0 73 Antioxi-
dants
Placebo Unclear Unclear Low High Unclear
Sateesh
2009
56 3 53 Antioxi-
dants
No ac-
tive inter-
vention
Unclear High High Low Unclear
Siriwar-
dena
2007
43 0 43 Antioxi-
dants
Placebo Low Low Low Low High
Vege
2015
28 Not
stated
28 Antioxi-
dants
Placebo Unclear Low Low Low Unclear
Chooklin
2007
34 Not
stated
34 Antioxi-
dants plus
Corticos-
teroids
No ac-
tive inter-
vention
Unclear Unclear Unclear High Unclear
MRC
Multi-
centre
Trial
1977
(this is
a 3-armed
264 7 257 Aprotinin Placebo Unclear Low High High High
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Table 1. Characteristics of included studies (ordered by comparisons) (Continued)
trial; the
numbers
stated in-
cluded all
3 arms)
Balldin
1983
55 Not
stated
55 Aprotinin No ac-
tive inter-
vention
Unclear Unclear Unclear Low High
Berling
1994
48 Not
stated
48 Aprotinin No ac-
tive inter-
vention
Unclear Low Low Low High
Imrie
1978
161 Not
stated
161 Aprotinin Placebo Unclear Low Unclear Low High
Imrie
1980
50 Not
stated
50 Aprotinin Placebo Unclear Low Unclear High Unclear
Storck
1968
43 Not
stated
43 Aprotinin Placebo Unclear Low Unclear High Unclear
Trapnell
1974
105 Not
stated
105 Aprotinin Placebo Low Low Unclear High High
MRC
Multi-
centre
Trial
1977
(this is
a 3-armed
trial; the
numbers
stated in-
cluded all
3 arms)
264 7 257 Aprotinin Glucagon Unclear Low High High High
Goebell
1979
94 Not
stated
94 Calci-
tonin
Placebo Unclear Low Unclear Low Unclear
Martinez
1984
31 0 31 Calci-
tonin
Placebo Unclear Unclear Low High Unclear
Perezdeoteyza
1980
40 Not
stated
40 Cimeti-
dine
Placebo Unclear Low Unclear High Unclear
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Table 1. Characteristics of included studies (ordered by comparisons) (Continued)
Sillero
1981
60 Not
stated
60 Cimeti-
dine
Placebo Low Unclear Unclear High Unclear
Tykka
1985
64 0 64 EDTA Placebo Unclear Low Low Low High
Frulloni
1994
116 Not
stated
116 Gabexate Aprotinin Unclear Unclear Unclear Low Unclear
Pederzoli
1993b
199 17 182 Gabexate Aprotinin Unclear Low High Low Unclear
Buchler
1993
223 Not
stated
223 Gabexate Placebo Low Low Low Low Unclear
Chen
2000
52 Not
stated
52 Gabexate Placebo Unclear Unclear Unclear Low Unclear
Freise
1986
50 Not
stated
50 Gabexate Placebo Unclear Low Unclear Low Unclear
Goebell
1988
162 11 151 Gabexate Placebo Unclear Low High Low Unclear
Valder-
rama
1992
105 5 100 Gabexate Placebo Low Low High Low High
Kirsch
1978
150 Not
stated
150 Glucagon Atropine Unclear Unclear Unclear Low Unclear
MRC
Multi-
centre
Trial
1977
(this is
a 3-armed
trial; the
numbers
stated in-
cluded all
3 arms)
264 7 257 Glucagon Placebo Unclear Unclear Unclear Low High
Debas
1980
66 Not
stated
66 Glucagon Placebo Unclear Low Unclear Low Unclear
Dürr
1978
69 Not
stated
69 Glucagon Placebo Unclear Low Unclear High Unclear
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Table 1. Characteristics of included studies (ordered by comparisons) (Continued)
Kalima
1980
80 9 71 Glucagon Placebo Unclear Unclear High Low Unclear
Kronborg
1980
22 Not
stated
22 Glucagon Placebo Unclear Low Unclear High Unclear
Gilsanz
1978
62 Not
stated
62 Glucagon Oxyphe-
nonium
Unclear Low Unclear Low Unclear
Hansky
1969
24 Not
stated
24 Iniprol No ac-
tive inter-
vention
Unclear High Unclear High High
Johnson
2001
291 1 290 Lexi-
pafant
Placebo Unclear Low High Low High
Kingsnorth
1995
83 Not
stated
83 Lexi-
pafant
Placebo Unclear Low Unclear High High
McKay
1997b
51 1 50 Lexi-
pafant
Placebo Unclear Low High High High
Bredkjaer
1988
66 9 57 NSAID Placebo Unclear Unclear Unclear High Unclear
Ebbehøj
1985
30 0 30 NSAID Placebo Unclear Low Low High High
McKay
1997a
58 0 58 Oc-
treotide
Placebo Low Low Low Low Unclear
Ohair
1993
180 Not
stated
180 Oc-
treotide
Placebo Unclear Unclear Unclear High Unclear
Paran
1995
51 13 38 Oc-
treotide
No ac-
tive inter-
vention
Unclear High High Low Unclear
Uhl 1999 302 0 302 Oc-
treotide
Placebo Unclear Low Low Low High
Wang
2013c
372 Not
stated
372 Oc-
treotide
No ac-
tive inter-
vention
Unclear Unclear High Low Low
Yang
2012
163 6 157 Oc-
treotide
No ac-
tive inter-
vention
Unclear Unclear High High Low
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Table 1. Characteristics of included studies (ordered by comparisons) (Continued)
Wang
2013b
354 Not
stated
354 Oc-
treotide
plus
NSAID
Oc-
treotide
Unclear Unclear Unclear High Unclear
Guo
2015
120 Not
stated
120 Oc-
treotide
plus uli-
nastatin
Oc-
treotide
Unclear Unclear Unclear Low Unclear
Besselink
2008
298 2 296 Probi-
otics
Placebo Low Low High Low High
Olah
2007
83 21 62 Probi-
otics
No ac-
tive inter-
vention
Unclear Low High High Unclear
Plaudis
2010
90 Not
stated
58 Probi-
otics
No ac-
tive inter-
vention
Unclear Low Unclear High Unclear
Sharma
2011
50 0 50 Probi-
otics
Placebo Unclear Low Low High High
Zhu
2014
39 Not
stated
39 Probi-
otics
Placebo Unclear Low Unclear High Unclear
Grupo
Español
1996
70 9 61 Somato-
statin
Placebo Unclear Low High High Unclear
Choi
1989
71 Not
stated
71 Somato-
statin
No ac-
tive inter-
vention
Unclear Unclear Unclear Low Unclear
Gjørup
1992
63 Not
stated
63 Somato-
statin
Placebo Unclear Low Unclear Low Unclear
Luengo
1994
100 Not
stated
100 Somato-
statin
No ac-
tive inter-
vention
Unclear Low Unclear High Unclear
Moreau
1986
87 3 84 Somato-
statin
Placebo Unclear Low Unclear High High
Usadel
1985
77 Not
stated
77 Somato-
statin
Placebo Unclear Low Unclear High Unclear
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Table 1. Characteristics of included studies (ordered by comparisons) (Continued)
Wang
2013a
(this is
a 3-armed
trial; the
numbers
stated in-
cluded all
3 arms)
183 Not
stated
183 Somato-
statin
No ac-
tive inter-
vention
Unclear Low Unclear Low Low
Yang
1999
48 Not
stated
48 Somato-
statin
No ac-
tive inter-
vention
Unclear Unclear Unclear High Unclear
Xia 2014 140 Not
stated
140 Somato-
statin
plus
omepra-
zole
No ac-
tive inter-
vention
Unclear Unclear Unclear Low Unclear
Wang
2013a
(this is
a 3-armed
trial; the
numbers
stated in-
cluded all
3 arms)
183 Not
stated
183 Somato-
statin
plus uli-
nastatin
Placebo Unclear Unclear Unclear High Unclear
Wang
2013a
(this is
a 3-armed
trial; the
numbers
stated in-
cluded all
3 arms)
183 Not
stated
183 Somato-
statin
plus uli-
nastatin
Somato-
statin
Unclear Low Unclear Low Low
Wang
2016
(this is
a 4-armed
trial; the
numbers
stated in-
cluded all
4 arms)
492 0 492 Somato-
statin
plus uli-
nastatin
Somato-
statin
Low Low Low Low Low
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Table 1. Characteristics of included studies (ordered by comparisons) (Continued)
Wang
2016
(this is
a 4-armed
trial; the
numbers
stated in-
cluded all
4 arms)
492 0 492 Somato-
statin
plus
gabexate
Somato-
statin
Low Low Low Low Low
Wang
2016
(this is
a 4-armed
trial; the
numbers
stated in-
cluded all
4 arms)
492 0 492 Somato-
statin
plus uli-
nas-
tatin plus
gabexate
Somato-
statin
Low Low Low Low Low
Wang
2016
(this is
a 4-armed
trial; the
numbers
stated in-
cluded all
4 arms)
492 0 492 Somato-
statin
plus uli-
nastatin
Somato-
statin
plus
gabexate
Low Low Low Low Low
Wang
2016
(this is
a 4-armed
trial; the
numbers
stated in-
cluded all
4 arms)
492 0 492 Somato-
statin
plus uli-
nas-
tatin plus
gabexate
Somato-
statin
plus
gabexate
Low Low Low Low Low
Wang
2016
(this is
a 4-armed
trial; the
numbers
stated in-
cluded all
4 arms)
492 0 492 Somato-
statin
plus uli-
nas-
tatin plus
gabexate
Somato-
statin
plus uli-
nastatin
Low Low Low Low Low
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Table 1. Characteristics of included studies (ordered by comparisons) (Continued)
Wang
2011
24 Not
stated
24 Thy-
mosin
Placebo Unclear Low Unclear High Unclear
Abraham
2013
135 6 129 Ulinas-
tatin
Placebo Unclear Low High Low Unclear
Chen
2002a
68 6 62 Ulinas-
tatin
Gabexate Unclear Unclear High High Unclear
Chen
2002b
26 1 25 Ulinas-
tatin
Oc-
treotide
Unclear Unclear High High Unclear
Table 2. Potential effect modifiers (ordered by comparisons)
Study name Treatment 1 Treatment 2 Severe pancre-
atitis
Necrotising
pancreatitis
Organ failure Infection
Pettila 2010 Activated
protein C
Placebo yes not stated not stated not stated
Barreda 2009 Antibiotics No active inter-
vention
not stated yes not stated not stated
Delcenserie
1996
Antibiotics No active inter-
vention
yes not stated not stated not stated
Delcenserie
2001
Antibiotics No active inter-
vention
not stated yes not stated not stated
Dellinger 2007 Antibiotics Placebo yes yes not stated no
Finch 1976 Antibiotics No active inter-
vention
not stated not stated not stated not stated
Garcia-Barrasa
2009
Antibiotics Placebo yes yes not stated not stated
Hejtmankova
2003
Antibiotics No active inter-
vention
yes not stated not stated not stated
Isenmann 2004 Antibiotics Placebo not stated not stated not stated not stated
Llukacaj 2012 Antibiotics Placebo not stated yes not stated no
Luiten 1995 Antibiotics No active inter-
vention
yes not stated not stated no
Nordback 2001 Antibiotics Placebo not stated yes no not stated
220Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Potential effect modifiers (ordered by comparisons) (Continued)
Pederzoli 1993a Antibiotics No active inter-
vention
not stated yes not stated not stated
Rokke 2007 Antibiotics No active inter-
vention
yes yes not stated not stated
Sainio 1995 Antibiotics No active inter-
vention
not stated yes not stated not stated
Spicak 2002 Antibiotics No active inter-
vention
yes not stated not stated not stated
Spicak 2003 Antibiotics No active inter-
vention
yes not stated not stated not stated
Xue 2009 Antibiotics No active inter-
vention
yes yes not stated no
Bansal 2011 Antioxidants No active inter-
vention
not stated not stated not stated not stated
Birk 1994 Antioxidants No active inter-
vention
yes not stated not stated not stated
Marek 1999 Antioxidants Placebo not stated not stated not stated not stated
Sateesh 2009 Antioxidants No active inter-
vention
not stated not stated not stated not stated
Siriwardena
2007
Antioxidants Placebo not stated not stated not stated not stated
Vege 2015 Antioxidants Placebo not stated not stated not stated not stated
Chooklin 2007 Antiox-
idants plus corti-
costeroids
No active inter-
vention
yes not stated not stated not stated
Balldin 1983 Aprotinin No active inter-
vention
yes not stated not stated not stated
Berling 1994 Aprotinin No active inter-
vention
yes not stated not stated not stated
Imrie 1978 Aprotinin Placebo not stated not stated not stated not stated
Imrie 1980 Aprotinin Placebo not stated not stated not stated not stated
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Table 2. Potential effect modifiers (ordered by comparisons) (Continued)
MRC
Multicentre Trial
1977
Aprotinin Placebo not stated not stated not stated not stated
Storck 1968 Aprotinin Placebo not stated not stated not stated not stated
Trapnell 1974 Aprotinin Placebo not stated not stated not stated not stated
Goebell 1979 Calcitonin Placebo not stated not stated not stated not stated
Martinez 1984 Calcitonin Placebo yes not stated not stated not stated
Perezdeoteyza
1980
Cimetidine Placebo not stated not stated not stated not stated
Sillero 1981 Cimetidine Placebo not stated not stated not stated not stated
Tykka 1985 EDTA Placebo not stated not stated not stated not stated
Buchler 1993 Gabexate Placebo not stated not stated not stated not stated
Chen 2000 Gabexate Placebo yes not stated yes not stated
Freise 1986 Gabexate Placebo not stated not stated not stated not stated
Goebell 1988 Gabexate Placebo not stated not stated not stated not stated
Valderrama
1992
Gabexate Placebo not stated not stated not stated not stated
Debas 1980 Glucagon Placebo not stated not stated not stated not stated
Dürr 1978 Glucagon Placebo not stated not stated not stated not stated
Kalima 1980 Glucagon Placebo not stated not stated not stated not stated
Kronborg 1980 Glucagon Placebo not stated not stated not stated not stated
MRC
Multicentre Trial
1977
Glucagon Placebo not stated not stated not stated not stated
Hansky 1969 Iniprol No active inter-
vention
not stated not stated not stated not stated
Johnson 2001 Lexipafant Placebo not stated not stated not stated not stated
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Table 2. Potential effect modifiers (ordered by comparisons) (Continued)
Kingsnorth
1995
Lexipafant Placebo not stated not stated not stated not stated
McKay 1997b Lexipafant Placebo not stated not stated not stated not stated
Bredkjaer 1988 NSAID Placebo not stated not stated not stated not stated
Ebbehøj 1985 NSAID Placebo not stated not stated not stated not stated
McKay 1997b Octreotide Placebo not stated not stated not stated not stated
Ohair 1993 Octreotide Placebo not stated not stated not stated not stated
Paran 1995 Octreotide No active inter-
vention
not stated not stated not stated not stated
Uhl 1999 Octreotide Placebo not stated not stated not stated not stated
Wang 2013c
(mild pancreati-
tis)
Octreotide No active inter-
vention
no not stated not stated not stated
Wang 2013c (se-
vere pancreatitis)
Octreotide No active inter-
vention
yes not stated not stated not stated
Yang 2012 Octreotide No active inter-
vention
no not stated not stated not stated
Besselink 2008 Probiotics Placebo not stated not stated not stated not stated
Olah 2007 Probiotics No active inter-
vention
yes not stated not stated not stated
Plaudis 2010 Probiotics No active inter-
vention
yes not stated not stated not stated
Sharma 2011 Probiotics Placebo not stated not stated not stated not stated
Zhu 2014 Probiotics Placebo yes not stated not stated not stated
Choi 1989 Somatostatin No active inter-
vention
not stated not stated not stated not stated
Gjørup 1992 Somatostatin Placebo not stated not stated not stated not stated
Grupo Español
1996
Somatostatin Placebo yes not stated not stated not stated
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Table 2. Potential effect modifiers (ordered by comparisons) (Continued)
Luengo 1994 Somatostatin No active inter-
vention
not stated not stated not stated not stated
Moreau 1986 Somatostatin Placebo not stated not stated not stated not stated
Usadel 1985 Somatostatin Placebo not stated not stated not stated not stated
Wang 2013a Somatostatin No active inter-
vention
yes not stated not stated not stated
Yang 1999 Somatostatin No active inter-
vention
not stated not stated not stated not stated
Xia 2014 Somatostatin
plus omeprazole
No active inter-
vention
yes not stated not stated not stated
Wang 2013a Somatostatin
plus ulinastatin
No active inter-
vention
yes not stated not stated not stated
Wang 2011 Thymosin Placebo yes not stated not stated not stated
Abraham 2013
(mild pancreati-
tis)
Ulinastatin Placebo no not stated not stated no
Abraham 2013
(severe
pancreatitis)
Ulinastatin Placebo yes not stated not stated not stated
Frulloni 1994 Gabexate Aprotinin not stated yes not stated not stated
Pederzoli 1993b Gabexate Aprotinin not stated not stated not stated not stated
Kirsch 1978 Glucagon Atropine not stated not stated not stated not stated
Chen 2002a Ulinastatin Gabexate no no no not stated
MRC
Multicentre Trial
1977
Aprotinin Glucagon not stated not stated not stated not stated
Guo 2015 Octerotide plus
ulinastatin
Octreotide yes not stated not stated not stated
Wang 2013b Octreotide plus
NSAID
Octreotide not stated not stated not stated not stated
Chen 2002b Ulinastatin Octreotide yes yes not stated not stated
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Table 2. Potential effect modifiers (ordered by comparisons) (Continued)
Gilsanz 1978 Glucagon Oxyphenonium not stated not stated not stated not stated
Poropat 2015 Antibiotics No active inter-
vention
not stated not stated not stated no
Wang 2016 Somatostatin
plus gabexate
Somatostatin yes not stated not stated not stated
Wang 2013a Somatostatin
plus ulinastatin
Somatostatin yes not stated not stated not stated
Wang 2016 Somatostatin
plus ulinastatin
Somatostatin yes not stated not stated not stated
Wang 2016 Somatostatin
plus ulinastatin
plus gabexate
Somatostatin yes not stated not stated not stated
Wang 2016 Somatostatin
plus ulinastatin
Somatostatin
plus gabexate
yes not stated not stated not stated
Wang 2016 Somatostatin
plus ulinastatin
plus gabexate
Somatostatin
plus gabexate
yes not stated not stated not stated
Wang 2016 Somatostatin
plus ulinastatin
plus gabexate
Somatostatin
plus ulinastatin
yes not stated not stated not stated
Table 3. Length of hospital stay (days)
Study name Interven-
tion
Compara-
tor
Number of
partici-
pants in in-
tervention
Num-
ber of par-
ticipants in
control
Mean or
me-
dian (stan-
dard devia-
tion or in-
terquartile
range, if re-
ported)
hospital
stay
in interven-
tion group
Mean or
me-
dian (stan-
dard devia-
tion or in-
terquartile
range, if re-
ported)
hospital
stay in con-
trol group
Difference Statistical
sig-
nificance (P-
value if re-
ported)
Barreda
2009
Antibiotics No active in-
tervention
24 34 54 45 9 Not
significant
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Table 3. Length of hospital stay (days) (Continued)
Delcenserie
1996
Antibiotics No active in-
tervention
11 12 27.8 22 5.8 Not
significant
Finch 1976 Antibiotics No active in-
tervention
31 27 10.4 11.3 −0.9 Not
significant
Garcia-
Barrasa
2009
Antibiotics Placebo 22 19 21 19 2 Not signifi-
cant (0.80)
Hejt-
mankova
2003
Antibiotics No active in-
tervention
20 21 18 (7.2) 25 (14.8) −7 Not
significant
Isenmann
2004
Antibiotics Placebo 58 56 21 18 3 Not
significant
Luiten 1995 Antibiotics No active in-
tervention
50 52 30 32 −2 Not
significant
Rokke 2007 Antibiotics No active in-
tervention
36 37 18 22 −4 Not signifi-
cant (0.32)
Sainio 1995 Antibiotics No active in-
tervention
30 30 33.2 (22.1) 43.8 (43.1) −10.6 Not signifi-
cant (0.24)
Spicak 2002 Antibiotics No active in-
tervention
33 30 18.9 (8.1) 23.8 (19.3) −4.9 Not
significant
Spicak 2003 Antibiotics No active in-
tervention
20 21 18 (7.2) 25 (14.8) −7 Not
significant
Xue 2009 Antibiotics No active in-
tervention
29 27 28.3 30.7 −2.4 Not
significant
Bansal 2011 Antioxi-
dants
No active in-
tervention
19 20 12.8 15.1 −2.3 Not
significant
Sateesh
2009
Antioxi-
dants
No active in-
tervention
23 30 7.2 (5) 10.3 (7) −3.1 Not signifi-
cant (0.07)
Siriwardena
2007
Antioxi-
dants
Placebo 22 21 20.4 (24.4) 14.3 (15.7) 6.1 Not signifi-
cant (0.34)
Vege 2015 Antioxi-
dants
Placebo 14 14 3 5 −2 Not signifi-
cant (0.06)
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Table 3. Length of hospital stay (days) (Continued)
Balldin
1983
Aprotinin No active in-
tervention
26 29 17.3 16.5 0.8 Not
significant
Berling
1994
Aprotinin No active in-
tervention
22 26 25 (15-32) 33 (17-38) −8 Not signifi-
cant (0.24)
Goebell
1979
Calcitonin Placebo 50 44 18.3 (6.4) 20.2 (7.5) −1.9 Not
significant
Martinez
1984
Calcitonin Placebo 14 17 24 (20.2) 30 (21.7) −6 Not
significant
Buchler
1993
Gabexate Placebo 115 108 26 (20-43) 23 (28-34) 3 Not
significant
Debas 1980 Glucagon Placebo 33 33 26 (28.7) 20 (19.2) 6 Not
significant
Dürr 1978 Glucagon Placebo 33 36 32.6 26.9 5.7 Not
significant
Hansky
1969
Iniprol No active in-
tervention
15 9 14.7 (9.3) 18.7 (10.2) −4 Not
significant
Johnson
2001
Lexipafant Placebo 151 139 9 10 −1 Not
significant
McKay
1997b
Lexipafant Placebo 26 24 13.3 14.9 −1.6 Not
significant
Bredkjaer
1988
NSAID Placebo 27 30 9 10 −1 Not
significant
Ebbehøj
1985
NSAID Placebo 14 16 13 15 −2 Not
significant
McKay
1997a
Octreotide Placebo 28 30 10 10 0 Not
significant
Ohair 1993 Octreotide Placebo 90 90 7.3 8.2 −0.9 Not
significant
Paran 1995 Octreotide No active in-
tervention
19 19 17.9 (13.2) 34.1 (22.7) −16.2 Significant
(0.02)
Uhl 1999 Octreotide Placebo 199 103 21.5 21 0.5 Not
significant
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Table 3. Length of hospital stay (days) (Continued)
Wang 2013c
(mild acute
pancreatitis)
Octreotide No active in-
tervention
157 79 14.4 15.37 −0.97 Not
significant
Wang 2013c
(severe acute
pancreatitis)
Octreotide No active in-
tervention
91 45 16 16 0 Not
significant
Yang 2012 Octreotide No active in-
tervention
80 77 7.4 (2) 11.8 (4) −4.4 Significant
Besselink
2008
Probiotics Placebo 152 144 28.9 (41.5) 23.5 (25.9) 5.4 Not signifi-
cant (0.98)
Olah 2007 Probiotics No active in-
tervention
33 29 14.9 19.7 −4.8 Not
significant
Sharma
2011
Probiotics Placebo 24 26 13.23 (18.
19)
9.69 (9.69) 3.54 Not signifi-
cant (0.76)
Pettila 2010 Activated
protein C
Placebo 16 16 17.1 34.4 −17.3 Significant (P
< 0.05)
Gjørup
1992
Somato-
statin
Placebo 33 30 12 10 2 Not
significant
Luengo
1994
Somato-
statin
No active in-
tervention
50 50 14.92 (11.
46)
20.28 (15) −5.36 Significant
Wang 2011 Thymosin Placebo 12 12 37.1 (22.7) 60.6 (32.9) −23.5 Not signifi-
cant (0.06)
Abraham
2013
(mild acute
pancreatitis)
Ulinastatin Placebo 30 32 7 (5-22) 8 (5-15) −1 Not signifi-
cant (0.07)
Abraham
2013
(severe acute
pancreatitis)
Ulinastatin Placebo 35 32 9 (6-22) 10 (6-22) −1 Not signifi-
cant (0.21)
Guo 2015 Oc-
terotide plus
ulinastatin
Octreotide 60 60 11.8 (3.9) 23.7 (16.3) −11.9 Significant
Wang 2016 Somato-
statin plus
Somato-
statin
116 122 17.7 (32.1) 31.3 (37.6) -13.6 Significant
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Table 3. Length of hospital stay (days) (Continued)
uli-
nastatin plus
gabexate
Wang 2016 Somato-
statin plus
ulinastatin
Somato-
statin
124 122 22.6 (34.5) 31.3 (37.6) -8.7 Significant
Wang 2016 Somato-
statin plus
gabexate
Somato-
statin
130 122 23.2 (29.6) 31.3 (37.6) -8.1 Significant
Wang 2016 Somato-
statin plus
uli-
nastatin plus
gabexate
Somato-
statin plus
gabexate
116 130 17.7 (32.1) 23.2 (29.6) −5.5 Significant
Wang 2016 Somato-
statin plus
ulinastatin
Somato-
statin plus
gabexate
124 130 22.6 (34.5) 23.2 (29.6) −0.6 Significant
Wang 2016 Somato-
statin plus
uli-
nastatin plus
gabexate
Somato-
statin plus
ulinastatin
116 124 17.7 (32.1) 22.6 (34.5) −4.9 Significant
NSAID: non-steroidal anti-inflammatory drug.
Table 4. Length of intensive care unit (ICU) stay (days)
Study name Interven-
tion
Control Number of
partici-
pants in in-
tervention
Num-
ber of par-
ticipants in
control
Mean or
me-
dian (stan-
dard devia-
tion or in-
terquartile
range, if re-
ported) in-
tensive care
stay
in interven-
tion group
Mean or
me-
dian (stan-
dard devia-
tion or in-
terquartile
range, if re-
ported) in-
tensive care
stay in con-
trol group
Difference Statistical
significance
(P-value, re-
ported)
Garcia-
Barrasa
2009
Antibiotics Placebo 22 19 17 18 -1 Not signifi-
cant (P-value
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Table 4. Length of intensive care unit (ICU) stay (days) (Continued)
= 0.83)
Isenmann
2004
Antibiotics Placebo 58 56 8 6 2 Not
significant
Nordback
2001
Antibiotics Placebo 25 33 8 8 0 Not
significant
Rokke 2007 Antibiotics No active in-
tervention
36 37 8 7 1 Not signifi-
cant (P-value
= 0.78)
Sainio 1995 Antibiotics No active in-
tervention
30 30 12.7 (10.7) 23.6 (28.7) -10.9 Not signifi-
cant (P-value
= 0.06)
Spicak 2002 Antibiotics No active in-
tervention
33 30 11.4 (5.4) 15.9 (12) -4.5 Not
significant
Siriwardena
2007
Antioxi-
dants
Placebo 22 21 4 (10.3) 0 (0) 4 Not signifi-
cant (P-value
= 0.08)
Vege 2015 Antioxi-
dants
Placebo 14 14 0 0 0 Significant
(P-value = 0.
03)
Berling
1994
Aprotinin No active in-
tervention
22 26 9.5 (4 - 10) 12 (3-20) -2.5 Not signifi-
cant (P-value
= 0.47)
Johnson
2001
Lexipafant Placebo 151 139 9.5 11 -1.5 Not
significant
Besselink
2008
Probiotics Placebo 152 144 6.6 (17.1) 3 (9.3) 3.6 Not signifi-
cant (P-value
= 0.08)
Sharma
2011
Probiotics Placebo 24 26 4.94 (9.54) 4 (5.86) 0.94 Not signifi-
cant (P-value
= 0.94)
Wang 2011 Thymosin Placebo 12 12 24.6 (19.6) 50.5 (25.7) -25.9 Significant
(P-value = 0.
01)
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A P P E N D I C E S
Appendix 1. Glossary of terms
Acute: sudden.
Analogues: a substance that is similar to another substance.
Antioxidants: substances that inhibit oxidation.
Autodigestion: Breakdown of the same organ that secretes the substance.
Bacterial colonisation: growth and multiplication of bacteria.
Cholangiopancreatography: fully known as endoscopic retrograde cholangiopancreatography (ERCP); a procedure carried out on the
pancreatic and bile ducts using an endoscope and x-rays.
Colonisation: presence of bacteria without causing illness (in this context).
Endoscopic sphincterotomy: endoscopic operation to cut the muscle surrounding the common bile duct and the pancreatic duct.
Endoscopic: with the help of an endoscope, a tube inserted into body (in this context, through the mouth and into the stomach and
upper part of the small intestine).
Enzyme: substances that enable and speed up chemical reactions that are necessary for the normal functioning of the body.
Epigastric: upper central abdomen.
Epigastric pain: upper central abdominal pain.
Heterogeneity: variability.
Insulin: substance which helps regulate blood sugar.
Interstitial: space in between.
Morbidity: illness (in this context, it means complications).
Mortality: death.
Necrosectomy: removal of dead tissue.
Necrosis: death and decomposition of living tissue usually caused by lack of blood supply but can be caused by other pathological
insult.
Necrotising : causing necrosis.
Oedematous: excessive accumulation of serous fluid in the intercellular spaces of tissues.
Pancreatic pseudocysts: fluid collections in the pancreas or the tissues surrounding the pancreas, surrounded by a well defined wall and
contain only fluid with little or no solid material.
Pancreatitis: inflammation of the pancreas.
Pathologic insult: substance or mechanism that causes the condition.
Percutaneous: through the skin.
Peripancreatic tissues: tissues surrounding the pancreas.
Pharmacological: medicinal drugs.
Platelet activating factor: substance that causes platelets (cells responsible for clotting of blood) to clump together and is an intermediary
substance in the inflammatory pathway.
Probiotics: microorganisms that are believed to provide health benefits when consumed.
Prognostic: to predict the likely outcome.
Protease inhibitors: substances that inhibit proteases.
Protease: an enzyme that digests protein.
Pseudocyst: a fluid-filled cavity that resembles a cyst but lacks a wall or lining.
Radiology guided percutaneous treatments: treatments carried out by insertion of needle from the external surface of the body which
are guided by a scan (usually an ultrasound or CT (computed tomography) scan).
Randomisation: using chance methods to assign people to treatments.
Retrograde: moving backwards.
Sepsis: life-threatening illness due to blood infection with bacteria, fungus, or virus.
Serum: clear fluid that separates out when blood clots.
Sphincterotomy: a surgical procedure of the internal anal sphincter muscle.
Transabdominal: through the abdomen.
Transient: temporary.
Tumour necrosis factor-alpha antibody: antibody to tumour necrosis factor-alpha, an intermediary substance in the inflammatory
pathway.
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Appendix 2. CENTRAL search strategy
#1 MeSH descriptor: [Pancreatitis, Acute Necrotizing] this term only
#2 MeSH descriptor: [Pancreatitis] this term only and with qualifier(s): [Etiology - ET]
#3 MeSH descriptor: [Pancreas] this term only and with qualifier(s): [Abnormalities - AB, Pathology - PA, Physiopathology - PP]
#4 (acute near/3 pancrea*)
#5 (necro* near/3 pancrea*)
#6 (inflam* near/3 pancrea*)
#7 ((interstitial or edema* or oedema*) near/2 pancrea*)
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
Appendix 3. MEDLINE search strategy
1. Pancreatitis, Acute Necrotizing/
2. Pancreatitis/et
3. Pancreas/ab, pa, pp
4. (acute adj3 pancrea*).mp.
5. (necro* adj3 pancrea*).mp.
6. (inflam* adj3 pancrea$).mp.
7. ((interstitial or edema* or oedema*) adj2 pancrea*).mp.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. randomized controlled trial.pt.
10. controlled clinical trial.pt.
11. randomized.ab.
12. placebo.ab.
13. drug therapy.fs.
14. randomly.ab.
15. trial.ab.
16. groups.ab.
17. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
18. exp animals/ not humans.sh.
19. 17 not 18
20. 8 and 19
Appendix 4. Embase search strategy
1. acute hemorrhagic pancreatitis/
2. Pancreatitis/et
3. acute pancreatitis/
4. (acute adj3 pancrea*).mp.
5. (necro* adj3 pancrea*).mp.
6. (inflam* adj3 pancrea*).mp.
7. ((interstitial or edema* or oedema*) adj2 pancrea*).mp.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. Clinical trial/
10. Randomized controlled trial/
11. Randomization/
12. Single-Blind Method/
13. Double-Blind Method/
14. Cross-Over Studies/
15. Random Allocation/
16. Placebo/
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17. Randomi?ed controlled trial*.tw.
18. Rct.tw.
19. Random allocation.tw.
20. Randomly allocated.tw.
21. Allocated randomly.tw.
22. (allocated adj2 random).tw.
23. Single blind*.tw.
24. Double blind*.tw.
25. ((treble or triple) adj blind*).tw.
26. Placebo*.tw.
27. Prospective study/
28. or/9-27
29. Case study/
30. Case report.tw.
31. Abstract report/ or letter/
32. or/29-31
33. 28 not 32
34. 8 and 33
Appendix 5. Science Citation Index search strategy
# 1 TS=((acute or necro* or inflam* or interstitial or edema* or oedema*) near/3 pancrea*)
# 2 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta-analysis OR systematic review* OR meta-
analys*)
# 3 #2 AND #1
Appendix 6. ClinicalTrials.gov search strategy
“Interventional” [STUDY-TYPES] AND acute pancreatitis [DISEASE] AND ( “Phase 2” OR “Phase 3” OR “Phase 4” ) [PHASE]
Appendix 7. Planned methods
We planned to conduct networkmeta-analyses to compare multiple interventions simultaneously for each of the primary and secondary
outcomes when there was direct and indirect evidence for at least one comparison. Network meta-analysis combines direct evidence
within trials and indirect evidence across trials (Mills 2012).
We planned to obtain a network plot (Figure 9) to ensure that the trials were connected by treatments using Stata/IC 11 (StataCorp LP)
(see Appendix 9 for the Stata commands used). We planned to apply network meta-analysis to each connected network. We planned
to conduct a Bayesian network meta-analysis using the Markov chain Monte Carlo method in WinBUGS 1.4. We planned to model
the treatment contrast (e.g. log OR for binary outcomes, MD or SMD for continuous outcomes, rate ratio for count outcomes, HR
for time-to-event outcomes) for any two interventions (’functional parameters’) as a function of comparisons between each individual
intervention and an arbitrarily selected reference group (’basic parameters’) (Lu 2004).We planned to use inactive control (combination
of placebo and no-intervention) as the reference group.We planned to perform the network analysis as per the guidance from the NICE
DSU documents (Dias 2013). We planned to perform the network meta-analysis using arm level data. Further details of the codes we
planned to use and the technical details of how we planned to perform the analysis are shown in Appendix 10 and Appendix 11. In
short, we planned to use three chains and a burn in of 10,000 simulations to ensure convergence, and to obtain the posterior estimates
after a further 20,000 simulations. We planned to run the fixed-effect and random-effects models (assuming homogeneous between-
trial variance across comparisons) for each outcome. We planned to choose the fixed-effect model if it resulted in an equivalent or
better fit (assessed by residual deviances, number of effective parameters, and deviance information criterion (DIC)) than the random-
effects model. A lower DIC indicates a better model fit. We planned to use the random-effects model if it resulted in a better model fit
as indicated by a DIC lower than that of the fixed-effect model by at least three. In addition, we planned to perform a random-effects
inconsistency model suggested by NICE DSU (Dias 2012b). We planned to consider the inconsistency model to be better than the
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random-effects consistency model (standard random-effects network meta-analysis model) if the model fit of the inconsistency model
(as indicated by DIC) was at least three lower than the random-effects consistency model.
Figure 9. Network plot showing the treatment comparisons that included short-term mortality. The circles
represent treatments while the lines represent the comparisons between the treatments.
For multi-arm trials, one can enter the data from all the arms in a trial as: the number of people with events and the number of people
exposed to the event, using the binomial likelihood and logit link for binary outcomes; the mean and standard error using the normal
likelihood and identity link for continuous outcomes requiring calculation of the mean difference; the mean and standard error of the
treatment differences using the normal likelihood and identity link for continuous outcomes requiring calculation of the standardised
mean difference; the number of events and the number of people exposed to the event using the Poisson likelihood and log link for
count outcomes; the follow-up time in the study, number of people with the event and the number of people exposed to the event
using the binomial likelihood and cloglog link for time-to-event outcomes. We planned to report the treatment contrasts (e.g. log
ORs for binary outcomes, MDs for continuous outcomes, and so on) of the different treatments in relation to the reference treatment
(inactive intervention i.e. combined placebo and no-intervention), the residual deviances, number of effective parameters, and DIC
for the fixed-effect model and the random-effects model for each outcome. We also planned to report the parameters used to assess the
model fit (i.e. residual deviances, number of effective parameters, and DIC) for the inconsistency model for all the outcomes and the
between-trial variance for the random-effects model (Dias 2012a; Dias 2012b). If the inconsistency model resulted in a better model
fit than consistency models, the transitivity assumption is likely to be untrue and the effect estimates obtained may not be reliable. We
planned to highlight such outcomes where the inconsistency model results in a better model fit than consistency models.
We found significant clinical heterogeneity in the type of participants included under the different comparisons. To overcome the
heterogeneity in the type of people included in different comparisons (See ’Included studies’) we planned to perform a separate network
234Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
meta-analysis for interventions for mild pancreatitis separately from moderately severe or severe pancreatitis. This is because mild
pancreatitis has no local or systemic complications and combining participants with mild and severe acute pancreatitis in the same
network meta-analysis may violate the transitivity assumption (the assumption that the participants included in the different studies
with different treatments can be considered to be a part of a multi-arm randomised controlled trial - i.e. they should be reasonably
similar in characteristics). We then planned to assess inconsistency again. However, this was not appropriate in the subgroup of severe
acute pancreatitis because of the absence of any comparison in which direct and indirect comparison was available. If there was no
evidence of inconsistency in the revised analysis, we planned to present the results of the analysis for mild and moderate or severe acute
pancreatitis separately. If there was persistent evidence of inconsistency, we planned to present the results from the direct comparison
in the ’Summary of findings’ table.
We planned to calculate the 95% CrIs of treatment effects (e.g. ORs for binary outcomes, MDs for continuous outcomes, and so
on) in the Bayesian meta-analysis, which is similar in use to the 95% confidence intervals in the frequentist meta-analysis. These are
the 2.5th percentile and 97.5th percentiles of the simulations. We planned to report the mean effect estimate and the 95% CrI for
each pair-wise comparison in a table. We also planned to estimate the probability that each intervention ranks at one of the possible
positions, and have presented this information in graphs. It should be noted that a less than 90% probability that the treatment is the
best treatment is unreliable (i.e. one should not conclude that the treatment is the best treatment for that outcome if the probability
of it being the best treatment is less than 90%) (Dias 2012a). We also planned to present the cumulative probability of the treatment
ranks (i.e. the probability that the treatment is within the top two, the probability that the treatment is within the top three, etc.) in
graphs. We also planned to plot the probability that each treatment is best for each of the different outcomes (rankograms) which are
generally considered more informative (Dias 2012a; Salanti 2011). We planned to perform direct comparisons using the same codes.
This would have allowed us to assess the heterogeneity in the comparisons and provide additional information in the ’Summary of
findings’ table. We also planned to use the Tau² statistic to measure heterogeneity among the trials in each analysis. The Tau² statistic
provides a measure of the variability of the effect estimate across studies in a random-effects model (Higgins 2011). If we identified
substantial heterogeneity, we planned to explore it by meta-regression. We also planned to assess the differences in the effect estimates
between the subgroups using meta-regression for each source of heterogeneity (i.e. one analysis for each source of heterogeneity) with
the help of the code shown in Appendix 12. We planned to perform the following subgroup analyses regardless of heterogeneity. We
planned to calculate the interaction term (Dias 2012c). If the 95% CrI of the regression coefficient of the interaction term does not
overlap zero, we considered this statistically significant.
In the presence of adequate data where authors report the outcomes of participants at multiple follow-up time points, we planned to
follow the methods suggested by Lu 2007 to perform the meta-analysis.
We planned to use methods and recommendations described for grading network meta-analysis (Puhan 2014). This includes grading
the quality for direct comparison, indirect comparison, and network meta-analysis and presenting the information in tabular format.
Appendix 8. WHO ICTRP search strategy
Acute pancreatitis
Appendix 9. Stata code for network plot
networkplot t1 t2, labels(T1 T2 T3 ..)
Appendix 10. Winbugs code
Binary outcome
Binary outcome - fixed-effect model
# Binomial likelihood, logit link
# Fixed effects model
model{ # *** PROGRAM STARTS
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for(i in 1:ns){ # LOOP THROUGH STUDIES
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood
# model for linear predictor
logit(p[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]
# expected value of the numerators
rhat[i,k] <- p[i,k] * n[i,k]
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))
}
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Binary outcome - random-effects model
# Binomial likelihood, logit link
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood
logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
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resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions (with multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment for multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Binary outcome - inconsistency model (random-effects)
# Binomial likelihood, logit link, inconsistency model
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH trials
delta[i,1]<-0 # treatment effect is zero in control arm
mu[i] ~ dnorm(0,.0001) # vague priors for trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood
logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor
#Deviance contribution
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))
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}# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ~ dnorm(d[t[i,1],t[i,k]] ,tau)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
for (c in 1:(nt-1)) { # priors for all mean treatment effects
for (k in (c+1):nt) { d[c,k] ~ dnorm(0,.0001) }
}
sd ~ dunif(0,5) # vague prior for between-trial standard deviation
var <- pow(sd,2) # between-trial variance
tau <- 1/var # between-trial precision
} # *** PROGRAM ENDS
Continuous outcome (mean difference)
Continuous outcome (mean difference) - fixed-effect model
# Normal likelihood, identity link
# Fixed effect model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
y[i,k] ~ dnorm(theta[i,k],prec[i,k])
# model for linear predictor
theta[i,k] <- mu[i] + d[t[i,k]] - d[t[i,1]]
#Deviance contribution
dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k]
}
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for control arm
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- rank(d[],k) # assumes lower is better
# rk[k] <- nt+1-rank(d[],k) # assumes lower outcome is worse
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
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Continuous outcome (mean difference) - random-effects model
# Normal likelihood, identity link
# Random effects model for multi-arm trials
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
y[i,k] ~ dnorm(theta[i,k],prec[i,k])
theta[i,k] <- mu[i] + delta[i,k] # model for linear predictor
#Deviance contribution
dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k]
}
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific MD distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of MD distributions, with multi-arm trial correction
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of MD distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment, multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for control arm
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- rank(d[],k) # assumes lower is better
# rk[k] <- nt+1-rank(d[],k) # assumes lower outcome is worse
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Continuous outcome (standardised mean difference)
The standardised mean difference and its standard error for each treatment comparison will be calculated using the statistical algorithms
used by RevMan.
Continuous outcome (standardised mean difference) - fixed-effect model
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# Normal likelihood, identity link
# Trial-level data given as treatment differences
# Fixed effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns2) { # LOOP THROUGH 2-ARM STUDIES
y[i,2] ~ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials
#Deviance contribution for trial i
resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]
}
for(i in (ns2+1):(ns2+ns3)) { # LOOP THROUGH THREE-ARM STUDIES
for (k in 1:(na[i]-1)) { # set variance-covariance matrix
for (j in 1:(na[i]-1)) {
Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)
}
}
Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i„]) #Precision matrix
# multivariate normal likelihood for 3-arm trials
y[i,2:na[i]] ~ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)])
#Deviance contribution for trial i
for (k in 1:(na[i]-1)){ # multiply vector & matrix
ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)]
z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)])
}
resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)])
}
for(i in 1:(ns2+ns3)){ # LOOP THROUGH ALL STUDIES
for (k in 2:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
delta[i,k] <- d[t[i,k]] - d[t[i,1]]
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- nt+1-rank(d[],k) # assumes higher HRQoL is “good”
#rk[k] <- rank(d[],k) # assumes higher outcome is “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Continuous outcome (standardised mean difference) - random-effects model
# Normal likelihood, identity link
# Trial-level data given as treatment differences
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns2) { # LOOP THROUGH 2-ARM STUDIES
y[i,2] ~ dnorm(delta[i,2],prec[i,2]) # normal likelihood for 2-arm trials
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#Deviance contribution for trial i
resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]
}
for(i in (ns2+1):(ns2+ns3)) { # LOOP THROUGH THREE-ARM STUDIES
for (k in 1:(na[i]-1)) { # set variance-covariance matrix
for (j in 1:(na[i]-1)) {
Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)
}
}
Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i„]) #Precision matrix
# multivariate normal likelihood for 3-arm trials
y[i,2:na[i]] ~ dmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)])
#Deviance contribution for trial i
for (k in 1:(na[i]-1)){ # multiply vector & matrix
ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)]
z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)])
}
resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)])
}
for(i in 1:(ns2+ns3)){ # LOOP THROUGH ALL STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
for (k in 2:na[i]) { # LOOP THROUGH ARMS
var[i,k] <- pow(se[i,k],2) # calculate variances
prec[i,k] <- 1/var[i,k] # set precisions
}
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific SMD distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of random effects distributions, with multi-arm trial correction
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of random effects distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment, multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# ranking on relative scale
for (k in 1:nt) {
rk[k] <- nt+1-rank(d[],k) # assumes higher HRQoL is “good”
# rk[k] <- rank(d[],k) # assumes higher outcome is “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
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Count outcome
Count outcome - fixed-effect model
# Poisson likelihood, log link
# Fixed effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dpois(theta[i,k]) # Poisson likelihood
theta[i,k] <- lambda[i,k]*E[i,k] # failure rate * exposure
# model for linear predictor
log(lambda[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]
#Deviance contribution
dev[i,k] <- 2*((theta[i,k]-r[i,k]) + r[i,k]*log(r[i,k]/theta[i,k])) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
# pairwise RRs and LRRs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
rater[c,k] <- exp(d[k] - d[c])
lrater[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Count outcome - random-effects model
# Poisson likelihood, log link
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dpois(theta[i,k]) # Poisson likelihood
theta[i,k] <- lambda[i,k]*E[i,k] # failure rate * exposure
# model for linear predictor
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log(lambda[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]]
#Deviance contribution
dev[i,k] <- 2*((theta[i,k]-r[i,k]) + r[i,k]*log(r[i,k]/theta[i,k])) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions (with multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment for multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
}
}
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good”
rk[k] <- rank(d[],k) # assumes events are “bad”
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Time-to-event outcome
Time-to-event outcome - fixed-effect model
# Binomial likelihood, cloglog link
# Fixed effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
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r[i,k] ~ dbin(p[i,k],n[i,k]) # Binomial likelihood
# model for linear predictor
cloglog(p[i,k]) <- log(time[i]) + mu[i] + d[t[i,k]] - d[t[i,1]]
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for control arm
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- rank(d[],k) # assumes lower is better
rk[k] <- nt+1-rank(d[],k) # assumes lower outcome is worse
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Time-to-event outcome - random-effects model
# Binomial likelihood, cloglog link
# Random effects model
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dbin(p[i,k],n[i,k]) # Binomial likelihood
# model for linear predictor
cloglog(p[i,k]) <- log(time[i]) + mu[i] + delta[i,k]
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions, with multi-arm trial correction
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment, multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
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}}
totresdev <- sum(resdev[]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
# vague priors for treatment effects
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# ranking on relative scale
for (k in 1:nt) {
# rk[k] <- rank(d[],k) # assumes lower is better
rk[k] <- nt+1-rank(d[],k) # assumes lower outcome is worse
best[k] <- equals(rk[k],1) #calculate probability that treat k is best
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th best
}
} # *** PROGRAM ENDS
Appendix 11. Technical details of network meta-analysis
The posterior probabilities (effect estimates or values) of the treatment contrast (i.e. log odds ratio, mean difference, standardised mean
difference, rate ratio, or hazard ratio) may vary depending on the initial values to start the simulations. In order to control the random
error due to the choice of initial values, we performed the network analysis for three different initial values (priors) as per the guidance
from The National Institute for Health and Care Excellence (NICE) Decision Support Unit (DSU) documents (Dias 2013). If the
results from three different priors are similar (convergence), then the results are reliable. It is important to discard the results of the initial
simulations as they can be significantly affected by the choice of the priors and only include the results of the simulations obtained after
the convergence. The discarding of the initial simulations is called ’burn in’. We ran the models for all outcomes for 10,000 simulations
for ’burn in’ for three different chains (a set of initial values). We ran the models for another 20,000 simulations to obtain the effect
estimates. We obtained the effect estimates from the results of all the three chains (different initial values). We also ensured that the
results in the three different chains are similar in order to control for random error due to the choice of initial values. This was done in
addition to the visual inspection of convergence obtained after simulations in the burn in.
We ran three different models for each outcome. The fixed-effect model assumes that the treatment effect is the same across studies.
The random-effects consistency model assumes that the treatment effect is distributed normally across the studies but assumes that
the transitivity assumption is satisfied (i.e. the population studied, the definition of outcomes, and the methods used were similar
across studies and that there is consistency between the direct comparison and indirect comparison). A random-effects inconsistency
model does not make the transitivity assumption. If the inconsistency model resulted in a better model fit than the consistency model,
the results of the network meta-analysis can be unreliable and so should be interpreted with extreme caution. If there is evidence of
inconsistency, we planned to identify areas in the network where substantial inconsistency might be present in terms of clinical and
methodological diversities between trials and, when appropriate, limit the network meta-analysis to a more compatible subset of trials.
The choice of the model between fixed-effect and random-effects was based on the model fit as per the guidelines of the NICE TSU
(Dias 2013). The model fit will be assessed by deviance residuals and Deviance Information Criteria (DIC) according to NICE TSU
guidelines (Dias 2013). A difference of three or five in the DIC is not generally considered important (Dias 2012c).We used the simpler
model, i.e. fixed-effect model if the DIC are similar between the fixed-effect and the random-effects models. We used the random-
effects model if it results in a better model fit as indicated by a DIC lower than that of the fixed-effect model by at least three.
We planned to calculate the effect estimates of the treatment and the 95% credible intervals using the following additional code.
# pairwise ORs and MD for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
OR[c,k] <- exp(d[k] - d[c])
#MD[c,k] <- (d[k]-d[c])
}
}
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where c indicates control group, k indicates intervention group, OR indicates odds ratio or other ratios, and MD indicates mean
difference or other differences.
Appendix 12. Winbugs code for subgroup analysis
Categorical covariate
Only the code for random-effects model for a binary outcome is shown. The differences in the code are underlined. We planned to
make similar changes for other outcomes.
# Binomial likelihood, logit link, subgroup
# Random effects model for multi-arm trials
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood
# model for linear predictor, covariate effect relative to treat in arm 1
logit(p[i,k]) <- mu[i] + delta[i,k] + (beta[t[i,k]]-beta[t[i,1]]) * x[i]
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions (with multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment for multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
beta[1] <- 0 # covariate effect is zero for reference treatment
for (k in 2:nt){ # LOOP THROUGH TREATMENTS
d[k] ~ dnorm(0,.0001) # vague priors for treatment effects
beta[k] <- B[k] # exchangeable covariate effect
B[k] ~ dnorm(0,.0001) # vague prior for covariate effect
}
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# treatment effect when covariate = z[j]
for (k in 1:nt){ # LOOP THROUGH TREATMENTS
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for (j in 1:nz) { dz[j,k] <- d[k] + (beta[k]-beta[1])*z[j] }
}
# *** PROGRAM ENDS
Continuous covariate
# Binomial likelihood, logit link, continuous covariate
# Random effects model for multi-arm trials
model{ # *** PROGRAM STARTS
for(i in 1:ns){ # LOOP THROUGH STUDIES
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm
delta[i,1] <- 0 # treatment effect is zero for control arm
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines
for (k in 1:na[i]) { # LOOP THROUGH ARMS
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood
# model for linear predictor, covariate effect relative to treat in arm 1
logit(p[i,k]) <- mu[i] + delta[i,k] + (beta[t[i,k]]-beta[t[i,1]]) * (x[i]-mx)
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators
#Deviance contribution
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) }
# summed residual deviance contribution for this trial
resdev[i] <- sum(dev[i,1:na[i]])
for (k in 2:na[i]) { # LOOP THROUGH ARMS
# trial-specific LOR distributions
delta[i,k] ~ dnorm(md[i,k],taud[i,k])
# mean of LOR distributions (with multi-arm trial correction)
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k]
# precision of LOR distributions (with multi-arm trial correction)
taud[i,k] <- tau *2*(k-1)/k
# adjustment for multi-arm RCTs
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]])
# cumulative adjustment for multi-arm trials
sw[i,k] <- sum(w[i,1:k-1])/(k-1)
}
}
totresdev <- sum(resdev[]) # Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
beta[1] <- 0 # covariate effect is zero for reference treatment
for (k in 2:nt){ # LOOP THROUGH TREATMENTS
d[k] ~ dnorm(0,.0001) # vague priors for treatment effects
beta[k] <- B[k] # exchangeable covariate effect
B[k] ~ dnorm(0,.0001) # vague prior for covariate effect
}
sd ~ dunif(0,5) # vague prior for between-trial SD
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)
# treatment effect when covariate = z[j] (un-centring treatment effects)
for (k in 1:nt){
for (j in 1:nz) { dz[j,k] <- d[k] - (beta[k]-beta[1])*(mx-z[j]) }
}
# pairwise ORs and LORs for all possible pair-wise comparisons, if nt>2
for (c in 1:(nt-1)) {
for (k in (c+1):nt) {
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# at mean value of covariate
or[c,k] <- exp(d[k] - d[c])
lor[c,k] <- (d[k]-d[c])
# at covariate=z[j]
for (j in 1:nz) {
orz[j,c,k] <- exp(dz[j,k] - dz[j,c])
lorz[j,c,k] <- (dz[j,k]-dz[j,c])
}
}
}
} # *** PROGRAM ENDS
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248Pharmacological interventions for acute pancreatitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
